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Obi, Engels Nnamdi. Ph.D., Purdue University, December 2013. Patients’ Perceptions of 
Provider Communication, Provider Knowledge, and Provider Competence and 
Associations with Potentially Inappropriate Medication Use among Medicare Part D 
Beneficiaries. Major Professor: Joseph Thomas III 
The objectives for this study were to determine prevalence and incidence of potentially 
inappropriate medication (PIM) use among community-dwelling Medicare Part D 
beneficiaries, and to assess associations between patients’ perceptions of provider 
communication, provider knowledge, and provider competence with PIM use.  A 
retrospective observational analysis was conducted using data from the Medicare Current 
Beneficiary Survey.  Individuals were included in the prevalence sample if they were 
aged 65 years or older in 2008, continuously enrolled in Medicare Part D from October 
2007 through December 2008, and living in the community from October 2007 through 
December 2008.  Individuals were included in the incidence sample if they were aged 65 
years or older in 2008, continuously enrolled in Medicare Part D from October 2007 
through December 2008, living in the community from October 2007 through December 
2008, and did not receive any PIMs during the last quarter of 2007.  Potentially 
inappropriate medications were identified based on the 2012 Beers criteria in each of four 
broad categories including inappropriate drug choice, excess dose, excess duration, and 
drug-disease interaction.  Patients’ perceptions of provider communication, provider 





Multiple logistic regression models were developed to examine associations between 
patients’ perceptions of provider communication, provider knowledge, and provider 
competence and PIM use.  One-year prevalence of PIM use among community-dwelling 
Medicare Part D beneficiaries was 27.6 percent for inappropriate drug choice PIMs, 3.3 
percent for excess dose PIMs, 3.5 percent for excess duration PIMs, and 3.2 percent for 
drug-disease interaction PIMs.  Overall one-year prevalence of use of any PIM was 33.0 
percent.  One-year incidence of PIM use among community-dwelling Medicare Part D 
beneficiaries was 17.2 percent for inappropriate drug choice PIMs, 1.2 percent for excess 
dose PIMs, 2.6 percent for excess duration PIMs, and 1.8 percent for drug-disease 
interaction PIMs.  Overall one-year incidence of use of any PIM was 20.7 percent.  
Individuals with more positive perceived provider knowledge scores of six (OR=0.62, 
95% CI=0.39 to 0.97, p=0.036), seven (OR=0.44, 95% CI=0.22 to 0.87, p=0.018), or 
eight (OR=0.55, 95% CI=0.34 to 0.88, p=0.012) were less likely than those with scores 
ranging from two to five to receive PIMs identified in the inappropriate drug choice 
category after adjusting for demographic and clinical characteristics.  There were no 
associations found between perceived provider communication or perceived provider 








 Medications with adverse risks outweighing potential benefits in older adults or 
persons aged 65 years or older are considered potentially inappropriate (Beers, Ouslander 
et al., 1991; Stuck, Beers et al., 1994).  Older adults are at risk for potentially 
inappropriate medication (PIM) use because of high prevalence of chronic disease and 
multiple medication use, and age-related changes in pharmacokinetic and 
pharmacodynamic parameters of many medications (Dimitrow, Airaksinen et al., 2011; 
Mangoni and Jackson 2004; Spinewine, Schmader et al., 2007).  There is evidence of 
associations between PIM use and adverse health outcomes including higher risk for 
adverse drug events, hospitalization, mortality, and more healthcare expenditure 
(Dedhiya, Hancock et al., 2010; Guaraldo, Cano et al., 2011; Spinewine, Schmader et al. 
2007).  Nevertheless, with a rapidly aging US population and greater medication 
availability, use of PIMs by older adults may increase and become a larger public health 
concern (Gallagher, Barry et al., 2007). 
Literature Review 
Medication Therapy Challenges in Older Adults 
Medication therapy in persons aged 65 years or older or older adults can be 





pharmacokinetics, altered pharmacodynamics, and use of medications that are potentially 
inappropriate.   
Polypharmacy 
 Medication consumption increases with advancing age (Barat, Andreasen et al., 
2000; Kaufman, Kelly et al., 2002).  Older adults frequently have complex medical 
conditions and multiple comorbidities that require polypharmacy or concurrent use of 
multiple medications (Barat, Andreasen et al. 2000).  Studies examining drug utilization 
patterns in older adults have found estimates of concurrent use of five or more 
medications to range from 23 percent to 34 percent (Barat, Andreasen et al. 2000; 
Kaufman, Kelly et al. 2002; Qato, Alexander et al., 2008).  Kaufman et al. surveyed 
2,590 non-institutionalized adults in the US using data from February 1998 through 
December 1999 and found 23 percent of women aged 65 years or older took 5 or more 
prescription medications and 12 percent took 10 or more prescription medications 
(Kaufman, Kelly et al. 2002).  Qato et al. surveyed 3,000 US community dwelling 
individuals aged 57 to 85 years between June 2005 and May 2006 and found 29 percent 
of individuals used at least 5 prescription medications concurrently (Qato, Alexander et 
al. 2008).  A 46 percent prevalence of concurrent use of over-the-counter (OTC) 
medications, and a 52 percent prevalence of concurrent use of dietary supplements was 
reported in the same study (Qato, Alexander et al. 2008).  Barat et al. surveyed 492 
community dwelling adults in Denmark aged 75 years and found that 34 percent of 
individuals used five or more prescription medications concurrently, 60 percent used 
three or more prescription medications concurrently, and 30 percent used 3 or more OTC 
medications concurrently (Barat, Andreasen et al. 2000).  
 A higher risk for adverse drug-related outcomes including adverse events, drug-





medications concurrently (Goldberg, Mabee et al., 1996).  Goldberg et al. found the risk 
for adverse drug interactions in a high-risk population of emergency department patients 
increased from 13 percent in patients taking two drugs, to 38 percent in patients taking 
four drugs, and 82 percent in patients taking seven or more drugs (Goldberg, Mabee et al. 
1996).  Older adults frequently use multiple medications and are vulnerable to the 
adverse drug-related outcomes associated with such medication use because of age-
related changes in pharmacokinetic and pharmacodynamic parameters of many drugs 
(Everitt and Avorn 1986; Gallagher, Barry et al. 2007), prevalent but frequently 
unrecognized duplicate prescribing of drugs in the same class (Goldberg, Mabee et al. 
1996; Hajjar, Cafiero et al., 2007),  and use of even more drugs to treat drug-related 
adverse events (Hajjar, Cafiero et al. 2007).  
Altered Pharmacokinetics  
 Older adults present age-related alterations in many pharmacokinetic processes 
including drug distribution, metabolism and excretion that may increase or decrease their 
sensitivity to medications.  
Drug Distribution 
 As people age, there is decrease in lean body mass and total body water, and a 
corresponding increase in adipose tissue (Everitt and Avorn 1986; Gallagher, Barry et al. 
2007).  The change in body composition increases the volume of distribution for lipid 
soluble drugs such as diazepam, thiopentone, and lignocaine in older adults leading to 
prolongation of half-life and delayed therapeutic effect (Christensen, Andreasen et al., 
1981; Greenblatt, Allen et al., 1980; Nation, Triggs et al., 1977; Turnheim 2003).  





ethanol decreases leading to higher serum levels of such drugs in older adults and greater 
risk for adverse effects (Cusack, Kelly et al., 1979; Vestal, McGuire et al., 1977). 
 Several drugs are distributed in the body in both an inactive protein-bound and 
active unbound state (Everitt and Avorn 1986).  Although, no significant age-related 
decreases in the amount of proteins available for drug binding have been observed, 
malnutrition and chronic illness often seen in older adults may decrease serum albumin 
levels (Fu and Nair 1998).  Low serum albumin levels increase the active unbound drug 
fraction for highly protein-bound drugs such as phenytion, wafarin, digoxin, theophylline, 
furosemide, and phenylbutazone (Everitt and Avorn 1986; Gallagher, Barry et al. 2007).  
Because the unbound drug fraction is responsible for pharmacological action, having 
above normal serum concentrations of unbound drug can increase the risk for adverse 
effects.  The concurrent use of multiple medications frequently observed in older adults 
may result in displacement of protein-bound drugs and further increase the risk for 
adverse effects (Everitt and Avorn 1986). 
Drug Metabolism 
 Advancing age is associated with a reduction in liver mass and blood flow which 
may reduce the metabolism of drugs that undergo first-pass metabolism in the liver such 
as beta-blockers, tricyclic antidepressants, and nitrates (Anantharaju, Feller et al., 2002; 
Page, Linnebur et al., 2010; Woodhouse and Wynne 1988).  A consequence of reduced 
first-pass metabolism of such drugs is significantly increased bioavailability (Castleden 
and George 1979; Greenblatt, Harmatz et al., 1991), which can in turn lead to potentially 
dangerous accumulation of the drug in the body and adverse effects.  For pro-drugs such 
as enalapril and perindopril that are activated in the liver, a reduction in first-pass 
metabolism due to advancing age reduces their bio-availability (Davies, Gomez et al., 





 Age-related changes in liver mass and blood flow have also been associated with 
significant reductions in the clearance of several drugs metabolized via hepatic phase I 
reactions (Schmucker 2001; Swift, Homeida et al., 1978).  Therefore, drugs metabolized 
primarily through hepatic phase I oxidation reactions such as flurazepam, diazepam, 
qunidine, and theophylline tend to be more bioavailable in older adults (Everitt and 
Avorn 1986). 
Drug Excretion 
 Advancing age has been associated with a reduction in many aspects of renal 
function including renal blood flow, glomerular filtration, and active tubular secretion 
(Everitt and Avorn 1986).  A reduction in renal function decreases the clearance of 
several drugs including digoxin (Portnoi 1979), indomethacin (Oberbauer, Krivanek et 
al., 1993), diuretics (Somogyi, Hewson et al., 1990), lithium (Hewick, Newbury et al., 
1977), and water soluble antibiotics (Lumholtz, Kampmann et al., 1974; Triggs, Johnson 
et al., 1980).  Decreased renal clearance prolong the half-lives of potentially toxic drugs 
such as aminoglycoside antibiotics, digoxin, and lithium drugs resulting in drug 
accumulation and possibly serious adverse effects (Mangoni and Jackson 2004). 
Altered Pharmacodynamics 
 Advancing age is associated with increased individual patient variability in drug 
response.  An increase in receptor sensitivity in older adults has been found for 
analgesics, cardiovascular drugs such as digoxin (Everitt and Avorn 1986), and 
psychotropic drugs such as diazepam and lorazepam (Gallagher, Barry et al. 2007; 
Mangoni and Jackson 2004).  Thus drug levels within the ‘normal’ therapeutic range may 
have a larger than normal pharmacologic effect.  Adjusting drug doses in older adults to 





receptor sensitivity, is especially important for drugs with a narrow therapeutic index 
such as digoxin to reduce the risk for severe adverse reactions.  
Conversely, a decrease in receptor sensitivity has been found in older adults for 
beta-agonists such as salbutamol, beta-blockers such as propanolol (Gallagher, Barry et 
al. 2007; Vestal, Wood et al., 1979), as well as for verapamil (Mangoni and Jackson 
2004), and insulin (Everitt and Avorn 1986).  The inhibition of synthesis of vitamin K-
dependent clotting factors was found to be greater in persons aged between 62 years and 
89 years when compared to persons between the ages of 27 years and 37 years (Shepherd, 
Hewick et al., 1977).  Doses of drugs having decreased receptor sensitivity in older adults 
may need to be increased in to order to achieve an adequate therapeutic response. 
Potentially Inappropriate Medications (PIMs) 
Gallagher et al. define potentially inappropriate medications (PIMs) as 
“medications that introduce a significant risk of an adverse event where there is evidence 
for an equally or more effective but lower risk alternative therapy available for treating 
the same condition” (Gallagher, Barry et al. 2007).   Inappropriate medication use may 
also include the “underuse of beneficial medicines which are clinically indicated but not 
prescribed for ageist or irrational reasons” (Gallagher, Barry et al. 2007).  Older adults 
are at higher risk of receiving medications considered to be inappropriate, and having 
adverse drug-related events as a result of such medication use (Dimitrow, Airaksinen et 
al. 2011; Mangoni and Jackson 2004; Spinewine, Schmader et al. 2007).  The higher risk 
of adverse drug-related events from inappropriate medication use in older adults has been 
linked to age-related factors including polypharmacy, altered pharmacokinetics, and 






Approaches used to examine Appropriateness of Medications 
in Older Adults 
The approaches commonly used to identify inappropriate medication use in older 
adults are categorized as explicit (criteria-based), or implicit (judgment-based).  
Explicit Approaches 
Explicit approaches for identifying potentially inappropriate medication use in 
older adults are drug or disease-specific criteria that can be applied with little or no 
clinical judgment.  They are established from published reviews and expert consensus for 
the purpose of identifying potential mis-prescribing or under-prescribing of medications 
to older adults (Spinewine, Schmader et al. 2007).  Mis-prescribing involves the use of 
medications that ought to be avoided in older adults either in the presence or absence of 
comorbid conditions (Chang and Chan 2010).  Under-prescribing involves the under-use 
of medications that although beneficial and clinically indicated, are not prescribed 
because of ageist or otherwise invalid reasons (Gallagher, Barry et al. 2007; Spinewine, 
Schmader et al. 2007).   
A major advantage of explicit approaches is their ease of implementation in a 
large number of people (Dimitrow, Airaksinen et al. 2011; Spinewine, Schmader et al. 
2007) because of the limited range of medications and clinical conditions specified  
(Chang and Chan 2010).  Disadvantages include concerns about their validity, reliability 
(Anderson, Beers et al., 1997; Tinetti, Bogardus et al., 2004), specificity, and scope 
(Spinewine, Schmader et al. 2007).  Explicit criteria used to assess appropriateness of 
medication use in older adults include the Beers criteria, Zhan criteria, McLeod criteria, 
Improved Prescribing in the Elderly Tool (IPET), Screening Tool of Older Person’s 
Prescriptions (STOPP), and Screening Tool to Alert doctors to Right Treatment 






The Beers criteria was developed in 1991 as a guide for determining inappropriate 
medication use in nursing home residents aged 65 years or older (Beers, Ouslander et al. 
1991).  It is the most commonly used criteria for identifying potentially inappropriate 
medication use in older adults.  The criteria were developed using a consensus expert 
panel of US geriatric specialists and pharmacotherapists, and consisted of a list of 
medications to be avoided in persons aged 65 years or older because of their 
ineffectiveness or because of the unnecessary risk use of such medications posed to 
persons aged 65 years or older.  The list also included doses and durations of therapy that 
should not be exceeded for certain drugs.  The Beers criteria were updated and expanded 
in 1997 and 2002 to include inappropriate prescribing for persons aged 65 years or older 
living in the community or other settings (Beers 1997; Fick, Cooper et al., 2003).   
In 2012, a fourth edition of the Beers criteria was published (American Geriatrics 
Society 2012 Beers Criteria Update Expert Panel 2012).  The latest version of the Beers 
criteria was developed using enhanced evidence-based methodology recommended by 
the Institute of Medicine in its 2011 report on developing practice guidelines.  The 2012 
Beers criteria differed from 2002 criteria in that drugs available after publication of the 
2002 criteria were added, drugs no longer available were removed, and a new group of 
drugs to be used with caution in older adults was added.  The 2012 Beers criteria consist 
of 53 medications or medication classes divided into 4 categories.  The first category 
consists of drugs considered generally inappropriate in older adults.  The second category 
consists of drugs considered potentially inappropriate because of dose limitations.  The 
third category consists of drugs considered potentially inappropriate because of duration 
of use limitations.  The fourth category consists of drugs considered potentially 






Although the Beers criteria is accepted as an indicator of inappropriate medication 
use (Viswanathan, Bharmal et al., 2005), the use of some drugs on the criteria may be 
justified for use in certain patients if the benefits outweigh the risk (Anderson, Beers et 
al. 1997; Beers, Ouslander et al. 1991; Zhan, Sangl et al., 2001).  To account for this, 
Zhan et al. (Zhan, Sangl et al. 2001) convened a panel of experts in geriatrics, 
pharmacoepidemiology, and pharmacy and categorized drugs listed in the 1997 Beers 
criteria according to their level of risk.  The updated criteria consisted of 33 drugs 
categorized as drugs to always avoid, drugs that are rarely appropriate, and drugs that are 
sometime appropriate. 
McLeod Criteria / Improved Prescribing in the Elderly Tool (IPET) 
The McLeod Criteria (McLeod, Huang et al., 1997) was developed in Canada in 
1997 to assess inappropriate prescribing practices in older adults.  The criteria was 
developed using a 32-member expert panel of Canadian clinical pharmacologists, 
geriatricians, family practitioners, and pharmacists, and consisted of a list of medications 
that are considered inappropriate in older adults due to the risk of serious adverse effect 
when there was equally or more effective and less risky alternative therapy available.  
The clinical significance of each medication was rated on a scale of 1 being none 
significant, to 4 being highly significant.  The final criteria consisted of 38 distinct 
therapies or therapeutic combinations with a mean clinical significance rating of at 3.0 or 
greater, divided into 3 categories including medications contraindicated in older adults 
due to unacceptable benefit-risk ratios, medications involved in drug-drug interactions, 
and medications involved in drug-disease interactions. 
The Improved Prescribing in the Elderly Tool or IPET (Naugler, Brymer et al., 





McLeod Criteria.  This screening tool was developed by applying the McLeod Criteria to 
abstracted hospital charts to identify what PIMs were most prevalent in older adults, and 
consisted of 14 instances of potentially inappropriate prescribing.  Although brief and 
easy to use (Naugler, Brymer et al. 2000), IPET was found to be less sensitive than the 
2002 Beers criteria at detecting PIMs because it does not include many of the drugs 
found in the Beers list (Barry, O'Keefe et al., 2006).  IPET has been seldom used in non-
Canadian studies (Laroche, Charmes et al., 2009; O'Mahony and Gallagher 2008). 
Screening Tool of Older Person’s Prescriptions (STOPP) 
The Screening Tool of Older Person’s Prescriptions (STOPP) was developed by 
Gallagher et al. (Gallagher, Ryan et al., 2008) and consists of criteria for identifying 
PIMs in older adults.  The screening tool was developed using an 18-member consensus 
expert panel of specialists in geriatric pharmacotherapy in Ireland and the United 
Kingdom and consists of 65 criteria grouped according to 7 physiological systems, drugs 
adversely affecting persons who fall, analgesic drugs, and duplicate drug classes.   
Screening Tool to Alert doctors to Right Treatment (START) 
The Screening Tool to Alert doctors to Right Treatment (START) consists of 
criteria for appraising under-prescribing of appropriate drugs in older adults (Gallagher, 
Ryan et al. 2008).  START was developed using an 18-member consensus expert panel of 
specialists in geriatric pharmacotherapy in Ireland and the United Kingdom and 
comprises of 22 criteria grouped according to 6 physiological systems.  It was designed 
to be ideally used with STOPP to obtain a holistic appraisal of appropriateness of 







Implicit approaches used to examine potentially inappropriate medication use in 
older adults are person-oriented, and rely on a clinician’s judgment rather than pre-
defined criteria to determine medication appropriateness (Dimitrow, Airaksinen et al. 
2011; Spinewine, Schmader et al. 2007).  They are based on an individual’s clinical 
information and published literature (Spinewine, Schmader et al. 2007).  Advantages of 
implicit approaches include their higher sensitivity, and ability to account for patient 
preferences (Spinewine, Schmader et al. 2007).  Disadvantages of implicit approaches 
include they require more time to apply relative to explicit approaches, and can have low 
reliability because different clinicians may judge appropriateness differently (Dimitrow, 
Airaksinen et al. 2011; Spinewine, Schmader et al. 2007).  Because of the issues with 
their practicality of use, implicit approaches are less commonly used in health outcomes 
studies examining potentially inappropriate medication use (Dimitrow, Airaksinen et al. 
2011).  The Medication Appropriateness Index was the only implicit approach found that 
was used to assess potentially inappropriate medication use in older adults and is 
described below.  
Medication Appropriateness Index (MAI) 
The MAI (Hanlon, Schmader et al., 1992) was developed in 1992 to evaluate the 
appropriateness of drug therapy and consists of 10 criteria that assess various elements of 
drug prescribing including indication, effectiveness, dosage, directions, practicality, drug-
drug interaction, drug-disease interaction, duplication, duration, and expense.  The index 
provides operational definitions and explicit instructions for each criterion to aid 
standardization of use.  Each evaluator uses these guidelines as well their implicit 
judgment to rate the appropriateness of drug use on a 3 point Likert scale.  Individual 





the overall appropriateness of a specific drug.  To enhance the utility of the MAI, a 
weighing scheme was developed in 1994 that generates a single summated score for each 
medication evaluated (Samsa, Hanlon et al., 1994).   
Prevalence of PIM use in Older Adults 
 Sixty-eight studies were found that reported PIM prevalence rates among older 
adults.  The PIMs were identified in individuals receiving care from various care settings 
including ambulatory care (38 of 68 studies), hospitals (13 of 68 studies), nursing homes 
(11 of 68 studies), residential care/assisted living facilities (5 of 68 studies), and 
emergency departments (4 of 68 studies).  Four studies did not specify the setting at 
which care was received (Akazawa, Imai et al., 2010; Fahlman, Lynn et al., 2007; Mort 
and Sailor 2011; Simon, Chan et al., 2005).  The studies identified PIMs using various 
criteria including the Beers criteria (49 of 68 studies), Zhan criteria (13 of 68 studies), 
STOPP criteria (9 of 68 studies), McLeod criteria/IPET (4 of 68 studies), and the MAI (4 
of 68 studies).  PIM prevalence was reported either as patient based rates i.e. percentage 
of individuals in the study population receiving PIMs (63 studies) or as visit-based 
prevalence rates i.e. percentage of visits involving the prescription of PIMs (5 studies). 
Ambulatory Settings 
Thirty-eight studies were found that determined prevalence of PIM use in older 
adults in ambulatory settings.  Potentially inappropriate medications were identified using 
Beers criteria (1991, 1997, and/or 2002 versions), Zhan criteria, McLeod criteria/IPET, 








Four studies were found that estimated PIM prevalence in ambulatory settings 
using the 1991 Beers criteria (Aparasu and Fliginger 1997; Aparasu and Sitzman 1999; 
Stuck, Beers et al. 1994; Willcox, Himmelstein et al., 1994).  Aparasu et al. estimated 
prevalence of PIMs prescribing by office-based physicians to persons aged 65 years or 
older using data from the 1992 National Ambulatory Care Survey (Aparasu and Fliginger 
1997).  They defined PIMs based on a subset of the 1991 Beers criteria consisting of 
drugs considered generally inappropriate in older adults.  They found 7.6 percent of 
individuals receiving prescriptions were prescribed PIMs.  The most frequently 
prescribed PIMs were propoxyphene, amitriptyline, dipyridamole, diazepam, and 
chlorporpamide.  
Stuck et al. determined prevalence of PIM use among 414 community-dwellers 
aged 75 years or older in Santa Monica, California (Stuck, Beers et al. 1994).  
Inappropriate medications were identified with a subset of the 1991 Beers criteria 
consisting of drugs considered generally inappropriate in older adults.  They found 14.0 
percent of individuals received at least one PIMs with such drug use  comprising 16.9 
percent of all reported prescription medications received.  The most common 
inappropriate drugs or drug classes were long-acting benzodiazepines, persantine, 
amitriptyline, and chlorpropamide.  
Willcox et al. determined prevalence of PIM use among 6,171 community 
residents aged 65 years or older using data from the 1987 National Medical Expenditure 
Survey (Willcox, Himmelstein et al. 1994).  Potentially inappropriate medications were 
identified based on a subset of 1991 Beers criteria consisting of drugs considered 
generally inappropriate in older adults.  They found 23.5 percent of individuals received 
at least one PIM, with 79.6 percent receiving only one PIM, 16.5 percent receiving 2 





frequently received PIMs were dipyridamole (6.4%), propranolol (6.3%), propoxyphene 
(4.8%), methyldopa (4.5%), and amitriptyline (3.1%). 
Aparasu et al. estimated prevalence of PIM use in outpatients aged 65 years or 
older based on a subset of the 1991 Beers criteria consisting of drugs considered 
generally inappropriate in older adults (Aparasu and Sitzman 1999).  They examined 
outpatient records from the 1994 National Hospital Ambulatory Medical Care Survey, 
and reported visit-based PIM prevalence rates.  They found approximately 4.5 percent of 
visits involving prescriptions, or 2.9 percent of total outpatient visits, were associated 
with receiving PIMs.  The most commonly prescribed PIMs were diazepam (0.8%), 
propoxyphene (0.7%), dipyridamole (0.4%), amitriptyline (0.3%), and chlordiazepoxide 
(0.3%). 
Nine studies were found that determined prevalence of PIM use in ambulatory 
settings based on the 1997 Beers criteria (Cannon, Choi et al., 2006; de Oliveira Martins, 
Soares et al., 2006; Fialova, Topinkova et al., 2005; Fick, Waller et al., 2001; Goulding 
2004; Howard, Dolovich et al., 2004; Rigler, Jachna et al., 2005; Stuart, Kamal-Bahl et 
al., 2003; Viswanathan, Bharmal et al. 2005).  Stuart et al. assessed prevalence of PIM 
use among community dwellers aged 65 years or older (Stuart, Kamal-Bahl et al. 2003).  
They analyzed data from the Medicare Current Beneficiary Survey data for 7,628 
individuals in the 1995 survey and 8,902 individuals in the 1999 survey.  Potentially 
inappropriate drugs were identified with a subset of the 1997 Beers criteria consisting of 
drugs considered generally inappropriate in older adults, with the exception of oral 
meperidine.  They found PIM use decreased from 24.8 percent in 1995 to 21.3 percent in 
1999.  A decrease in prevalence of PIMs associated with high severity adverse outcomes 
(from 11.8% in 1995 to 8.7% in 1999) accounted for most of the decrease in overall PIM 





in 1991 and 1999 and included propoxyphene, antihistamines, gastrointestinal 
antispasmodics, and amitriptyline.   
Goulding et al. examined trends in PIM prescribing at 22,031 ambulatory care 
visits by older adults using 1995 to 2000 data from the National Ambulatory Medical 
Care Survey, and National Hospital Ambulatory Medical Care Survey (Goulding 2004).  
Potentially inappropriate medications were defined based on a subset of the 1997 Beers 
criteria consisting of drugs considered generally inappropriate in older adults.  They 
found PIMs were prescribed at 7.8 percent of all ambulatory care visits.  The most 
frequently prescribed PIMs comprised 58.0 percent of all PIMs prescribed and included 
propoxyphene (1.5%), hydroxyzine (1.1%), diazepam (0.7%), amitriptyline (0.7%), and 
oxybutynin (0.7%).   
Viswanathan et al. determined prevalence of PIM use in an ambulatory population 
with subsets of 1997 and 2002 Beers criteria that consisted of drugs considered generally 
inappropriate in older adults (Viswanathan, Bharmal et al. 2005).  They examined 
ambulatory visits for 7,243 patients aged 65 years or older using data from the 2001 
National Ambulatory Medical Care Survey and National Hospital Ambulatory Medical 
Care Survey.  Visit-based PIM prevalence rates were reported.  They found PIMs 
identified with the 1997 Beers criteria were received in 8.8 percent of visits and PIMs 
identified with the 2002 Beers criteria were received in 13.4 percent of visits.  The most 
commonly prescribed PIMs based on 2002 Beers criteria were propoxyphene, doxazosin, 
amiodarone, nitrofurantion, and amitriptyline. 
Rigler et al. characterized patterns of PIM use among 858 Kansas Medicaid 
beneficiaries aged 60 years or older receiving home and community-based services, and 
among 1,163 beneficiaries not receiving such services, using pharmacy claims data from 
2000 to 2001 (Rigler, Jachna et al. 2005).  Potentially inappropriate medication were 





generally inappropriate in older adults.  Forty-eight percent of individuals receiving home 
and community-based services were found to use PIMs, whereas, 21.0 percent of 
individuals not receiving such services used PIMs.  The most common potentially 
inappropriate drug or drug classes among Medicaid beneficiaries receiving home and 
community-based services versus those not receiving such services were analgesics 
(23,4% vs. 8.7%), antihistamines (12.9% vs. 5.3%), antidepressants (11.1% vs. 5.4%) , 
muscle relaxants (6.3% vs. 4.4%), and oxybutynin (5.8% vs. 1.6%).   
Fialova et al. applied 1997 Beers criteria to determine prevalence of PIM use in 
2,707 patients aged 65 years of older receiving home care in metropolitan areas of eight 
European countries including the Czech Republic, Denmark, Finland, Iceland, Italy, the 
Netherlands, Norway, and the United Kingdom between September 2001 to January 2002 
(Fialova, Topinkova et al. 2005).  Potentially inappropriate medications were identified 
with a subset of the 1997 Beers criteria consisting of drugs considered generally 
inappropriate in older adults (excluding stimulant laxatives), and drugs considered 
inappropriate at doses or durations beyond specific limits.  They found PIM prevalence 
rates of 3.2 percent in Denmark, 5.9 percent in Iceland and the United Kingdom, 9.1 
percent in the Netherlands, 9.8 percent in Norway, 13.6 percent in Italy, 15.7 percent in 
the Czech Republic, and 17.1 percent in Finland.   
De Oliviera Martin et al. determined prevalence of PIM use among 213 
outpatients aged 65 years or older visiting 12 community pharmacies in Lisbon, Portugal 
between October 2002 and January 2003 (de Oliveira Martins, Soares et al. 2006).  They 
defined inappropriate medications with a subset of 1997 Beers criteria consisting of drugs 
considered generally inappropriate in older adults, and drugs considered inappropriate at 
doses or durations beyond specific limits.  They found a PIM prevalence of 27.7 percent, 
with approximately 78.0 percent of individuals receiving one PIM, 17.0 percent receiving 





most frequently received inappropriate medications accounting for 56.0 percent of 
inappropriate medications based on the 1997 Beers criteria 
Howard et al. determined prevalence of PIM use among 889 older adults visiting 
family physicians in Southern Ontario, Canada (Howard, Dolovich et al. 2004).  They 
identified PIMs using a modified subset of the 1997 Beers criteria consisting of drugs 
considered generally inappropriate in older adults, and drugs considered inappropriate at 
doses or durations beyond specific limits.  The Beers criteria was modified to include 
short-acting benzodiazepines of more than 30 days’ supply, and simultaneous 
prescription of more than one benzodiazepine or non-steroidal anti-inflammatory drug.  
The authors reported a PIM prevalence of 16.3 percent.  The most frequently prescribed 
inappropriate drugs or drug classes were short-acting benzodiazepines (6.4%), and 
oxybutynin (3.7%). 
Cannon et al. identified prevalence of PIM use among 786 Medicare beneficiaries 
aged 65 years or older receiving home health care after discharge from a Texas hospital 
(Cannon, Choi et al. 2006).  Potentially inappropriate medications were identified based a 
subset of the 1997 Beers criteria that consisted of drugs considered generally 
inappropriate in older adults.  Thirty-one percent of Medicare beneficiaries were 
identified as PIM users. 
Fick et al. determined the prevalence of PIM use in ambulatory Medicare 
managed care beneficiaries (Fick, Waller et al. 2001).  They reviewed 1997 to 1998 
claims data for 2,336 Medicare beneficiaries aged 65 years or older enrolled in a 
Southeastern health maintenance organization.  Potentially inappropriate medications 
were identified based on a subset of 1997 Beers criteria consisting of drugs considered 
generally inappropriate in older adults.  They found PIM prevalence of 24.2 percent for 





two or more PIMs.  The most frequently prescribed PIMs were propoxyphene (9.6%), 
amitriptyline (3.1%), cyclopenzaprine (2.1%), hyroxyzine (1.6%), and diazepam (1.5%).   
Twelve studies were found that determined PIM prevalence in ambulatory 
settings based on 2012 Beers criteria (Bao, Shao et al., 2012; Buck, Atreja et al., 2009; 
Chang, Chen et al., 2011; de Oliveira Martins, Soares et al. 2006; Fialova, Topinkova et 
al. 2005; Fick, Mion et al., 2008; Golden, Qiu et al., 2011; Lund, Carnahan et al., 2010; 
Ryan, O'Mahony et al., 2009; Skaar and O'Connor 2012; Thorpe, Thorpe et al., 2012; 
Woelfel, Patel et al., 2011).  Thorpe et al. determined the prevalence of PIM use in 
dementia patients and their informal caregivers using study data from a 6-site, 
randomized intervention study conducted from 1996 to 2001 (Thorpe, Thorpe et al. 
2012).  The authors identified PIM use with a subset of the 2002 Beers criteria consisting 
of drugs considered generally inappropriate in older adults.  The study sample comprised 
of 566 dyads of older patients with dementia and their caregivers.  Approximately 30.0 
percent of dementia patients and 39 percent of their caregivers were found to receive at 
least one PIM.  The most common inappropriate drugs or drug classes were 
antihistamines with anticholinergic effects (11.8%), oral estrogens (11.6%), muscle 
relaxant or antispasmodics (9.4%), fluoxetine (8.0%), and short-acting nifedipine (6.6%).  
The most common inappropriate drugs or drug classed received by caregivers of 
dementia patients were oral estrogens (34.9%), NSAIDs (8.6%), long-acting 
benzodiazepine (6.2%), and fluoxetine (5.5%). 
Bao et al. estimated prevalence of PIM use among 3,124 home health patients 
aged 65 years or older using data from the 2007 National Home and Hospice Care Survey  
(Bao, Shao et al. 2012).  They identified PIMs with a subset of the 2002 Beers criteria 
comprising of drugs considered generally inappropriate in older adults.  Potentially 
inappropriate medications were further categorized based on 2002 Beers criteria into 





with low-severity adverse outcomes.  Thirty percent of home care patients were found to 
receive PIMs with 26.0 percent of patients receiving PIMs associated with high-severity 
adverse outcomes and 18.0 percent receiving PIMs associated with low-severity adverse 
outcomes.  The most frequently used inappropriate drugs or drug classes were 
propoxyphene (9.0%), antiadrenergics (7.0%), and antihistamines (6.0%). 
Golden et al. assessed prevalence of PIM use in nursing home-eligible older 
adults enrolled in a Florida home and community-based Medicaid waiver program in 
2009 (Golden, Qiu et al. 2011).  They identified PIMs with a subset of the 2002 Beers 
criteria comprised of drugs considered generally inappropriate in older adults and 
associated with high severity adverse outcomes.  The study sample included 3,911 dually 
eligible Medicare and Medicaid beneficiaries, aged 65 years and older.  A total of 25.2 
percent of beneficiaries in the study sample were using PIMs.  The most commonly used 
potentially inappropriate drugs or drug classes among beneficiaries were 
diphenhydramine (10.3%), oxybutynin (3.5%), fluoxetine (3.2%), promethazine (2.5%), 
high doses of short-acting benzodiazepines (2.4%), and hydroxyzine (2.4%). 
Chang et al. determined prevalence of PIM use among 193 outpatients aged 65 
years or older visiting two hospitals in Taipei, Taiwan (Chang, Chen et al. 2011).  They 
identified PIMs based a subset of the 2002 Beers criteria consisting of medications 
considered generally inappropriate in older adults and associated with high severity 
adverse outcomes.  Fifty-five percent of outpatients were found to have received PIMs.  
The most commonly received PIMs were doxazocin (12.4%), alprazolam (7.8%), and 
dipyridamole (7.3%).   
Fialova et al. in their study of 2,707 patients aged 65 years or older receiving 
home care in eight European countries from September 2001 to January 2002 applied 
2002 Beers criteria to assess PIM prevalence (Fialova, Topinkova et al. 2005).  





consisting of drugs considered generally inappropriate in older adults with the exclusion 
of stimulant laxatives, and drugs considered inappropriate at doses or durations beyond 
specific limits.  The authors reported PIM prevalence rates of 5.8 percent in Denmark, 
13.1 percent in the Netherlands, 13.5 percent in the United Kingdom, 14.7 percent in 
Norway, 15.1 percent in Iceland, 20.3 percent in Finland, 25.2 percent in the Czech 
Republic, and 25.7 percent in Italy.   
Woelfel et al. determined prevalence of PIM use in ambulatory Medicare 
beneficiaries (Woelfel, Patel et al. 2011).  Prevalence rates were based on a subset of the 
2002 Beers criteria consisting of drugs considered generally inappropriate in older adults 
and drugs considered inappropriate at doses or durations beyond specific limits.  The 
authors analyzed 295 Medicare beneficiaries aged 65 years to 98 years attending nine 
community outreach events throughout central and northern California in 2008 and found 
a PIM prevalence rate of 18.3 percent.  The most common drug classes among PIMs 
received were benzodiazepines (27%), and antiarrhythmics (25.5%).  The most common 
PIMs among individuals receiving PIMs were alprazolam (17%), clonidine (15%), 
estrogen (15%), amiodarone (11%), digoxin (11%). 
Buck et al. examined prevalence of PIMs received at outpatient primary care 
clinics in Utah and Ohio using electronic health records (Buck, Atreja et al. 2009).  
Prescription claims for 37,247 patients from Utah primary care clinics and 24,004 
patients from Ohio primary care clinics were analyzed.  They identified PIMs with a 
subset of 2002 Beers criteria consisting of drugs considered generally inappropriate in 
older adults (excluding estrogens), and drugs considered inappropriate at doses or 
durations beyond specific limits.  The prevalence of PIMs was higher in patients 
receiving care from Utah primary care clinics (23.3%) than patients receiving care from 
Ohio primary care clinics (23.0%).  Receipt of PIMs associated with high-severity 





primary care clinics (15.8%, p<.001).  The most common high-severity PIMs in both 
Utah and Ohio patients were fluoxetine (4.1% vs. 1.5%), amitriptyline (2.4% vs. 1.7%), 
and promethazine (2.2% vs. 0.6%). 
Skarr et al. estimated prevalence of PIM use among older community dwellers 
visiting the dentist (Skaar and O'Connor 2012).  Potentially inappropriate medications 
were defined based on a subset of the 2002 Beers criteria that included drugs considered 
generally inappropriate in older adults and drugs considered inappropriate at doses or 
durations beyond specific limits.  They examined 2006 Medicare Current Beneficiary 
Survey data for continuously enrolled beneficiaries aged 65 years or older and found 34.4 
percent of beneficiaries received at least one PIM and 13.3 percent received two PIMs.  
The most commonly prescribed PIMs were estrogens (5.3%), digoxin (4.3%), naproxen 
(3.5%), alprazolam (3.3%), and lorazepam (3.3%).   
De Oliviera Martin et al. determined prevalence of inappropriate prescriptions 
among 213 outpatients aged 65 years or older visiting 12 community pharmacies in 
Lisbon, Portugal between October 2002 and January 2003 (de Oliveira Martins, Soares et 
al. 2006).  They defined inappropriate medications with a subset of 2002 Beers criteria 
consisting of drugs considered generally inappropriate in older adults and drugs 
considered inappropriate at doses or durations beyond specific limits.  The prevalence of 
PIM use based on the 2002 Beers criteria was 38.5 percent.  Approximately 70.0 percent 
of individuals received one inappropriate prescription, 23.2 percent received two 
inappropriate medications, and 6.8 percent received three inappropriate medications.  
Diazepam and ticlopidine were the most frequently received PIMs (36.8%). 
Fick et al. examined prevalence of PIM use among older community dwellers 
(Fick, Mion et al. 2008).  Potentially inappropriate medications were identified with a 
subset of the 2002 Beers criteria consisting of drugs considered generally inappropriate in 





limits.  A total of 17,971 individuals 65 years or older continuously enrolled in a large 
managed care organization in the Southeast United States from January 2000 to June 
2000 were included in the study sample.  The authors found 40.0 percent of individuals 
received at least one PIM, and 13.0 percent received 2 or more.  The most commonly 
received potentially inappropriate drugs or drug classes among individuals in the study 
population were estrogens (9.6%), propoxyphene (7.4%), short-acting benzodiazepines 
(7.4%), digoxin (4.7%), and NSAIDs (4.6%). 
Ryan et al. determined the rate of potentially inappropriate prescriptions in 
primary care practices in Ireland using 2002 Beers criteria (Ryan, O'Mahony et al. 2009).  
Potentially inappropriate prescriptions were defined based on all drugs in the 2002 Beers 
criteria.  They examined 1,329 patients 65 years or older prescribed at least one daily 
medication in three large general practices in County Cork, Ireland, between January 
2007 and July 2008 and found PIM prescriptions in 18.3 percent of patients.  The most 
commonly prescribed potentially inappropriate drugs or drug classes among all PIMs 
prescribed were long-acting benzodiazepines (31.8%), and doxazosin (30.1%). 
Lund et al. determined prevalence of inappropriate prescribing among 236 
veterans aged 65 years or older visiting primary care clinics at the Iowa City Veterans 
Affairs Medical Center (Lund, Carnahan et al. 2010).  The authors defined PIMs using all 
drugs in the 2002 Beers criteria and found 48.7 percent of veterans received a 
prescription for one or more PIMs. 
Zhan Criteria 
Nine studies were found that determined prevalence of PIM use in ambulatory 
settings based on Zhan criteria (Barnett, Perry et al., 2006; Buck, Atreja et al. 2009; 
Goulding 2004; Lane, Bronskill et al., 2004; Pugh, Fincke et al., 2005; Pugh, Rosen et al., 





2011).  Pugh et al. reported prevalence of PIM use in a sample of 850,154 veterans aged 
65 years or older, using national inpatient and outpatient administrative data from a 
national Veterans Affairs healthcare database (Pugh, Rosen et al. 2008).  The study 
sample comprised of individuals having with a minimum of one outpatient clinic visit in 
1999 or 2000, and receiving a prescription medication in 2000.  Potentially inappropriate 
medications were defined based on all medications and medication categories listed in 
Zhan criteria.  Approximately 26.2 percent of veterans were found to have received PIMs 
based on the Zhan criteria.   
Barnett et al. compared rates of PIM use between ambulatory veterans receiving 
care from the Veterans Affairs healthcare system and enrollees from private sector 
Medicare health maintenance organizations (Barnett, Perry et al. 2006).  They analyzed 
Veteran Affairs healthcare administrative claims from ten different regions in the US for 
123,633 veterans 65 years of age or older.  Potentially inappropriate medications were 
identified based on all 33 medications in the Zhan criteria.  The PIM prevalence rate for 
private sector patients was obtained from a prior study (Simon, Chan et al. 2005).  The 
authors found lower prevalence of PIM use in ambulatory veterans (21.3%) than private 
sector patients (29.0%).  Compared to private sector patients, ambulatory veterans had 
lower prevalence of PIM use for all categories of medications in the Zhan criteria 
including medications to always avoid (2.0% vs. 5%), medications that are rarely 
appropriate (8.0% vs. 13.0%), and medication with some indications (15% vs. 17%). 
Buck et al. compared prevalence of PIM use at ambulatory clinics in Utah and 
Ohio using 2006 data from hospital electronic health records (Buck, Atreja et al. 2009).  
They identified PIMs using all medications or medication categories listed in Zhan 
criteria.  The study population comprised of 61,251 patients aged 65 years or older with 
multiple clinic visits within the prior two years.  A total of 37,247 patients were from 





receiving care at ambulatory clinics in Utah had a lower prevalence of PIM prescriptions 
(16.2%) than those receiving care in Ohio (17.3%).  The receipt of PIMs classified in 
Zhan criteria as “always avoid” was more prevalent in Utah clinics (1.7%) than Ohio 
clinics.  Compared to persons receiving care from Ohio clinics, those receiving care from 
Utah clinics had a lower prevalence of PIMs classified as “always avoid” (1.7% vs. 
1.9%), and “rarely appropriate” (7.0% vs. 9.5%).  However, PIMs classified as having 
some indications were more prevalent in Utah clinics than Ohio clinics (9.2% vs. 7.7%).  
Fluoxetine and propoxyphene were the most commonly prescribed PIMs among patients 
receiving care from Utah and Ohio clinics.  
Pugh et al. determined extent of inappropriate prescribing among veterans aged 
65 years or older using national Veteran Affairs Claims data from October 1999 to 
September 2000 (Pugh, Fincke et al. 2005).  They identified inappropriate medications 
using all medications listed in Zhan criteria and dose-limitation criteria defined in the 
1997 Beers criteria.  They found 23 percent of individuals were prescribed at least one 
PIM based on Zhan criteria and dose-limited drugs.  Among individuals receiving PIMs, 
17.5 percent received two PIMs, while 4.4 percent received 3 or more PIMs.  The four 
most commonly received PIM drug classes comprised 61.0 percent of all PIM use and 
included pain relievers, musculoskeletal agents, antidepressants, and 
benzodiazepines/hypnotics. 
Zhang et al. compared prevalence of PIM use in older adults in 1996 and 2007 
using Medical Expenditure Panel Survey data (Zhang, Liu et al. 2011).  The study 
population comprised of community-dwelling adults aged 65 years or older.  They 
identified PIMs using all medications and medication categories listed in Zhan criteria.  
They found PIM rates decreased from 21.3 percent in 1996 to 13.8 percent in 2007.   
Zhan et al. applied Zhan criteria to determine prevalence of PIM use in 





Expenditure Panel Survey (Zhan, Sangl et al. 2001).  Potentially inappropriate 
medications were identified using all medications and medication categories in the Zhan 
criteria.  They found 21.3 percent of individuals received at least one PIM.  The most 
frequently received PIMs were propoxyphene and amitriptyline.  
Lane et al. applied a subset of Zhan criteria, consisting of medications classified 
as always avoid or rarely appropriate, to 2001 data from a Canadian provincial drug plan 
to examine patterns of PIM prescribing (Lane, Bronskill et al. 2004).  A total of 
1,216,900 community-dwelling adults aged 66 years and older were included in the study 
sample.  About 3.3 percent of individuals were found to have received PIMs and the most 
commonly dispensed PIMs were diazepam, flurazepam, chlordiazepoxide, and 
chlorpropamide.   
Viswanathan et al. determined PIM prevalence using 2001 data from the National 
Ambulatory Medical Care Survey and the National Hospital Ambulatory Medical Care 
Survey (Viswanathan, Bharmal et al. 2005).  The study sample consisted of 7,243 
ambulatory visits by individuals aged 65 years or more.  They applied the “always avoid” 
and “rarely appropriate” subset of medications listed in Zhan criteria and reported visit-
based PIM prevalence rates.  The authors found PIMs were prescribed in 4.2 percent of 
ambulatory visits.   
Goulding et al. examined trends in prevalence of PIM prescribing from 1995 to 
2000 in patients aged 65 years or older visiting office-based physicians using data from 
the National Ambulatory Care Survey (Goulding 2004).  Potentially inappropriate 
medications were identified using a subset of Zhan criteria that included medications 
classified as to always avoid or rarely appropriate.  The authors found of 3.7 percent of 
all visits in 1995 and 3.8 percent of visits in 2000 were associated with the prescription of 
PIMs.  The prevalence of PIM use in 1995 was not significantly different from the rate of 





McLeod Criteria/Improved Prescribing in the Elderly Tool 
Only one study was found that determined prevalence of PIM use in ambulatory 
settings based on McLeod Criteria (Fialova, Topinkova et al. 2005).  Fialova et al. 
estimated prevalence of PIM use among older adults receiving home care services in 
metropolitan areas of eleven European countries including the Czech Republic, Denmark, 
Finland, Iceland, Italy, the Netherlands, Norway, and the United Kingdom.  A subset of 
McLeod criteria was applied that consisted of medications considered inappropriate 
regardless of drug-drug and drug-disease limitations.  The study sample included 2,707 
patients aged 65 years or older.  The prevalence of PIM use based on McLeod criteria 
varied significantly across the countries examined.  Potentially inappropriate medication 
rates were found to be 3.0 percent in Denmark, 4.4 percent in Iceland, 5.2 percent in the 
United Kingdom, 6.8 percent in Italy, 7.6 percent in the Netherlands, 11.3 percent in 
Norway, 14.4 percent in Finland, and 31.8 percent in the Czech Republic.   
Screening Tool of Older Person’s potentially  
Inappropriate Prescriptions (STOPP) 
Two studies were found that determined PIM prevalence in ambulatory settings 
based on the Screening Tool of Older Person’s potentially Inappropriate Prescriptions or 
STOPP criteria (Bradley, Fahey et al., 2012; Ryan, O'Mahony et al. 2009).  Ryan et al. 
applied STOPP criteria to determine the prevalence of PIM prescriptions among 1329 
ambulatory patients aged 65 years of age or older in the United Kingdom (Ryan, 
O'Mahony et al. 2009).  Study data was obtained from case records for patients visiting 
two urban and one rural general practices in the Munster region of Ireland from 2007 to 
2008.  The authors reported that 21.4 percent of patients received PIMs.  The five most 
commonly prescribed PIM categories based on STOPP criteria among all PIMs 





for more than eight weeks (24.5%), long-term long-acting benzodiazepines (19.9%), 
NSAIDs in patients with hypertension (11.3%), duplicate drug classes (8.4%), and 
cardio-selective beta blockers in individuals with chronic obstructive pulmonary disease 
(6.3%).   
Bradley et al. estimated prevalence of PIM use in persons aged 70 years or older 
in Northern Ireland (Bradley, Fahey et al. 2012).  They applied STOPP criteria to July 
2009 to June 2010 United Kingdom National Health Service Enhanced Prescribing data 
and found 34 percent of the 166,108 individuals in the study population received PIMs.  
Approximately 24.0 percent of individuals received one PIM, 7.2 percent received two 
PIMs, and 2.8 percent received three or more PIMs.  The most frequently received PIMs 
among individuals in the study population were proton-pump inhibitors at maximum 
therapeutic dose for more than 8 weeks (10.8%), non-steroidal anti-inflammatory drugs 
for more than three months (8.8%), long-term long-acting benzodiazepines (6.1%), and 
first-generation antihistamines (3.6%).  
Medication Appropriateness Index  
Three studies were found that determined prevalence of PIM use in ambulatory 
settings based on the Medication Appropriateness Index or MAI (Castelino, Bajorek et 
al., 2010; Lund, Carnahan et al. 2010; Rossi, Young et al., 2007).  Lund et al. determined 
the prevalence of inappropriate prescribing in ambulatory patients aged 65 years or older 
based on all 10 criteria comprising the MAI (Lund, Carnahan et al. 2010).  The study 
population consisted of 231 veterans seen at primary care clinics at the Iowa City 
Veterans Affairs Medical Center.  They found that 98.7 percent of patients and 54.3 
percent of medications had inappropriate rating on at least one MAI criterion.  The 





(93.2%), cost (74.6%), dosage (72.0%), practical directions (51.7%), and duration of 
therapy (50.0%).   
Castelino et al. assessed appropriateness of prescribing in 270 cases from a 
collaborative service provided to community-dwelling older adults in Australia between 
February 2006 and October 2009 (Castelino, Bajorek et al. 2010).  Inappropriate 
prescriptions were identified with all 10 criteria in the MAI.  Prior to initiation of the 
collaborative service almost all (99.0%) individuals had at least one inappropriate rating 
on the MAI with 50.0 percent of individuals having a cumulative MAI score of 16 or 
more.   
Rossi et al. determined prevalence of unnecessary drug use among 128 
community-dwelling veterans aged 60 years or older visiting a Veterans Affairs primary 
care clinic in Pittsburgh (Rossi, Young et al. 2007).  Unnecessary drug use was defined 
with a subset of the MAI consisting of 3 specific questions on whether there was drug 
indication, whether medication was effective for specific condition, and whether 
unnecessary drug duplications were made.  The authors reported 58.6 percent of patients 
received one or more unnecessary prescriptions.  The most common reasons for 
unnecessary drug prescriptions were lack of effectiveness (41.4%), no indication 
(39.8%), and therapeutic duplication (8.6%).  The five most frequently prescribed 
unnecessary drug classes were drugs affecting the central nervous system (19.5%), 
gastrointestinal drugs (18.5%), vitamins (16.4%), nutrients/minerals/electrolytes (10.2%), 
and cardiac drugs (10.2%). 
Hospital Settings 
Thirteen studies were found that determined prevalence of PIM use among older 
adults in hospital settings (Barry, O'Keefe et al. 2006; Edwards, Harrison et al., 2003; 





2005; Hanlon, Artz et al., 2004; Lang, Hasso et al., 2010; Liu, Peng et al., 2012; Onder, 
Landi et al., 2005; Page and Ruscin 2006; Rothberg, Pekow et al., 2008; Vishwas, 
Harugeri et al., 2012; Wawruch, Zikavska et al., 2006).  Potentially inappropriate 
medications were identified based several criteria including Beers criteria (1997 and 2002 
versions), Zhan criteria, McLeod criteria/IPET, STOPP criteria, and MAI. 
Beers criteria 
Only one study was found that determined prevalence of PIM use in hospital 
settings based on the 1997 Beers criteria (Edwards, Harrison et al. 2003).  Edwards et al. 
applied all drugs in 1997 Beers criteria to examine PIM prescribing at two units of a 
tertiary care teaching hospital in North Carolina.  Study participants were 65 years of age 
or older and comprised of 176 patients from the hospital’s acute care of the elderly unit 
and 173 patients from the hospital’s general medicine service unit.  Potentially 
inappropriate medications were grouped according to potential associations with high or 
low severity adverse outcomes.  Prevalence rates for PIMs with high or low-severity 
outcomes in the acute care elderly unit were not significantly different from rates in the 
general medicine service unit.  Eleven percent of patients in the acute care of the elderly 
unit were prescribed PIMs with high-severity outcomes as compared to 12.7 percent of 
elderly patients in the general medicines unit.  Also, 33.5 percent of patients in the acute 
care elderly unit were prescribed PIMs with low-severity outcomes as compared to 30.1 
percent of patients in the general medicine service unit.  The most commonly prescribed 
PIMs associated with high-severity outcomes were long-acting benzodiazepines (28.0%), 
gastrointestinal antispasmodics (18.0%), ticlodipine (18.0%), and digoxin (18.0%) were 
the most common.  The most commonly prescribed PIMs associated with low-severity 
outcomes were iron at doses greater than 325 mg per day (31%), and anticholinergic 





There were seven studies found that determined PIM prevalence in hospital 
settings based on 2002 Beers criteria (Barry, O'Keefe et al. 2006; Gallagher and 
O'Mahony 2008; Onder, Landi et al. 2005; Page and Ruscin 2006; Rothberg, Pekow et al. 
2008; Vishwas, Harugeri et al. 2012; Wawruch, Zikavska et al. 2006).  Wawruch et al. 
compared the prevalence of PIM use at admission and discharge from a Slovak general 
hospital between December 2003 and March 2005 (Wawruch, Zikavska et al. 2006).  
They identified PIMs using all drugs in the 2002 Beers criteria.  A total of 600 patients 
aged 65 years and older were included in the study population.  They found no significant 
difference between PIM prevalence rates at hospital admission and discharge.  Overall, 
20.2 percent of patients received PIMs at admission compared to 20.0 percent of patients 
receiving PIMs at discharge.  The prevalence of PIM use for patients receiving one or 
two PIMs was similar at hospital admission and discharge.  Among patients receiving 
PIMs at hospital admission, 18.2 percent received one PIM and 2.0% received two PIMs.  
Among patients receiving PIMs at hospital discharge, 18.0% received one PIM and 2.0% 
received two PIMs.  The three most commonly prescribed PIM among patients at 
admission and discharge were the same and included digoxin (7.3% vs. 7.2%), ticlopidine 
(4.7% vs. 4.7%), and amiodarone (3.2% vs. 3.0%) 
Vishwas et al. determined the prevalence of PIM prescribing in 540 patients aged 
60 years or older, hospitalized between June 2009 and February 2010 in a tertiary care 
hospital in India (Vishwas, Harugeri et al. 2012).  Potentially inappropriate medications 
were identified using all drugs in the 2002 Beers criteria.  The reported PIM prevalence 
rate based on the 2002 Beers criteria was 24.6%.  The most frequently prescribed PIMs 
were mineral oil, diazepam, digoxin, dicycloverine and chlorpheniramine 
Gallagher et al. prospectively evaluated PIM use in a sample of 715 patients aged 
65 years or older admitted to a university teaching hospital in the United Kingdom over a 





all drugs in the 2002 Beers criteria and found a PIM prevalence rate of 25.0 percent.  The 
most frequently used potentially inappropriate drugs or drug classes were 
diphenhydramine, oxybutynin, fluoxetine, promethazine, and short-acting 
benzodiazepines.  
Barry et al. assessed the incidence of PIM prescribing among patients admitted to 
an geriatric medicine unit in Ireland (Barry, O'Keefe et al. 2006).  They identified PIMs 
using all drugs in 2002 Beers criteria.  The study population included 350 community-
dwelling patients 65 years of age or older consecutively admitted to the hospital for acute 
care between January and April 2003.  Thirty-four percent of patients were found to have 
received PIMs.   
Page et al. reviewed data for 389 patients aged 75 years or older admitted to two 
adult internal medicine units of a US university teaching hospital between 2000 and 2001 
(Page and Ruscin 2006).  They applied a subset of 2002 Beers criteria that consisted of 
drugs considered generally inappropriate in older adults (excluding estrogens and 
doxazosin), and drugs considered inappropriate beyond specific dose limits.  A total of 
27.5 percent of patients were found to have been prescribed PIMs.  The most common 
potentially inappropriate drugs or drug classes were amiodarone, oxybutin, 
anticholinergics/antihistamines, long-acting benzodiazepines, and propoxyphene.   
Onder et al. used a 2002 Beers criteria subset consisting of drugs considered 
generally inappropriate in older adults and drugs considered inappropriate at doses 
beyond specific limits, to identify PIM use in a sample of hospital patients in Italy 
(Onder, Landi et al. 2005).  They examined 5,152 patients aged 65 years or older 
admitted to hospitals between 1997 and 1998 and found 28.6 percent of patients received 
PIMs during their hospital stay.  The PIMs most commonly received by patients were 





Rothberg et al. applied a subset of the 2002 Beers criteria consisting of drugs 
considered generally inappropriate in older adults (excluding laxatives), and drugs 
considered inappropriate at doses or durations beyond specific limits, to determine rate of 
PIM prescribing in a large US inpatient sample (Rothberg, Pekow et al. 2008).  They 
examined medical records of 493,971 patients aged 65 years or more admitted to US 
hospitals between September 2002 and June 2005, and found 49 percent of patients 
received at least one PIM.  The most prevalent PIMs were promethazine, 
diphenhydramine, propoxyphene, clonidine, and amiodarone.  
Zhan Criteria 
One study was found that reported PIM prevalence in a hospital setting based on 
Zhan criteria (Finlayson, Maselli et al. 2011).  The authors determined PIM prevalence in 
older adults undergoing surgery using data from the 2006 to 2008 Perspective database.  
The study sample included 272,351 patients aged 65 years or older who underwent 
elective inpatient surgery.  Approximately 55.0 percent of patients were found to have 
received PIMs during their hospital admission.  One-quarter of patients received 
medications categorized in Zhan criteria as always avoid or rarely appropriate.  
Meperidine was the most commonly used PIM among medications categorized in Zhan 
criteria as always avoid.  Diazepam and cyclobenzaprine were the most commonly used 
PIMs among medications categorized in Zhan criteria as rarely appropriate.  
Diphenhydramine and promethazine were the most commonly used PIMs among 
medications categorized in Zhan criteria as having some indications.  
McLeod Criteria/Improved Prescribing in the Elderly Tool 
One study was found that used the Improved Prescribing in the Elderly Tool or 





hospitalized patients (Barry, O'Keefe et al. 2006).  Barry et al. applied IPET to 350 
patients aged 65 years or older admitted to an Irish geriatric medicine unit over a four-
month period from January 2003 to April 2003.  They reported a PIM prevalence rate of 
22 percent, with approximately 14.6 percent of patients receiving one PIM, 5.1 percent 
receiving two or more PIMs, and 2.3 percent receiving three or more PIMs.  The most 
frequently received inappropriate drugs or drug classes were benzodiazepines, chronic 
NSAID use in persons with osteoarthritis, and NSAID use in persons with a history of 
hypertension. 
Screening Tool of Older Person’s potentially  
Inappropriate Prescriptions (STOPP) 
Four studies were found that used the STOPP criteria to examine PIM prevalence 
in hospitalized older adults (Gallagher, Ryan et al. 2008; Lang, Hasso et al. 2010; Liu, 
Peng et al. 2012; Vishwas, Harugeri et al. 2012).  Vishwas et al. applied STOPP criteria 
to determine prevalence of PIM use in 540 patients aged 60 years or older hospitalized 
between June 2009 and February 2010 in a tertiary care hospital in India (Vishwas, 
Harugeri et al. 2012).  They reported a PIM prevalence of 13.3 percent.  The most 
frequently prescribed PIMs were glibenclamide in persons with type 2 diabetes mellitus, 
chlorpheniramine, and diazepam in persons prone to falls.   
Gallagher et al. determined prevalence of PIM use in 715 patients aged 65 years 
or older admitted to a university teaching hospital in the United Kingdom over a four-
month interval in 2007 (Gallagher and O'Mahony 2008).  The authors reported PIM 
prevalence of 35 percent based on STOPP criteria.  The most common PIMs were long-
term long-acting benzodiazepines, duplicate drugs, proton pump inhibitors for peptic 
ulcer disease at full dose more than 8 weeks, and NSAIDs in persons with moderate to 





Liu et al. applied STOPP criteria to evaluate the prevalence of PIM use among 
520 patients 65 years of age or older discharged from a Veterans general hospital in 
Taiwan (Liu, Peng et al. 2012).  They found 36.2 percent of patients received at least one 
PIM, twenty-six percent received only one PIM, 6.3 percent received two PIMs, 2.7 
percent received 3 PIMs, and 1.2 percent received 4 PIMs. 
Lang et al. used STOPP criteria to examine prevalence of PIM use in 150 older 
patients with cognitive and/or psychiatric comorbidities admitted to two geriatric units in 
Switzerland between January 2008 and December 2008 (Lang, Hasso et al. 2010).  
Seventy-seven percent of patients were found to have received PIMs.  The most 
frequently used PIMs were benzodiazepines and neuroleptics in persons prone to falls, 
anti-depressants in persons with depression, calcium and vitamin D supplements in 
persons with osteoporosis, and proton-pump inhibitors for peptic ulcer disease at full 
therapeutic dosage for more than eight weeks.  
Medication Appropriateness Index 
Two studies were found that determined PIM prevalence in hospital settings 
based on the Medication Appropriateness Index or MAI (Hajjar, Hanlon et al. 2005; 
Hanlon, Artz et al. 2004).  Hajjar et al. determined prevalence of unnecessary drug use at 
hospital discharge among 384 frail patients aged 65 years or older at medical or surgical 
wards of eleven US Veterans Affairs Medical Centers (Hajjar, Hanlon et al. 2005).  The 
authors applied a MAI subset consisting of three of ten MAI criteria including questions 
on indication, efficacy, and therapeutic duplication.  They found 44 percent of individuals 
received at least one unnecessary drug at discharge.  The most common reasons for 
unnecessary drug use were lack of indication, lack of efficiency, and therapeutic 





Hanlon et al. determined prevalence of inappropriate prescribing in hospitalized 
older veterans using all criteria included in the MAI (Hanlon, Artz et al. 2004).  They 
examined 397 veterans aged 65 years or older at medical or surgical wards of eleven US 
Veterans Affairs Medical Centers.  Approximately 92.0 percent of patients had one or 
more medications rated as inappropriate by one or more MAI criteria.  The most common 
reasons for inappropriate drug use were lack of cost-effectiveness, lack of practical 
directions, and inappropriate dosage.  
Nursing Home Settings 
 Eleven studies were found that determined PIM prevalence among older adult 
residents of nursing homes (Beers, Ouslander et al., 1992; Chen, Tangiisuran et al., 2012; 
Dedhiya, Hancock et al., 2010; Dhall, Larrat et al., 2002; Dhalla, Anderson et al., 2002; 
Garcia-Gollarte, Baleriola-Julvez et al., 2012; Lane, Bronskill et al. 2004; Lau, Kasper et 
al., 2004; Papaioannou, Bedard et al., 2002; Rigler, Jachna et al. 2005; Zuckerman, 
Hernandez et al., 2005).  Potentially inappropriate medications were identified based on 
several criteria including Beers criteria (1991, 1997, and 2002 versions), Zhan criteria, 
McLeod criteria, and STOPP criteria.   
Beers criteria 
Only one study was found that determined prevalence of PIM use in nursing 
home settings based on 1991 Beers criteria (Beers, Ouslander et al. 1992).  Beers et al. 
evaluated appropriateness of prescriptions among 1,106 nursing home residents in Los 
Angeles using the 1991 Beers criteria (Beers, Ouslander et al. 1992).   Receipt of all 
drugs comprising the 1991 Beers criteria was assessed.  They found 40.0 percent of 





Five studies were found that applied 1997 Beers criteria to determine prevalence 
of PIM use in nursing home settings (Dhall, Larrat et al. 2002; Dhalla, Anderson et al. 
2002; Lau, Kasper et al. 2004; Rigler, Jachna et al. 2005; Zuckerman, Hernandez et al. 
2005).  Lau et al. examined data from the Nursing Home Component of the 1996 Medical 
Expenditure Panel Survey to estimate prevalence of PIM prescriptions among 3,372 
nursing home residents aged 65 years or older (Lau, Kasper et al. 2004).  Potentially 
inappropriate medications were identified using all drugs in the 1997 Beers criteria.  
Among residents with a nursing home stay of 3 months or longer, 50.0 percent received 
at least one PIM.  The five most-commonly received PIMs were propoxyphene, 
diphendydramine, hydroxine, oxybutynin, and cyproheptadine. 
Dhall et al. used data from the Systematic Assessment of Geriatric Drug Use via 
Epidemiology database on 44,562 older adults admitted to nursing homes, to examine 
patterns of PIM use (Dhall, Larrat et al. 2002).  They applied a subset of 1997 Beers 
criteria consisting of drugs considered generally inappropriate in older adults and drugs 
considered inappropriate at doses or durations beyond specific limits.  Thirty-three 
percent of individuals were found to use PIMs at admission to nursing home.  The most 
frequently used PIMs were propoxyphene (10.1%), digoxin (>0.125 mg/day, 5.2%), iron 
supplements (ferrous sulphate >325 mg/day, 5.1%), amitriptyline (2.5%), and 
diphendydramine (2.5%).  Approximately 18.0 percent of individuals not using PIMs at 
admission received them after admission.  The most frequently initiated PIMs were 
propoxyphene (5.1%), diphenhydramine (2.3%), hydroxyzine (1.6%), amitriptyline 
(1.4%), and digoxin (1.5%).   
Dhalla et al. used a subset of the 1997 Beers criteria to compare prevalence of 
PIM prescribing before and after admission to nursing homes in Ontario, Canada (Dhalla, 
Anderson et al. 2002).  The subset of 1997 Beers criteria consisted of medications 





individuals aged 65 years or older recently admitted to nursing homes in Ontario between 
April 1997 and March 1999.  The authors found prevalence of PIM use decreased from 
25.4 percent before nursing home admission to 20.8 percent after nursing home 
admission.  The most frequently received potentially inappropriate drugs or drug classes 
were benzodiazepines (7.7%), antidepressants (7.4%), oxybutynin (5.4%), platelet 
inhibitors (2.9%), and narcotics (2.3%) in the one year before nursing home admission, 
and antidepressants (6.4%), benzodiazepines (5.9%), oxybutynin (5.3%), platelet 
inhibitors (2.8%), and NSAIDs (1.5%) in the one year after admission.   
Zukerman et al. applied a subset of 1997 Beers criteria to compare prevalence of 
PIM prescribing before and after nursing home admission in residents with and without 
dementia (Zuckerman, Hernandez et al. 2005).  The subset of 1997 Beers criteria 
consisted of medications considered generally inappropriate in older adults.  The study 
population consisted of 546 dually eligible Medicaid and Medicare residents aged 65 
years or older and admitted one of 59 nursing homes in Maryland between 1992 and 
1995.  Among nursing home residents without dementia, the mean monthly prevalence of 
PIM use increased from 20 percent before nursing home admission to 28 percent after 
admission.  Among residents with dementia, mean monthly prevalence of PIM use 
decreased from 23 percent before nursing home admission to 19 percent after admission.  
The likelihood of receiving PIMs in residents with and without dementia was not 
significantly different before and after nursing home admission.   
Rigler et al. identified PIM use in a sample of 1,164 Kansas Medicaid 
beneficiaries aged 60 years or older and resident in nursing homes, using a subset of 1997 
Beers criteria consisting of drugs considered generally inappropriate in older adults 
(Rigler, Jachna et al. 2005).  Thirty-eight percent of individuals in the study sample were 
found to have received PIMs.  The most commonly used inappropriate drug classes were 





Only one study was found that determined estimates of PIM use in nursing home 
settings based on 2002 Beers criteria (Dedhiya, Hancock et al. 2010).  Dedhiya et al. 
applied 2002 Beers criteria to determine one-year incidence of PIM use among 7,594 
nursing home residents 65 years of age or older enrolled in Indiana Medicaid in 2003.  
Potentially inappropriate medications were identified using all drugs in the 2002 Beers 
criteria.  The one-year incidence of PIM use was found to be 42.1 percent.  
Zhan Criteria 
Only one study was found that determined prevalence of PIM use in nursing 
home settings based on Zhan criteria (Lane, Bronskill et al. 2004).  Lane et al. applied a 
subset of Zhan criteria consisting of medications classified as always avoid and rarely 
appropriate, to determine PIM prevalence in 58,719 nursing home residents aged 66 years 
or older receiving drugs from a Canadian provincial drug plan in 2001.  The authors 
found 2.3 percent of nursing home residents were received PIMs.  More specifically, 0.8 
percent of nursing home residents received at least one PIM in the always avoid category, 
and 1.5 percent received at least one PIM in the rarely appropriate category.  The most 
commonly received PIMs were diazepam (1.23%), Flurazepam (0.58%), and 
chlordiazepoxide (0.25%). 
McLeod Criteria/Improved Prescribing in the Elderly Tool 
Only one study was found that determined prevalence of PIM use in nursing 
home settings based on McLeod criteria (Papaioannou, Bedard et al. 2002).  Papaioannou 
et al. applied McLeod criteria to identify PIM prevalence using prescription data from a 
single pharmacy serving long-term facilities in Ontario, Canada.  Because disease 
diagnosis could not be identified from the prescription data, drug prescriptions specific to 





interactions” category of McLeod criteria.  The disease conditions were chronic 
obstructive pulmonary disease, gout, glaucoma, benign prostrate hyperplasia, heart 
failure, hypertension, peptic ulcer disease, and osteoarthritis.  The authors examined 356 
older long-term care residents receiving prescriptions in November 2000 and found a 
PIM prevalence rate of 14.9 percent.  Among PIM recipients, 37.7 percent received two 
PIMs and 15.1 percent received three or more PIMs.  The most commonly received PIM 
prescriptions were long-term NSAID for osteoarthritis (21.7%), tricyclic antidepressants 
with active metabolites for depression (20.5), and long-term NSAIDs in patients with a 
history of heart failure or hypertension (15.7%). 
Screening Tool of Older Person’s potentially  
Inappropriate Prescriptions (STOPP) 
Two studies were found that examined PIM prevalence in nursing home settings 
based on STOPP criteria (Chen, Tangiisuran et al. 2012; Garcia-Gollarte, Baleriola-
Julvez et al. 2012).  Chen et al. applied STOPP criteria to determine PIM prevalence in 
211 older residents of  four nursing homes in Malaysia over a 2 month period in 2011 
(Chen, Tangiisuran et al. 2012).  They found 23.7 percent of individuals were prescribed 
at least one PIM, and 5.2 percent prescribed 2 or more PIMs.  The most common PIMs 
prescriptions were for first generation antihistamines in individuals with a history of falls 
(23.4%), duplicate drugs (15.6%), glibenclamide or chlorpropamide in individuals with 
type II diabetes (10.9%), anticholinergics to treat extrapyramidal side-effects of 
neuroleptic medications (9.4%).   
Garcia-Gollarte et al. used STOPP criteria to determine prevalence of PIM use in 
100 patients more than 65 years of age admitted to six assisted living nursing facilities in 
Valencia, Spain in 2008 (Garcia-Gollarte, Baleriola-Julvez et al. 2012).  Seventy-nine 





percent received 2 or more PIMs.  The most frequently prescribed PIMs were proton-
pump inhibitors for peptic ulcer disease at full therapeutic dosage for more than 8 weeks 
(52%), benzodiazepines in persons prone to falls (36%), neuroleptic drugs in persons 
prone to falls (26%), long-term neuroleptics as long term hypnotics (23%), and long-term 
long-acting benzodiazepines and benzodiazepines with long-term metabolites (13%). 
Residential Care/Assisted Living Settings 
Five studies were found that determined prevalence of PIM use among older 
adults living in residential care/assisted living facilities (Gray, Hedrick et al., 2003; 
Parsons, Johnston et al., 2012; Rhoads and Thai 2003; Sloane, Zimmerman et al., 2002; 
Stafford, Alswayan et al., 2011).  The studies identified PIMs using several criteria 
including Beers criteria (1997 and 2002 versions), McLeod criteria, and STOPP criteria. 
Beers criteria 
Three studies were found that examined PIM prevalence in residential care or 
assisted living settings using 1997 Beers criteria (Gray, Hedrick et al. 2003; Rhoads and 
Thai 2003; Sloane, Zimmerman et al. 2002).  Sloane et al. applied a subset of 1997 Beers 
criteria to examine PIM use in 2,014 residential care/assisted living residents aged 65 
years and older from 193 facilities in four US states (Sloane, Zimmerman et al. 2002).  
The Beers criteria subset consisted of medications considered generally inappropriate in 
older adults, with the exception of flecainide, phenylbutazone, cyclandelate, haloperidol, 
thioridazine, non-sedating antihistamines, oral iron preparations, digoxin, short-acting 
benzodiazepines, and trazodone.  About 16 percent of individuals received PIMs with the 
most frequently received PIMs including oxybutin (16,8%), propoxyphene (15.2%), 





Rhoads et al. examined medication profiles of 456 residents aged 65 years or 
older living in 124 US assisted living facilities (Rhoads and Thai 2003).  The authors 
defined PIMs using a subset of the 1997 Beers criteria consisting of medications 
considered generally inappropriate in older adults and drugs considered inappropriate at 
doses or durations beyond specified limits.  They found 31.6 percent of residents received 
PIMs.  The most frequently received PIMs were oxybutin (19.6%), diphenhydramine 
(15.2%), propoxyphene (10.8%), and promethazine (7.4%). 
Gray et al. applied a modified subset of 1997 Beers criteria to determine PIM 
prevalence and incidence in community residential care facilities (Gray, Hedrick et al. 
2003).  The study population comprised of 282 Medicaid recipients aged 65 years or 
older admitted to a community residential facility in Washington State between April 
1998 and December 1998.  The criteria which consisted of medications considered 
generally inappropriate in older adults (excluding digoxin), and drugs considered 
inappropriate at doses or durations beyond specified limits, was modified to include 
clonazepam, clorazepate, and prazepam.  The prevalence of PIM use was found to be 
22.0 percent at baseline and 43.7 percent during the follow-up period.  The most 
commonly received inappropriate drug classes at baseline were tricyclic antidepressants 
(6.0%), antihistamines (5.3%), urinary antispasmodics (3.5%), and long-acting 
benzodiazepines (3.5%).  The most commonly received inappropriate drug classes during 
the one-year follow up period were antihistamines (15.9%), tricyclic antidepressants 
(9.0%), analgesics (9.0%), and urinary antispasmodics (6.9%).  The incidence of new-use 
of PIMs within the follow up period was 23.4 percent.  
Only one study was found that determined PIM prevalence in residential care or 
assisted living settings using 2002 Beers criteria (Stafford, Alswayan et al. 2011).  
Stafford et al. applied 2002 Beers criteria to determine prevalence of inappropriate 





care homes in Tasmania, Australia between 2006 and 2007.  They found 35.3 percent of 
care home residents received at least one PIM.  The most commonly received PIMs were 
temazepam (30.6%), amitriptyline (16.3%), oxybutynin (11.7%), and estradiol (8.7%). 
McLeod Criteria/Improved Prescribing in the Elderly Tool 
Only one study determined prevalence of PIM use in residential care or assisted 
living settings based on McLeod criteria (Stafford, Alswayan et al. 2011).  In their study 
on older adults living in residential care homes in Tasmania, Australia between 2006 and 
2007, Stafford et al. applied McLeod criteria to determine prevalence of inappropriate 
prescribing and found a PIM prevalence of 18.7 percent.  The most commonly received 
PIMs were dipyridamole in individuals with stroke or cerebrovascular accident (11.9%), 
celecoxib in individuals with hypertension (7.3%), diazepam in individuals with dementia 
(7.1%), celecoxib in individuals with osteoarthrosis (6.8%), and oxybutynin in 
individuals with dementia (6.6%). 
Screening Tool of Older Person’s potentially  
Inappropriate Prescriptions (STOPP) 
One study examined prevalence of PIM use in residential care settings using 
STOPP criteria (Parsons, Johnston et al. 2012).  Parsons et al. applied STOPP criteria to 
estimate prevalence of inappropriate prescribing in 133 older adults with dementia living 
in six residential care homes in England in 2011.  A subset of STOPP criteria was used 
consisting of 31 inappropriate medications identifiable in absence of concomitant disease 
diagnosis.  The prevalence of inappropriate prescribing was determined at two time-
points sixteen weeks apart.  At the first time-point, 46.2 percent of individuals were 
prescribed PIMs, and 9.2 percent prescribed two or more PIMs.  At the second time-





or more PIMs.  The most frequently used PIMs were the same at both time points and 
included long term neuroleptics (21.0% versus 19.1%), proton-pump inhibitors at 
maximum therapeutic dosage for more than 8 weeks (8.4% versus 9.1%), and long-term 
use of NSAID for pain relief (9.2% versus 7.3%). 
Emergency Department Settings 
Five studies were found that assessed PIM prevalence in emergency department 
patients (Chen, Hwang et al., 2009; Hustey, Wallis et al., 2007; Meurer, Potti et al., 2010; 
Nixdorff, Hustey et al., 2008).  Potentially inappropriate medications were defined based 
on 1997 or 2002 Beers criteria. 
Beers criteria 
One study determined prevalence of PIM use in emergency department settings 
based on 1997 Beers criteria (Chin, Wang et al., 1999).  Chin et al. determined the 
frequency of PIM prescriptions in 898 patients 65 years of age or older visiting an urban 
academic emergency department in Chicago from October 1995 to June 1996.  They 
identified PIMs with a subset of the 1997 Beers criteria that consisted of medications 
generally considered inappropriate in older adults, medications considered inappropriate 
beyond specific duration limits, and medications considered inappropriate in individuals 
with specific concomitant conditions.  The prevalence of PIM use was assessed at three 
time points including at presentation to emergency department, during emergency 
department care, and at discharge from emergency department.  The authors found PIM 
prevalence was 10.6 percent at presentation to emergency department, 3.6 percent during 
emergency department care, and 5.6 percent at discharge from emergency department.  
The most commonly received PIMs during emergency department care were 





cyclobenzaprine (14.2%).  The most commonly received PIMs at discharge from 
emergency department were indomethacin (30.4%), diphenhydramine (26.0%), and 
cyclobenzaprine (13.0%).   
Four studies determined prevalence of PIM use in emergency department settings 
using the 2002 Beers criteria (Chen, Hwang et al. 2009; Hustey 2008; Meurer, Potti et al. 
2010; Nixdorff, Hustey et al. 2008).  Chen et al. assessed PIM use with a subset of 2002 
Beers criteria consisting of drugs considered generally inappropriate in older adults and 
associated with high severity adverse outcomes (Chen, Hwang et al. 2009).  They 
examined 2001 to 2004 emergency department claims for older adults covered under 
Taiwan’s National Health Insurance.  They found 19.3 percent of patients visiting 
emergency departments received at least one PIM annually, and 14.7 percent of all 
emergency department visits were associated with PIM prescriptions.  The most 
commonly prescribed inappropriate drugs or drug categories were short acting nifedipine 
(5.3%), muscle relaxants and antispasmodics (2.8%), antihistamines with anticholinergic 
effect (1.9%), ketorolac (1.8%), and gastrointestinal antispasmodic drugs (1.4%).   
Meurer et al. applied a 2002 Beers criteria subset consisting of drugs considered 
generally inappropriate in older adults to examine emergency department visits of 
discharged older adults using data from the 2000 to 2006 National Hospital Ambulatory 
Medical Care Survey (Meurer, Potti et al. 2010).  The authors found 16.8 percent of visits 
were associated PIM prescriptions.  Patients received one PIM in 13.3% of emergency 
department visits, two PIMs in 3.0% of such visits, three PIMs in 0.5% of such visits, and 
four PIMs in 0.04% of such visits.  The most frequently received PIMs were 
promethazine (5.1%), ketorolac (3.2%), propoxyphene (2.6%), meperidine (2.4%), and 
diphenhydramine (1.2%). 
Nixdorff et al. applied 2002 Beers criteria to examine PIM prevalence in 174 





(Nixdorff, Hustey et al. 2008).  They found 29 percent of patients used PIMs at 
presentation to the emergency department, 6.5 percent of patients received PIMs during 
emergency department care, and 13 percent of patients prescribed medications at 
discharge received PIMs.  The most frequently prescribed PIMs were propoxyphene, 
diphenhydramine, clonidine, naproxen, and doxazosin.  
Hustey et al. determined prevalence of PIM use in 352 consecutive emergency 
department visits by older adults at an urban teaching hospital during a two-week period 
in June 2004 (Hustey, Wallis et al. 2007).  Inappropriate medications were identified with 
the 2002 Beers criteria.  Thirty-two percent of patients were using PIMs upon 
presentation at the emergency department with the most common inappropriate drugs or 
drug classes including propoxyphene (7%), muscle relaxants (4%), antihistamines (3%), 
and amiodarone (3%).  Thirteen percent of patients receiving a prescription at discharge 
from the emergency department were prescribed PIMs.  
Unspecified Care Settings  
Four studies were found that determined prevalence of PIM use among older 
adults without indicating setting of care (Akazawa, Imai et al. 2010; Fahlman, Lynn et al. 
2007; Mort and Sailor 2011; Simon, Chan et al. 2005).  The patient populations included 
managed care beneficiaries (Fahlman, Lynn et al. 2007; Simon, Chan et al. 2005), 
Medicare Part D beneficiaries (Mort and Sailor 2011), and beneficiaries from an 
employer’s health insurance plan (Akazawa, Imai et al. 2010).  Potentially inappropriate 
medications were identified using 2002 Beers criteria (Akazawa, Imai et al. 2010; Mort 








Akazawa et al. applied a modified subset of 2002 Beers criteria to determine PIM 
use among Japanese patients aged 65 years or older (Akazawa, Imai et al. 2010).  The 
modified Beers criteria subset consisted of drugs that should generally be avoided in 
older Japanese patients.  Health insurance claims data from 2006 to 2007 were examined 
for 6,628 patients receiving at least two pharmacy claims in separate months.  The 
prevalence of PIM use in the study population was 43.6 percent with the most commonly 
prescribed inappropriate drug classes including histamine blockers (20.5%), 
benzodiazepines (11.4%), and anticholinergics and antihistamines (7.9%).  
Mort and Ryan compared the prevalence of PIM use between American Indians 
and all other Medicare Part D beneficiaries in South Dakota using Medicare Part D 
claims data from April 2009 to September 2009 (Mort and Sailor 2011).  They used a 
subset of the 2002 Beers criteria comprising of 18 PIMs selected by the Center for 
Medicaid and Medicare Services.  The prevalence of PIM use was over two times higher 
in American Indian Medicare Part D beneficiaries (28.7%) than in other Medicare Part D 
beneficiaries (14.4%).  The PIMs most frequently received by American Indian Medicare 
beneficiaries were skeletal muscle relaxants (37.9%), propoxyphene (33.7%), 
antihistamines (19.3%), nitrofurantoin (16.1%), and ketorolac (6.6%).  The PIMs most 
frequently received by other Medicare beneficiaries were propoxyphene (43.7%), 
nitrofurantoin (19.4%), skeletal muscle relaxants (18.6%), oral estrogens (13.4%), 
antihistamines (7.9%). 
Zhan Criteria 
Simon et al. applied Zhan criteria to determine prevalence of PIM use in 157, 517 
managed care enrollees aged 65 years or older, using 2001 to 2002 data from managed 





received PIMs.  The most commonly prescribed PIMs included propoxyphene (7.0%), 
amitriptyline (3.7%), oxybutynin (3.4%), cyclobenzaprine (2.9%), diazepam (2.8%), and 
promethazine (2.8%). 
Fahlman et al. applied Zhan criteria to examine PIM use in 4,602 Medicare plus 
Choice beneficiaries in their last year of life, using January 1998 to December 2000 data 
from a large national managed care organization (Fahlman, Lynn et al. 2007).  Forty-four 
percent of beneficiaries received at least one PIM and 15 percent received two or more 
PIMs.  The most frequently received PIMs were propoxyphene (15%), zolpiderm (3.8%), 
and amitriptyline (2.8%). 
Summary 
Sixty-eight studies were found that reported PIM prevalence rates among older 
adults, with reported rates varying from 2.3 percent to 99.0 percent according to the 
specific criteria used to identify PIMs, whether all elements of these criteria or subsets 
were applied, the setting care was received in, and how PIM prevalence rates were 
calculated.  Higher rates were reported in studies identifying PIMs with the MAI 
followed by studies identifying PIMs with STOPP or Beers criteria.  Higher PIM rates 
were reported in studies identifying PIMs using all drugs or drug classes in the Beers 
criteria, Zhan criteria, McLeod criteria, STOPP criteria, or the MAI relative to studies 
identifying PIMs with subsets of these criteria.  Higher PIM rates were reported in studies 
on ambulatory populations relative to studies on hospital, nursing home, residential 
care/assisted living, or emergency department populations.  Studies reporting patient-
based PIM prevalence had higher rates than those reporting visit-based PIM prevalence.   
The studies using Beers criteria to identify PIMs applied 1991, 1997, or 2002 





among older adults using the 2012 Beers criteria which is the most current version of the 
Beers criteria.  
Risk Factors for PIM Use 
 Forty-four studies were found that examined patient, health-system, and provider 
risk-factors for PIM use in older adults.  The studies and findings are described below.  
Patient  
 Patient factors examined for associations with PIM use in older adults include 
age, gender, race, education, polypharmacy, number of comorbid conditions, mental 
comorbidity, self-reported health status, functional status, and number of physician visits.   
Age 
 Studies examining associations between age and PIM use report mixed findings.  
Of nineteen studies found examining such associations, advancing age was associated 
with higher risk for PIM use in six studies (Cahir, Fahey et al., 2010; Lin, Liao et al., 
2008; Liu, Peng et al. 2012; Maio, Del Canale et al., 2010; Mort and Aparasu 2000; 
Wawruch, Fialova et al., 2008), advancing age was associated with lower risk of PIM use 
in seven studies (Chen, Hwang et al. 2009; Dhalla, Anderson et al. 2002; Finlayson, 
Maselli et al. 2011; Goulding 2004; Lau, Kasper et al. 2004; Meurer, Potti et al. 2010; 
Rothberg, Pekow et al. 2008), and no associations were found between advancing age 
and PIM use in six studies (Akazawa, Imai et al. 2010; Hajjar, Hanlon et al. 2005; 
Howard, Dolovich et al. 2004; Parsons, Johnston et al. 2012; Skaar and O'Connor 2012; 







 The findings on associations between gender and PIM use in older adults are 
mixed.  Of twenty-two studies examining such associations, females were found to be at 
higher risk for PIM use than men in sixteen studies (Buck, Atreja et al. 2009; Cahir, 
Fahey et al. 2010; Chen, Hwang et al. 2009; Dhall, Larrat et al. 2002; Fahlman, Lynn et 
al. 2007; Finlayson, Maselli et al. 2011; Goulding 2004; Howard, Dolovich et al. 2004; 
Lin, Liao et al. 2008; Maio, Del Canale et al. 2010; Meurer, Potti et al. 2010; Pugh, 
Fincke et al. 2005; Rothberg, Pekow et al. 2008; Skaar and O'Connor 2012; Zhan, Sangl 
et al. 2001; Zhang, Liu et al. 2011), and gender was not associated with PIM use in six 
studies (Akazawa, Imai et al. 2010; Chen, Tangiisuran et al. 2012; Hajjar, Hanlon et al. 
2005; Parsons, Johnston et al. 2012; Stuck, Beers et al. 1994; Wawruch, Fialova et al. 
2008).  
Ethnicity 
 The findings on associations between ethnicity and PIM use in older adults are 
mixed.  Of nine studies examining such associations, whites were found to be at higher 
risk for PIM use than non-whites in three studies (Fahlman, Lynn et al. 2007; Finlayson, 
Maselli et al. 2011; Rothberg, Pekow et al. 2008), Hispanics were found to be at higher 
risk for PIM use than non-Hispanics in one study (Pugh, Fincke et al. 2005) and race was 
not associated with PIM use in five studies (Goulding 2004; Hajjar, Hanlon et al. 2005; 
Meurer, Potti et al. 2010; Skaar and O'Connor 2012; Zhan, Sangl et al. 2001). 
Education 
 Studies examining associations between education and PIM use in older adults 
report mixed findings.  Of five studies that examined such associations, less education 





2004; Skaar and O'Connor 2012), while education was not associated PIM use in three 
studies (Hajjar, Hanlon et al. 2005; Howard, Dolovich et al. 2004; Zhan, Sangl et al. 
2001). 
Income 
 Three studies were found that examined associations between income and PIM 
use in older adults and they report mixed findings (Skaar and O'Connor 2012; Stuck, 
Beers et al. 1994; Zhang, Liu et al. 2011).  Skaar et al. found associations between 
belonging to a lower income bracket and higher risk for PIM use.  Zhang et al. found 
associations between belonging to a middle income bracket and higher risk for PIM use.  
Stuck et al. found no associations between income and PIM use.  
Polypharmacy 
 Polypharmacy in older adults was associated with higher risk for PIM use in all 
twenty-nine studies found that examined such associations (Akazawa, Imai et al. 2010; 
Aparasu and Mort 2000; Aparasu and Sitzman 1999; Bao, Shao et al. 2012; Bradley, 
Fahey et al. 2012; Buck, Atreja et al. 2009; Cahir, Fahey et al. 2010; Chen, Tangiisuran et 
al. 2012; Chen, Hwang et al. 2009; Dhall, Larrat et al. 2002; Gallagher, Lang et al., 2011; 
Goulding 2004; Gray, Hedrick et al. 2003; Hajjar, Hanlon et al. 2005; Hanlon, Artz et al. 
2004; Lang, Hasso et al. 2010; Lau, Kasper et al. 2004; Lau, Mercaldo et al., 2010; Lin, 
Liao et al. 2008; Liu, Peng et al. 2012; Maio, Del Canale et al. 2010; Meurer, Potti et al. 
2010; Parsons, Johnston et al. 2012; Pugh, Fincke et al. 2005; Sloane, Zimmerman et al. 
2002; Stafford, Alswayan et al. 2011; Wawruch, Fialova et al. 2008; Zhan, Sangl et al. 






Number of Comorbid Conditions 
 There were mixed findings from studies examining associations between number 
of comorbid conditions and PIM use in older adults.  Of nine studies examining such 
associations, having more comorbid conditions was associated with higher risk for PIM 
use in six studies (Hanlon, Artz et al. 2004; Lin, Liao et al. 2008; Maio, Del Canale et al. 
2010; Rigler, Perera et al., 2004; Skaar and O'Connor 2012; Stafford, Alswayan et al. 
2011).  The number of comorbid conditions was not associated with PIM use in three 
studies (Chen, Tangiisuran et al. 2012; Hajjar, Hanlon et al. 2005; Stuck, Beers et al. 
1994). 
Mental Status 
 Eleven studies were found that examined associations between mental status and 
PIM use in older adults.  Five studies specifically examined associations between 
depression diagnosis and PIM use and found individuals with depression had higher risk 
for PIM use (Akazawa, Imai et al. 2010; Aparasu and Sitzman 1999; Finlayson, Maselli 
et al. 2011; Stuck, Beers et al. 1994; Wawruch, Fialova et al. 2008).  Two studies 
examined associations between psychiatric comorbidity and PIM use and found 
individuals with psychiatric comorbidities had higher risk for PIM use (Pugh, Fincke et 
al. 2005; Stafford, Alswayan et al. 2011).  Four studies specifically examined 
associations between cognitive impairment and PIM use in older adults and they reported 
mixed findings (Dhall, Larrat et al. 2002; Gray, Hedrick et al. 2003; Lang, Hasso et al. 
2010; Sloane, Zimmerman et al. 2002).  Cognitive impairment was associated with 
higher risk for PIM use in the study by Lang et al., but associated with lower risk for PIM 
use in the studies by Dhall et al. and Sloane et al.  The study by Gray et al. found no 





Self-Reported Health Status 
 The findings on associations between older adults’ self-reported health status and 
PIM use in older adults are mixed.  Of seven studies assessing such associations, a lower 
health status rating was associated with higher risk for PIM use in five studies (Gray, 
Hedrick et al. 2003; Hanlon, Artz et al. 2004; Skaar and O'Connor 2012; Zhan, Sangl et 
al. 2001; Zhang, Liu et al. 2011), and health status was not associated with PIM use in 
two studies (Hajjar, Hanlon et al. 2005; Howard, Dolovich et al. 2004).  
Functional Status 
 Four studies were found that assessed associations between functional status and 
PIM use in older adults and they report mixed findings (Dhall, Larrat et al. 2002; Hajjar, 
Hanlon et al. 2005; Stuck, Beers et al. 1994; Wawruch, Fialova et al. 2008).  The studies 
by Dhall et al. and Wawruch et al. found associations between lower functional status and 
PIM use, but studies by Hajjar et al. and Stuck et al. found no such associations. 
Number of Care Visits 
 Two studies were found that examined associations between number of care visits 
by older adults and PIM use (Buck, Atreja et al. 2009; Pugh, Fincke et al. 2005).  Both 
studies found associations between higher number of care visits and higher risk for PIM 
use.  
Health-System 
 Health-system factors that have been assessed for associations with PIM use in 







 Studies examining associations between geographic location and PIM use in older 
adults report mixed findings.  Five studies found a lower risk for PIM use in individuals 
receiving care in the US northeast region as compared to those receiving care in other US 
regions (Finlayson, Maselli et al. 2011; Meurer, Potti et al. 2010; Mort and Aparasu 
2000; Rothberg, Pekow et al. 2008; Zhang, Liu et al. 2011).  One study found a higher 
risk for PIM use in individuals receiving care in the southern or western US regions as 
compared to those receiving care in other US regions (Skaar and O'Connor 2012).  Two 
studies found no associations between the geographic location care was received in and 
PIM use (Goulding 2004; Zhan, Sangl et al. 2001). 
Metropolitan Status 
 Two studies were found that examined associations between metropolitan status 
of residence and PIM use in older adults (Meurer, Potti et al. 2010; Mort and Aparasu 
2000).  Both studies found individuals receiving care in non-metropolitan areas were 
more likely than those in metropolitan areas to use PIMs. 
Size 
 Three studies were found that examined associations between facility size and 
PIM use in older adults (Beers, Ouslander et al. 1992; Lau, Kasper et al. 2004; Sloane, 
Zimmerman et al. 2002).  The studies by Beers et al. and Lau et al. found associations 
between larger facility size and higher risk for PIM use, whereas, the study by Sloane et 








 Provider factors assessed for associations with PIM use in older adults include 
age, sex, specialty, location, knowledge, communication, and competence. 
Age 
 In the two studies found that examined associations between provider age and 
PIM use by older adults, advancing provider age was associated with higher risk for PIM 
use (Chen, Hwang et al. 2009; Dhalla, Anderson et al. 2002).   
Gender 
 Three studies were found that examined associations between provider gender and 
PIM use in older adults and report mixed findings (Chen, Wynia et al., 2009; Dhalla, 
Anderson et al. 2002; Howard, Dolovich et al. 2004).  The study by Dhalla et al. found 
higher risk for PIM use in individuals seeing male providers as compared to those seeing 
female providers.  In contrast, the study by Chen et al. found higher risk for PIM use in 
individuals seeing female providers as compared to those seeing male providers.  The 
study by Howard et al. found no associations between provider gender and PIM use.  
Specialty 
 Seven studies were found that examined associations between provider specialty 
and PIM use in older adults.  Two studies found higher risk for PIM use found in 
individuals receiving care from general medicine practitioners (Akazawa, Imai et al. 
2010; Dhalla, Anderson et al. 2002) or psychiatrists/neurologists (Akazawa, Imai et al. 
2010) than those receiving care from other specialist providers.  One study found higher 
risk for PIM use in individuals receiving care from orthopedic surgeons as compared to 





found higher risk for PIM use in individuals receiving care from non-geriatricians as 
compared to those receiving care from geriatricians (Monroe, Carter et al., 2011; Pugh, 
Rosen et al. 2008; Rothberg, Pekow et al. 2008).  One study found no associations 
between provider specialty and PIM use (Hanlon, Artz et al. 2004). 
Location 
 Four studies were found that examined associations between provider location 
and PIM use in older adults (Aparasu and Sitzman 1999; Dhalla, Anderson et al. 2002; 
Goulding 2004; Mort and Aparasu 2000).  The studies by Aparasu et al., Dhalla et al., 
and Mort et al. found that providers practicing in non-metropolitan areas were more 
likely than those practicing in metropolitan areas to prescribe PIMs, but the study by 
Goulding et al. found no associations between provider location and the likelihood of 
older adults receiving PIMs.  
Communication 
 Only one study was found that examined associations between objective 
assessments of provider communication and medication use (Kawasumi, Ernst et al., 
2011).  Kawasumi et al. found no associations between provider communication based on 
test scores from a physician licensing examination and use of recommended 
corticosteroids in individuals with out-of-control asthma.  However, they focused on use 
of only one medication class and excluded persons aged 65 years or older who are at 
higher risk for problems with drug therapy.   
 Patients’ perceptions of care quality are considered to be an essential component 
of care quality assessment (Haddad, Potvin et al., 2000; Sofaer and Firminger 2005).  
Patients who perceive their providers as effective communicators have been reported to 





(Curtis, Patrick et al., 1999; Little, Everitt et al., 2001; Ruiz-Moral, Perez Rodriguez et 
al., 2006; Zachariae, Pedersen et al., 2003), increased adherence to therapy (Schneider, 
Kaplan et al., 2004; Schoenthaler, Chaplin et al., 2009), less anxiety during treatment 
(Rouse and Hamilton 1990), better disease self-management (Heisler, Bouknight et al., 
2002), and lower diagnostic testing expenditures (Epstein, Franks et al., 2005).  No 
studies were found that examined associations between perceptions of provider 
communication and PIM use in older adults.  Such information may provide important 
information on PIM use in this population.  
Knowledge 
 Only one study was found that examined associations between objective 
assessments of provider knowledge and medication use (Grad, Tamblyn et al., 1997).  
Grad et al. found no associations between provider knowledge of appropriate non-
steroidal anti-inflammatory drug prescribing in older adults and quality of therapeutic 
management.  However, the authors focused on use of only one medication class and 
analyzed a sample size of 37 physicians raising questions as to whether the study was 
adequately powered to detect significant associations.  
 Patients who perceive their providers to have adequate knowledge have been 
reported to have outcomes that suggest improved care quality including higher 
satisfaction with care (Sullivan, Stein et al., 2000; Topacoglu, Karcioglu et al., 2004) and 
increased adherence to provider advice (Safran, Taira et al., 1998).  No studies were 
found that examined associations between perceptions of provider knowledge and PIM 








 Only one study was found that examined associations between objective 
assessments of provider competence and medication use (Kawasumi, Ernst et al. 2011).  
Providers with higher competence, based on test scores from Part I (OR=1.06, 95% 
CI=1.02 to 1.11) and Part II (OR=1.07, 95% CI=1.02 to 1.11) of a physician licensing 
examination, were more likely to engage in appropriate prescribing of recommended 
corticosteroids in individuals with out-of-control asthma..  The authors focused on use of 
one medication class and excluded persons aged 65 years or older who are at higher risk 
for problems with drug therapy.   
 Patients who perceive their providers to be competent have been reported to have 
outcomes that suggest higher healthcare quality including higher satisfaction with care 
(Mehta, Zenilman et al., 2005; Rhee and Bird 1996) and increased adherence to 
medications (Cecere, Slatore et al., 2012).  No studies have examined associations 
between perceptions of provider competence and PIM use in older adults.  Such 
information may provide important information on PIM use in this population. 
Summary 
 Factors consistently found to be risk factors for PIM use in older adults include 
polypharmacy (29 of 29 studies), depression or other psychiatric mental comorbidity (7 
of 7 studies), non-geriatric or general medicine provider specialty (5 of 5 studies), and 
advancing provider age (2 of 2 studies).  Patient factors including female gender (16 of 
22 studies), higher number of comorbid conditions (6 of 9 studies), and poor or fair self-
reported health status (5 of 7 studies), were found to be significant risk factors for PIM 
use in over 65 percent of studies assessing such relationships.  Similarly, health system 
factors including non-northeast US geographic region (5 of 7 studies), rural location (2 of 





for PIM use in over 65 percent of studies examining these relationships.  A non-
metropolitan provider location was found to be a significant risk-factor for receiving 
PIMs in 3 of 4 studies assessing such associations.  Patient race (4 of 9 studies), 
education level (2 of 5 studies), and income (1 of 3 studies) were found to be significant 
risk-factors for PIM use in less than half of studies assessing such relationships.  An 
equal number of studies found positive associations, negative associations, or no 
associations between patient age, functional status, or provider gender and PIM use.  
 Studies examining the impact of provider communication, provider knowledge, or 
provider competence on medication use based on objective assessments of such provider 
behavior are rare.  The two studies found that assessed associations between these 
provider behaviors and medication use only examined use of one specific medication 
class, and neither study examined medication use in a broad category such as PIMs.  No 
studies were found that examined associations between patient perceptions of provider 
communication, provider knowledge, or provider competence and PIM use.  
Need for Research 
 The challenges of medication therapy in older adults place them at risk for PIM 
use and associated adverse outcomes including higher morbidity, mortality and increased 
healthcare expenditures (Guaraldo, Cano et al. 2011; Spinewine, Schmader et al. 2007).  
The Beers criteria are the most accepted and commonly used measure of PIM use in older 
adults, and were recently revised in 2012.  However, prevalence of PIM use in older 
adults based on the 2012 Beers criteria has not been reported. 
Providers who are effective communicators, knowledgeable, and competent 
should be able to elicit adequate information from patients about their conditions and 
medication history, and translate such information into accurate diagnoses and 





knowledge, and provider competence have been associated with measures of healthcare 
quality including satisfaction with care and adherence to therapy, it is expected that 
patient perceptions of such provider behavior would be associated with PIM use, another 
measure of health quality.  However, evidence is lacking on whether patient perceptions 
of provider communication, provider knowledge, or provider competence are associated 
with PIM use.  This study will inform on possible associations between perceived 
communication, perceived provider knowledge, and perceived provider competence and 
PIM use and findings may provide important insights on PIM use in older adults.  
Objectives 
Study objectives were to: 
1. Determine prevalence of PIM use among community-dwelling Medicare Part D 
beneficiaries 
2. Determine incidence of PIM use among community-dwelling Medicare Part D 
beneficiaries,  
3. Examine associations between perceived provider communication and PIM use 
among community-dwelling Medicare Part D beneficiaries,  
4. Examine associations between perceived provider knowledge and PIM use among 
community-dwelling Medicare Part D beneficiaries, and  
5. Examine associations between perceived provider competence and PIM use 
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 The objectives of this study were to determine prevalence and incidence of PIM 
use among community-dwelling Medicare Part D beneficiaries and to assess  associations 
between patient perceptions of provider communication, provider knowledge, and 
provider competence with PIM use among community-dwelling Medicare Part D 
beneficiaries. 
Data Source 
 Data for analysis was obtained from the Medicare Current Beneficiary Survey 
files maintained by the Centers for Medicare and Medicaid Services.  The Medicare 
Current Beneficiary Survey includes a nationally representative sample of the Medicare 
population, covering ambulatory and institutionalized Medicare beneficiaries who are 
aged and/or disabled.  Medicare Current Beneficiary Survey files contain enrollment-
related information, responses to survey questions, data on use of medical services, and 
pharmacy claims linked to the survey.    
Ethical Considerations 
 Permission for use of the Medicare Current Beneficiary Survey data was obtained 





from the Committee on the Use of Human Subjects in Research at Purdue University, 
West Lafayette, Indiana.   
Study Sample for Prevalence of PIM Use 
 Inclusion criteria for individuals in the prevalence sample were age 65 years or 
older in 2008, enrolled in Medicare Part D for consecutive months from October 2007 to 
December 2008, and living in the community from October 2007 to December 2008.  
There were no exclusion criteria for the prevalence sample. 
Study Sample for Incidence of PIM Use 
 Inclusion criteria for individuals in the incidence sample were age 65 years or 
older in 2008, enrolled in Medicare Part D for consecutive months from October 2007 to 
December 2008, and living in the community from October 2007 to December 2008.  
The exclusion criterion for individuals in the incidence sample was receiving PIMs at any 
time between October 2007 and December 2007. 
Study Variables 
Demographic Variables 
 Demographic variables included age, gender, ethnicity, education, income, and 
region.  Age was identified in each of two categories, 65 to 84 years, or 85 years or older.  
Ethnicity was identified in each of two categories, white, or non-white.  Education was 
identified in each of four categories, 8
th




 grade/high school 
graduate, post high school education excluding college graduation, or college 
graduate/post graduate.  Income was identified in each of four categories, zero to 15,000 





United States census regions were identified in each of four categories, West, Midwest, 
Northeast, or South/Puerto Rico.   
Clinical Variables 
Depression Diagnosis 
 Individuals with depression were identified using ICD-9 CM codes for depression 
from January 2007 through December 2008.  Three sources of information were used to 
identify ICD-9 CM codes for depression.  The first source was a systematic search of the 
Medline database from 2008 to 2013, using ‘ICD-9 CM code’ and ‘depression’ as 
keywords to identify published articles describing use of ICD-9 CM codes to identify 
diagnosis for depression.  The second source was an online searchable database of ICD-9 
CM codes compiled from files available from the National Center for Health Statistics 
(National Center for Health Statistics 2009).  To identify ICD-9 CM codes for depression 
using this database, the term ‘depression’ was entered into the database search engine.  
The third source was the Clinical Classifications Software for ICD 9-CM maintained by 
the Agency for Healthcare Resource and Quality and available online (Agency for 
Healthcare Research and Quality 2010).  Depression specific ICD-9 CM codes were 
identified from the Clinical Classification Software by manually searching appendices 
documenting ICD-9 CM codes for specific diagnoses.  The ICD-9 CM codes for 
depression identified in at least two of the three sources were used to identify individuals 
with depression.  A variable was created to indicate whether individuals had diagnosis for 
depression in 2007 or 2008 and assigned a value of ‘1’ if the individual had an ICD-9 







Self-reported Health Status 
 Self-reported health status in 2008 was assessed using individuals’ response to the 
survey question asking them to compare their general health to others the same age.  
Individuals’ responses were categorized as poor, fair, good, or very good/excellent.  
Number of Unique Medications 
 A variable indicating the number of unique medications received by each 
individual in 2008 was created.  A unique medication was defined as one count of a 
unique and distinct active ingredient.  A count of unique medications prescribed to each 
individual was calculated by summing all unique medications prescribed to each 
individual in 2008.  The number of unique medications received by each individual was 
identified in each of four categories, 0 to 5 medications, 6 to 10 medications, 11 to 15 
medications, or more than 15 medications. 
Potentially Inappropriate Medications (PIMs) 
 Potentially inappropriate medications (PIMs) listed in the 2012 Beers criteria 
(American Geriatrics Society 2012 Beers Criteria Update Expert Panel 2012) (Appendix 
Table A1) were identified in each of four broad categories including inappropriate drug 
choice, excess dose, excess duration, and drug-disease interaction.    
Inappropriate Drug Choice Category 
 These represent medications considered always potentially inappropriate in 
persons aged 65 years or older.  For each individual, the receipt of medications in 2008 in 
the inappropriate drug choice category was identified.  A separate variable was created 





medication associated with that specific variable in 2008.  Otherwise, a value of ‘0’ was 
assigned to the variable.   
 Some medications in the inappropriate drug choice category are considered 
potentially inappropriate except when used to treat certain conditions.  For each 
individual, the receipt of medications considered potentially inappropriate except for 
certain conditions in 2008 were identified.  A separate variable was created for each 
medication and the variable assigned a value of ‘1’ if the individual received the 
medication in 2008 but not as treatment for the specific condition for which use of the 
medication is not considered inappropriate.  Otherwise, a value of ‘0’ was assigned to the 
variable.  Individual medications and medication classes considered inappropriate except 
for certain conditions include growth hormone, metoclopramide, methyltestosterone, 
testosterone, topical vaginal estrogen creams, and antispasmodics.   
 Growth hormone is considered potentially inappropriate, except when used as 
hormone replacement after pituitary gland removal.  An individual was considered to 
have received growth hormone as hormone replacement after pituitary gland removal in 
2008 if they received growth hormone in 2008 and had a prior record of pituitary gland 
removal in 2007 or 2008.  Metoclopramide is considered potentially inappropriate except 
when used to treat gastroparesis.  An individual was considered to have received 
metoclopramide for treatment of gastroparesis if they received metoclopramide in 2008, 
had prior diagnosis for gastroparesis in 2007 or 2008, and did not have prior diagnosis in 
2007 or 2008 for another condition for which metoclopramide is indicated.  A list of 
conditions for which metoclopramide is indicated was compiled using the Micromedex, 
and Drugs Facts and Comparison databases.  
 Methyltestosterone and testosterone are considered potentially inappropriate 
except when used for treatment of moderate to severe hypogonadism.  However, because 





neither identified nor included in PIM analysis.  Topical vaginal estrogen creams are 
considered potentially inappropriate except when low-dose estrogen creams are used for 
treatment of dyspareunia, lower urinary tract infections, or other vaginal symptoms.  
However, because conditions comprising ‘other vaginal symptoms’ were neither 
mentioned in the 2012 Beers criteria nor could be independently identified, these drugs 
were neither identified nor included in PIM analysis.  Antispasmodics including 
belladonna alkaloids, clidinium-chlordiazepoxide, dicyclomine, hyoscyamine, 
propantheline, and scopolamine are considered potentially inappropriate except when 
used in short-term palliative care to decrease oral secretions.  However, because records 
to identify individuals receiving short-term palliative care were not available, these drugs 
were neither identified nor included in PIM analysis.  
 Individuals with a diagnosis of each condition were identified using ICD-9 CM 
codes from January 2007 through December 2008.  Three sources of information were 
used to identify ICD-9 CM codes for each condition.  The first source was a systematic 
search of the Medline database from 2008 to 2013, using ‘ICD-9 CM code’ and the name 
of the condition as keywords to identify published articles describing use of ICD-9 CM 
codes to identify diagnosis for the specific condition.  The second source was an online 
searchable database of ICD-9 CM codes compiled from files available from the National 
Center for Health Statistics (National Center for Health Statistics 2009).  To identify 
ICD-9 CM codes for a specific condition using this database, the name of the condition 
was entered into the database search engine.  The third source was the Clinical 
Classifications Software for ICD 9-CM maintained by the Agency for Healthcare 
Resource and Quality and available online (Agency for Healthcare Research and Quality 
2010).  The ICD-9 CM codes for specific conditions were identified from the Clinical 





for specific diagnoses.  Condition-specific ICD-9 CM codes identified in at least two of 
the three sources were used to identify individuals with that condition (Appendix Table 
B1).   
Excess Dose Category 
 These represent medications considered inappropriate at certain daily doses 
including reserpine, digoxin, doxepin, and spironolactone.  For each individual, the 
receipt of each medication in 2008 was identified and the daily dose calculated as the 
product of the medication’s dosage strength and quantity divided by the number of days 
supplied.  According to the 2012 Beers criteria, daily doses of reserpine greater than 0.1 
milligram; digoxin greater than 0.125 milligrams; and doxepin greater than 6 milligrams 
are considered inappropriate.  The variable associated with potentially inappropriate 
dosage of each medication was assigned a value of ‘1’ if the individual received the 
medication in 2008 and had a daily dose that exceeds the dose limit set for that 
medication in the 2012 Beers criteria.  Otherwise, a value of ‘0’ was assigned to the 
variable.   
 Spironolactone dosage of more than 25 micrograms per day is considered 
inappropriate in persons with heart failure.  The receipt of a spironolactone daily dose of 
more than 25 micrograms by individuals with heart failure was identified.  The variable 
associated with potentially inappropriate dosage of spironolactone was assigned a value 
of ‘1’ if the individual had a spironolactone daily dose greater than 25 micrograms in 
2008 and had prior diagnosis for heart failure in 2007 or 2008.  Otherwise, the variable 
was assigned a value of ‘0’.  Individuals with a diagnosis of heart failure were identified 
using ICD-9 CM codes from January 2007 through December 2008.  Three sources of 
information were used to identify ICD-9 CM codes for heart failure.  The first source was 





and ‘heart failure’ as keywords to identify published articles describing use of ICD-9 CM 
codes to identify diagnosis for heart failure.  The second source was an online searchable 
database of ICD-9 CM codes compiled from files available from the National Center for 
Health Statistics (National Center for Health Statistics 2009).  To identify ICD-9 CM 
codes for heart failure using this database, the term ‘heart failure’ was entered into the 
database search engine.  The third source was the Clinical Classifications Software for 
ICD 9-CM maintained by the Agency for Healthcare Resource and Quality and available 
online (Agency for Healthcare Research and Quality 2010).  Heart failure specific ICD-9 
CM codes were identified from the Clinical Classification Software by manually 
searching appendices that documented ICD-9 CM codes for specific diagnoses.  The 
ICD-9 CM codes for heart failure identified in at least two of the three sources were used 
to identify individuals with heart failure. 
 The use of spironolactone daily dose of more than 25 micrograms is considered 
potentially inappropriate in individuals with creatinine clearance less than 30 ml/min 
according to the 2012 Beers criteria.  However, because creatinine clearance records were 
not available, the receipt of spironolactone daily dose of more than 25 micrograms by 
individuals with creatinine clearance less than 30ml/min was neither identified nor 
included in PIM analysis. 
Excess Duration Category 
  These represent medications or medication classes considered inappropriate 
when used beyond a certain length of time including eszopiclone, zolpiderm, zaleplon, 
nitrofurantoin, and oral non-COX-selective non-steroidal anti-inflammatory drugs 
(NSAIDs).  For each individual, the receipt of each medication in 2008 was identified 
and the duration of use calculated as the sum of the number of days supplied for 





excess duration of eszopiclone, zolpiderm, or zaleplon is defined as duration of use 
greater than 90 days.  The variable associated with excess duration of each medication 
was assigned a value of ‘1’ if the individual received the medication in 2008 and had 
duration of use greater than 90 days.  Otherwise, a value of ‘0’ was assigned to the 
variable.   
 Nitrofurantoin is considered potentially inappropriate when used for long-term 
suppression of infection.  Nitrofurantoin use for long-term suppression of infection has 
been reported as duration of use greater than 6 months (Drug Facts and Comparisons 
2013).  The variable associated with potentially inappropriate duration of use of 
nitrofurantoin was assigned a value of ‘1’ if the individual received nitrofurantoin in 
2008 and had duration of use greater than six months.  Otherwise, a value of ‘0’ was 
assigned to the variable.  Duration of use of oral non-COX-2 NSAIDs greater than 90 
days is considered potentially inappropriate unless other treatment alternatives are not 
effective and the individual receives proton pump inhibitors or misoprostol.  However, 
because records on effectiveness of other treatment alternatives were not available, use of 
these drugs were neither identified nor included in PIM analysis. 
Drug-Disease Interaction Category 
 These represent medications in the 2012 Beers criteria considered inappropriate in 
persons having specific concomitant conditions.  The PIMs listed in the drug-disease 
interaction category include both individual medications and medication classes.  When 
not listed in the 2012 Beers criteria, medications associated with specific medication 
classes were identified using the Drug Facts and Comparison database.  An individual 
was considered to have received a PIM in the drug-disease interaction category if they 
had a diagnosis in 2007 or 2008 for a condition listed in the drug-disease interaction 





individuals with that specific condition.  A separate variable was created for each 
medication-disease combination listed in the drug-disease interaction category.  The 
variable was assigned a value of ‘1’ if the individual had a diagnosis in 2007 or 2008 for 
the condition associated with that variable prior to first receipt in 2008 of medication 
considered potentially inappropriate in individuals with that specific condition.  
Otherwise, a value of ‘0’ was assigned to the variable.   
 Dronedarone is considered potentially inappropriate when used in individuals 
with permanent atrial fibrillation.  However, because records to identify individuals with 
permanent atrial fibrillation were not available, the use of dronedarone in patients with 
permanent atrial fibrillation was neither identified nor included in PIM analysis.  
Nitrofurantoin is considered potentially inappropriate in individuals with creatinine 
clearance less than 60 ml/min.  However, because creatinine clearance records were not 
available, the use of nitrofurantoin by individuals with creatinine clearance less than 
60ml/min was neither identified nor included in PIM analysis. 
 Some medications in the drug-disease interaction category are considered 
potentially inappropriate when used for treatment of certain conditions.  For each 
individual, the receipt of medications in 2008 considered potentially inappropriate when 
used for treatment of certain conditions was identified.  A separate variable was created 
for each medication and the variable assigned a value of ‘1’ if the individual received the 
drug in 2008, had prior to drug receipt diagnosis in 2007 or 2008 for a condition for 
which use of the drug is considered inappropriate, and did not have prior to drug receipt 
diagnosis in 2007 or 2008 for another condition for which the drug is indicated.  
Otherwise, a value of ‘0’ was assigned to the variable.  A list of conditions for which 






 Alpha-one blockers including doxazosin, prazosin, and terazosin are considered 
potentially inappropriate when used to treat hypertension.  An individual was considered 
to have received a specific alpha-one blocker to treat hypertension if they received the 
alpha-one blocker in 2008, had prior to drug receipt diagnosis for hypertension in 2007 or 
2008, and did not have prior to drug receipt diagnosis for benign prostatic hyperplasia in 
2007 or 2008.  Benzodiazepines are considered potentially inappropriate when used to 
treat insomnia, agitation, or delirium.  An individual was considered to have received a 
benzodiazepine to treat insomnia, agitation, or delirium if they received the specific 
benzodiazepine in 2008, had prior to drug receipt diagnosis for insomnia, agitation, or 
delirium in 2007 or 2008, and did not have prior to drug receipt diagnosis another 
condition for which the specific benzodiazepine is indicated.  Some medications are 
considered potentially inappropriate when used as first-line therapy for certain conditions 
including clonidine as first-line treatment for hypertension and antiarrhythmic drugs as 
first-line treatment for atrial fibrillation.  However, because of unavailability of 
information to identify such drug use as first-line therapy they were neither identified nor 
included in PIM analysis.  
 Some medications in the drug-disease interaction category are considered 
potentially inappropriate when used by individuals with certain conditions except when 
safer alternatives are not available or effective.  They include aspirin daily dose greater 
than 325 milligrams, or non-COX-2 selective NSAIDs in individuals with history of 
gastric or duodenal ulcers; antipsychotics, benzodiazepines, non-benzodiazepine 
hypnotics, tricyclic antidepressants, or selective serotonin reuptake inhibitors in 
individuals with history of falls or fractures, and; oral antimuscarinics, 
nondihydropyridine calcium channel blockers, first-generation antihistamines, 





because there are no records on the availability, safety, or effectiveness of treatment 
alternatives, the use of these drugs was neither identified nor included in PIM analysis.  
 Individuals having disease conditions listed in the drug-disease category were 
identified using ICD-9 CM codes from January 2007 through December 2008.  Three 
sources of information were used to identify ICD-9 CM codes for each condition.  The 
first source was a systematic search of the Medline database from 2008 to 2013, using 
‘ICD-9 CM code’ and the name of the condition as keywords to identify published 
articles describing use of ICD-9 CM codes to identify diagnosis for the specific 
condition.  The second source was an online searchable database of ICD-9 CM codes 
compiled from files available from the National Center for Health Statistics (National 
Center for Health Statistics 2009).  To identify ICD-9 CM codes for a specific condition 
using this database, the name of the condition was entered into the database search 
engine.  The third source was the Clinical Classifications Software for ICD 9-CM 
maintained by the Agency for Healthcare Resource and Quality and available online 
(Agency for Healthcare Research and Quality 2010).  The ICD-9 CM codes for specific 
conditions were identified from the Clinical Classification Software by manually 
searching appendices documenting ICD-9 CM codes for specific diagnoses.  Condition-
specific ICD-9 CM codes identified in at least two of the three sources were used to 
identify individuals with that condition. 
Overall PIM Use 
 Individuals were identified as PIM users if they received a medication identified 
in any of the four PIM categories including inappropriate drug choice, excess dose, 





created.  The variable was assigned a value of ‘1’ if individuals received one or more 
PIMs.  Otherwise, the variable was assigned a value of ‘0’ if the individual received no 
PIMs.   
Perceived Provider Communication 
 Patient perceptions of provider communication were assessed using a previously 
validated index created using Medicare Current Beneficiary Survey data (Ward and 
Thomas 2013).  The perceived communication index was created from patient responses 
to five questions including ‘your doctor answers all of your questions,’ ‘your doctor often 
does not explain your medical problems to you,’ ‘you often have health problems that 
should be discussed but are not,’ ‘your doctor often acts as though they are doing you a 
favor by talking to you,’ and ‘your doctor tells you all you want to know about your 
condition and treatment.’ 
 All questions included in each domain must have been answered for the index to 
be created.  The response to each question was given a value from one to four.  One 
indicated a response of strongly disagree, two indicated disagree, three indicated agree, 
and four indicated strongly agree.  Negatively worded questions were reverse coded and 
values within each domain summed to create each index.  The communication index had 
a theoretical range of 4 to 20 and a higher score indicated more positive perceptions of 
providers. 
Perceived Provider Knowledge 
 Patient perceptions of provider knowledge were created using a previously 
validated index (Ward and Thomas 2013).  The perceived knowledge index was created 
from patient responses to two questions including ‘your doctor has good understanding of 





wrong with you.’  All questions included in each domain must have been answered for 
the index to be created.  The response to each question was given a value from one to 
four.  One indicated a response of strongly disagree, two indicated disagree, three 
indicated agree, and four indicated strongly agree.  Negatively worded questions were 
reverse coded and values within each domain summed to create each index.  The 
knowledge index had a range of 2 to 8 and a higher score indicated more positive 
perceptions of providers.   
Perceived Provider Competence 
 Patient perceptions of provider competence were assessed using a previously 
validated index (Ward and Thomas 2013).  The perceived competence index was created 
from patient responses to two questions including ‘your doctor is very careful to check 
everything when examining you,’ and ‘your doctor is competent and well trained.’  All 
questions included in each domain must have been answered for the index to be created.  
The response to each question was given a value from one to four.  One indicated a 
response of strongly disagree, two indicated disagree, three indicated agree, and four 
indicated strongly agree.  Negatively worded questions were reverse coded and values 
within each domain summed to create each index.  The competence index had a range of 
2 to 8 and a higher score indicated more positive perceptions of providers.   
Statistical Analysis 
 Statistical analyses were conducted using SAS for Linux version 9.2 (SAS 








Prevalence of PIM Use 
 Prevalence estimates were determined for individuals receiving PIMs from 
January 2008 through December 2008.  The total number of individuals and the 
proportion of individuals in the prevalence sample receiving PIMs were calculated.  
Potentially inappropriate medication users were identified as individuals receiving PIMs 
identified in the inappropriate drug choice, excess dose, excess duration, or drug-disease 
interaction categories.  The total number of PIM users was calculated by summing all 
individuals receiving at least one PIM.  The proportion of individuals receiving PIMs was 
calculated by dividing the total number of individuals receiving at least one PIM by the 
total number of individuals in the prevalence sample.  
 The total number of individuals and proportions of individuals in the prevalence 
sample receiving PIMs identified in each of inappropriate drug choice, excess dose, 
excess duration, and drug-disease interaction categories, were also calculated.  The total 
number of individuals receiving PIMs identified in each category was calculated by 
summing all individuals receiving at least one PIM identified in the specific category.  
The proportion of individuals receiving PIMs identified in each category was calculated 
by dividing the total number of individuals receiving at least one PIM identified in the 
specific category by the total number of individuals in the prevalence sample.  Ninety-
five percent confidence intervals were calculated for all PIM prevalence estimates. 
Incidence of PIM Use 
 Incidence estimates for PIM use were determined for individuals who received 
PIMs from January 2008 through December 2008 and did not receive any PIM from 
October 2007 through December 2007.  The total number of individuals and the 
proportion of individuals in the incidence sample receiving PIMs were calculated.  





identified in the inappropriate drug choice, excess dose, excess duration, or drug-disease 
interaction categories.  The total number of individuals receiving PIMs was calculated by 
summing all individuals receiving at least one PIM.  The proportion of individuals 
receiving PIMs was calculated by dividing the total number of individuals receiving at 
least one PIM by the total number of individuals in the incidence sample.  
 The total number of individuals and the proportions of individuals in the 
incidence sample receiving PIMs identified in each of inappropriate drug choice, excess 
dose, excess duration, and drug-disease interaction categories, were also calculated.  The 
total number of individuals receiving PIMs identified in each category was calculated by 
summing all individuals receiving at least one PIM identified in the specific category.  
The proportion of individuals receiving PIMs identified in each category was calculated 
by dividing the total number of individuals receiving at least one PIM identified in the 
specific category by the total number of individuals in the incidence sample.  Ninety-five 
percent confidence intervals were calculated for all PIM prevalence estimates. 
Unadjusted Comparisons of PIM Users and PIM Non-Users on Study Variables 
 Frequencies and percents were calculated for the demographic characteristics, 
age, gender, ethnicity, education, income, and region by PIM use or non-use.  
Frequencies and percents were calculated for the clinical characteristics, depression 
diagnosis, self-reported health status, and number of unique medications by PIM use or 
non-use.  Frequencies and percents were calculated for perceived provider 
communication, perceived provider knowledge, and perceived provider competence by 
PIM use or non-use.  Comparisons of the distribution of PIM users and PIM non-users on 
demographic and clinical characteristics, perceived provider communication, perceived 
provider knowledge, and perceived provider competence were made using chi-square 





Associations between Perceived Provider Communication and  
PIM Use 
 Simple logistic regression models were developed to assess associations between 
perceived provider communication and incident use of PIMs identified in each of 
inappropriate drug choice, excess dose, excess duration, and drug-disease interaction 
categories.  The response variable in each bivariate model was incident use of PIMs 
identified in one of the four specific PIM categories at any time in 2008.  The predictor 
variable was perceived provider communication.  Simple logistic regression models were 
also developed to assess associations between perceived provider communication and 
incident overall PIM use.  The response variable in the bivariate model was incident 
overall PIM use at any time in 2008.  The predictor variable was perceived provider 
communication. 
 Multiple logistic regression models were developed to assess associations 
between perceived provider communication and incident use of PIMs identified in each 
of inappropriate drug choice, excess dose, excess duration, and drug-disease interaction 
categories, adjusting for variables identified as risk factors for PIM use including age, 
gender, ethnicity, region, education, income, depression diagnosis, number of 
medications, and self-reported health status.  The response variable in each multiple 
logistic regression model was incident use of PIMs identified in one of the four specific 
PIM categories at any time in 2008.  The predictor variable was perceived provider 
communication.  Covariates included in the model were age, gender, ethnicity, region, 
education, income, depression diagnosis, number of medications, and self-reported health 
status.  Age was dichotomized such that the reference group was “65 to 84 years.”  The 
reference group for gender was “female.”  White was the reference group for ethnicity.  
The reference group for education was “8th grade or less.”  The reference category for 





“having no depression diagnosis.”  The reference group for self-reported health status 
was “poor.”  The reference group for number of unique medications was “zero to five.”   
 Multiple logistic regression models were also developed to assess associations 
between perceived provider communication and incident overall PIM use, adjusting for 
age, gender, ethnicity, region, education, income, depression diagnosis, number of 
medications, and self-reported health status.  The response variable in the model was 
incident overall PIM use at any time in 2008.  The predictor variable was perceived 
provider communication.  Covariates included in the model were age, gender, ethnicity, 
region, education, income, depression diagnosis, number of medications, and self-
reported health status.   
 The PROC LOGISTIC procedure in SAS with DESCENDING option was used 
for all models.  All two-way interactions were examined using the FORWARD 
SELECTION procedure in SAS PROC LOGISTIC.  A reduced model was developed 
that included only significant covariates and two-way interactions from the initial models 
and the reduced model used for final analyses.  To correct for multiple comparisons of 
levels of perceived provider communication which increase probability of false positive 
findings, a false discovery rate method was used.  The false discovery rate (FDR) was 
selected as the preferred multiplicity adjustment measure because it is considered more 
powerful in finding truly significant results than other multiplicity adjustment measures 
(Benjamini and Yekutieli 2001; Genovese, Lazar et al., 2002; Nichols and Hayasaka 
2003).  The SAS PROC MULTEST (INPVALUES, FDR) option was used to derive 
FDR adjusted p-values, and the FDR p-values <0.05 taken as statistically significant. 
 Overall model fit for the multiple logistic regression models were assessed using 
the Hosmer and Lemeshow goodness of fit test (Hosmer and Lemeshow 2000).   
Bivariate probit models developed using STATA were used to test for selection bias 





specified, using STATA (UCLA: Statistical Consulting Group 2013).  Influential subjects 
were identified graphically using plots of influence statistics against case number and 
predicted probability.  Revised analyses of models after removing subjects identified as 
having influential covariate patterns were conducted.  If significance of model parameter 
estimates were not altered in revised analyses then initial models were retained.  If 
significance of model parameter estimates were altered in revised analyses, then revised 
models were used.   
Associations between Perceived Provider Knowledge and  
PIM Use 
 Simple logistic regression models were developed to assess associations between 
perceived provider knowledge and incident use of PIMs identified in each of 
inappropriate drug choice, excess dose, excess duration, and drug-disease interaction 
categories.  The response variable in each bivariate model was incident use of PIMs 
identified in one of the four specific PIM categories at any time in 2008.  The predictor 
variable was perceived provider knowledge.  Simple logistic regression models were also 
developed to assess associations between perceived provider knowledge and incident 
overall PIM use.  The response variable in the bivariate model was incident overall PIM 
use at any time in 2008.  The predictor variable was perceived provider communication.      
 Multiple logistic regression models were developed to assess associations 
between perceived provider knowledge and incident use of PIMs identified in each of 
inappropriate drug choice, excess dose, excess duration, and drug-disease interaction 
categories, adjusting for variables identified as risk factors for PIM use including age, 
gender, ethnicity, region, education, income, depression diagnosis, number of 
medications, and self-reported health status.  The response variable in each multiple 





PIM categories at any time in 2008.  The predictor variable was perceived provider 
knowledge.  Covariates included in the model were age, gender, ethnicity, region, 
education, income, depression diagnosis, number of medications, and self-reported health 
status.  Age was dichotomized such that the reference group was 65 to 84 years.  The 
reference group for gender was female.  White was the reference group for ethnicity.  The 
reference group for education was 8
th
 grade or less.  The reference category for income 
was zero to 15,000 dollars.  The reference group for depression diagnosis was not having 
depression diagnosis.  The reference group for self-reported health status was poor.  The 
reference group for number of unique medications was zero to five.   
 Multiple logistic regression models were also developed to assess associations 
between perceived provider knowledge and incident overall PIM use, adjusting for age, 
gender, ethnicity, region, education, income, depression diagnosis, number of 
medications, and self-reported health status.  The response variable in the model was 
incident overall PIM use at any time in 2008.  The predictor variable was perceived 
provider knowledge.  Covariates included in the model were age, gender, ethnicity, 
region, education, income, depression diagnosis, number of medications, and self-
reported health status.   
 The PROC LOGISTIC procedure in SAS with DESCENDING option was used 
for all models.  All two-way interactions were examined using the FORWARD 
SELECTION procedure in SAS PROC LOGISTIC.  A reduced model was developed 
that included only significant covariates and two-way interactions from the initial models 
and the reduced model used for final analyses.  To correct for multiple comparisons of 
levels of perceived provider knowledge which increase probability of false positive 
findings, a false discovery rate (FDR) method was used.  The SAS PROC MULTEST 
(INPVALUES, FDR) option was used to derive FDR adjusted p-values, and the FDR p-





 Overall model fit for the multiple logistic regression models were assessed using 
the Hosmer and Lemeshow goodness of fit test (Hosmer and Lemeshow 2000).   
Bivariate probit models developed using STATA were used to test for selection bias 
(Pregibon 1980).  The link test was used to assess whether the model was properly 
specified, using STATA (UCLA: Statistical Consulting Group 2013).  Influential subjects 
were identified graphically using plots of influence statistics against case number and 
predicted probability.  Revised analyses of models after removing subjects identified as 
having influential covariate patterns were conducted.  If significance of model parameter 
estimates were not altered in revised analyses then initial models were retained.  If 
significance of model parameter estimates were altered in revised analyses, then revised 
models were used. 
Associations between Perceived Provider Competence and  
PIM use 
 Simple logistic regression models were developed to assess associations between 
perceived provider competence and incident use of PIMs identified in each of 
inappropriate drug choice, excess dose, excess duration, and drug-disease interaction 
categories.  The response variable in each bivariate model was incident use of PIMs 
identified in one of the four specific PIM categories at any time in 2008.  The predictor 
variable was perceived provider competence.  Bivariate logistic regression models were 
also developed to assess associations between perceived provider competence and 
incident overall PIM use.  The response variable in the bivariate model was incident 
overall PIM use at any time in 2008.  The predictor variable was perceived provider 
communication.      
 Multiple logistic regression models were developed to assess associations 





inappropriate drug choice, excess dose, excess duration, and drug-disease interaction 
categories, adjusting for variables identified as risk factors for PIM use including age, 
gender, ethnicity, region, education, income, depression diagnosis, number of 
medications, and self-reported health status.  The response variable in each multiple 
logistic regression model was incident use of PIMs identified in one of the four specific 
PIM categories at any time in 2008.  The predictor variable was perceived provider 
competence.  Covariates included in the model were age, gender, ethnicity, region, 
education, income, depression diagnosis, number of medications, and self-reported health 
status.  Age was dichotomized such that the reference group was 65 to 84 years.  The 
reference group for gender was female.  White was the reference group for ethnicity.  The 
reference group for education was 8
th
 grade or less.  The reference category for income 
was zero to 15,000 dollars.  The reference group for depression diagnosis was not having 
depression diagnosis.  The reference group for self-reported health status was poor.  The 
reference group for number of unique medications was zero to five.   
 Multiple logistic regression models were also developed to assess associations 
between perceived provider competence and incident overall PIM use, adjusting for age, 
gender, ethnicity, region, education, income, depression diagnosis, number of 
medications, and self-reported health status.  The response variable in the model was 
incident overall PIM use at any time in 2008.  The predictor variable was perceived 
provider competence.  Covariates included in the model were age, gender, ethnicity, 
region, education, income, depression diagnosis, number of medications, and self-
reported health status.   
 The PROC LOGISTIC procedure in SAS with DESCENDING option was used 
for all models.  All two-way interactions were examined using the FORWARD 
SELECTION procedure in SAS PROC LOGISTIC.  A reduced model was developed 





and the reduced model used for final analyses.  To correct for multiple comparisons of 
levels of perceived provider competence which increase probability of false positive 
findings, a false discovery rate (FDR) method was used.  The SAS PROC MULTEST 
(INPVALUES, FDR) option was used to derive FDR adjusted p-values, and the FDR p-
values <0.05 taken as statistically significant. 
 Overall model fit for the multiple logistic regression models were assessed using 
the Hosmer and Lemeshow goodness of fit test (Hosmer and Lemeshow 2000).   
Bivariate probit models developed using STATA were used to test for selection bias 
(Pregibon 1980).  The link test was used to assess whether the model was properly 
specified, using STATA (UCLA: Statistical Consulting Group 2013).  Influential subjects 
were identified graphically using plots of influence statistics against case number and 
predicted probability.  Revised analyses of models after removing subjects identified as 
having influential covariate patterns were conducted.  If significance of model parameter 
estimates were not altered in revised analyses then initial models were retained.  If 
significance of model parameter estimates were altered in revised analyses, then revised 
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Prevalence of PIM Use 
Sample Selection for Prevalence Estimates  
 A total of 2,705 individuals were identified in the sample for prevalence 
estimates, meeting criteria of being age 65 years or older in 2008, enrolled in Medicare 
Part D for consecutive months from October 2007 to December 2008, and living in the 
community from October 2007 through December 2008 (Figure 1).  
Sample Demographic Characteristics  
 Table 1 presents the distribution of the prevalence sample by demographic 
characteristics.  The mean age was 76.8 years for PIM users (standard error = 0.24) and 
77.6 years for PIM non-users (standard error = 0.17) (p=0.039).  More PIM users were 
female (67.08%) as compared to PIM non-users (58.44%).  There were more Whites in 
the PIM non-user group (85.32%) than in the PIM user group (81.30%).  A greater 
proportion of PIM users (45.91%) than PIM non-users (36.87%) were living in the South 
region of the US or Puerto Rico.  There were more PIM users at an educational level of 
8
th 
grade or lower (20.13%) as compared to PIM non-users (13.78%).  More PIM users 
























Figure 1: Sample Selection Flowchart for Prevalence Sample 
  
Medicare beneficiaries 65 years or 
older in 2008 
n = 12,017 
 
Beneficiaries living in the 
community from October 2007 to 
December 2008                      
n = 2705 
Beneficiaries enrolled in Part D in 
consecutive months from October 
2007 to December 2008 





Table 1:  Demographic Characteristics of PIM Prevalence Sample  
________________________________________________________________________ 
 PIM Users PIM Non-Users 
 N = 893 N = 1,812 
 ____________________________________ ____________________________________ 




Age (in years)  
 65 to 84 746 83.54 1,454 80.29 0.039 
 85+ 147 16.46 358 19.76 
Gender 
 Female 599 67.08 1,059 58.44 <.001 
 Male 294 32.92 753 41.56 
Ethnicity 
 White 726 81.30 1,546 85.32 0.007 
 Non-White 167 18.70 266 14.68  
Region 
 South or Puerto Rico 410 45.91 668 36.87 <.001  
 West 175 19.60 372 20.53  
 Midwest 180 20.16 449 24.78  









 Grade/HS Grad 339 44.88 879 48.64 
 Post HS excluding College 134 15.07 329 18.21 
 College Grad/Post Grad 177 19.91 350 19.37 
Income 
 $0 to $15,000 360 40.31 616 34.00 0.004 
 $15,001 to $30,000 295 33.03 613 33.83 
 $30,001 to $45,000 105 11.76 237 13.08 









Sample Clinical Characteristics  
 Table 2 presents the distribution of the prevalence sample by clinical 
characteristics.  The mean number of medications received by PIM users (13.4 
medications, standard error = 0.22) was greater than the mean number of medications 
received by PIM non-users (7.8 medications, standard error = 0.17) (p=<.001).  More  
PIM non-users (86.87%) had diagnosis for depression than PIM users (77.08%).  A 
greater proportion of PIM users (35.95%) than PIM non-users (20.86%) reported their 
health status as poor or fair.  
One-Year Prevalence of                                                                                                    
PIM Use 
Inappropriate Drug Choice Category 
 Table 3 shows the percentages and 95 percent confidence intervals for proportion 
of persons receiving PIMs identified in the inappropriate drug choice category at any 
time in 2008.  Approximately twenty-eight percent (27.6%) of individuals were 
prescribed at least one PIM identified in the inappropriate drug choice category in 2008 
(95% CI = 25.9 to 29.3).  Table 4 presents the prevalence of individual PIMs.  The most 
three commonly prescribed inappropriate drug choice PIMs were glyburide (4.88%), 
promethazine (4.51%) and estrogens (3.95%). 
Excess Dose Category 
 Approximately three percent (3.3%) of individuals in the prevalence sample 
received at least one PIM identified in the excess dose category at any time in 2008 (95% 
CI = 2.6 to 3.9) as shown in Table 3.  The most prevalent excess dose PIMs were Digoxin 
at a daily dose greater than 0.125 milligrams (2.29%) and Doxepin at a daily dose of 





Table 2:  Clinical Characteristics of PIM Prevalence Sample 
________________________________________________________________________ 
 PIM Users PIM Non-Users 
 N=893 N=1,812 
 ____________________________________ ____________________________________ 




Number of Medications 
 0 to 5 78 8.73 671 37.03 <.001 
 6 to 10 250 28.00 322 17.77 
 11 to 15 267 29.90 680 37.53 
 16+ 298 33.37 139 7.67 
Depression Diagnosis 
 No 688 77.08 1,574 86.87 <.001 
 Yes 205 22.96 238 13.13 
Self-Reported Health Status  
 Poor 86 9.63 91 5.02 <.001 
 Fair 235 26.32 287 15.84 
 Good 285 31.91 590 32.56 
 Very Good/Excellent 287 32.14 844 46.58 
________________________________________________________________________________________________________________________________________________ 
a 





Table 3:  Prevalence of Potentially Inappropriate Medications (PIMs) 
________________________________________________________________________ 
   Number of         
  Individuals  % Prevalence          
PIM Category Receiving PIM      N=2,705 95% CI 
________________________________________________________________________________________________________________________________________________ 
At least one PIM 893 33.01 31.24 – 34.7  
 Inappropriate drug choice 747 27.62 25.93 – 29.30 
 Excess dose 88 3.25 2.58 – 3.92 
 Excess duration 94 3.48 2.78 – 4.17  








Table 4:  Prevalence of Individual Potentially Inappropriate Medications Received by  
               Community-Dwelling Medicare Part D Beneficiaries 
________________________________________________________________________ 
   Total  Total 
   Individuals by Individuals by 
   Therapeutic Class  Medication 
   N= 2,705  N= 2,705 
  _____________________ ___________________ 
Therapeutic Class/Medications  n (Percent) n (Percent) 
________________________________________________________________________________________________________________________________________________ 
Inappropriate drug choice    
 Alpha agonists, central 4 (0.15)  
  Guanabenz    0 (0.00) 
  Guanfacine    3 (0.11) 
  Methyldopa    1 (0.04) 
 Analgesics, narcotic 6 (0.22) 
  Meperidine    4 (0.15) 
  Pentazocine    2 (0.07) 
 Analgesics, non-narcotic 88 (3.25) 
  Indomethacin    32 (1.18) 
  Ketorolac, includes parenteral   56 (2.07) 
 Antiarrhythmic  0 (0.00) 
  Disopyramide   0 (0.00) 
 Antihistamines, first generation 207 (7.65) 
  Brompheniramine   6 (0.22) 
  Carbinoxamine   0 (0.00) 
  Chlorpheniramine   16 (0.59) 
  Clemastine    0 (0.00) 
  Cyproheptadine    8 (0.30) 
  Dexbrompheniramine   0 (0.00) 
  Dexchlorpheniramine   1 (0.04) 
  Doxylamine    0 (0.00) 
  Hydroxyzine    68 (2.51) 
  Promethazine    122 (4.51) 
  Triprolidine    0 (0.00) 
 Antiemetics  67 (2.48) 
  Trimethobenzamide    0 (0.00) 
  Metoclopramide (avoid, except  
  for treatment of gastroparesis)    67 (2.48) 
 Antiparkinson agents 2 (0.07) 
  Benztropine, oral   1 (0.04) 






Table 4: Continued 
________________________________________________________________________ 
   Total  Total 
   Individuals by Individuals by 
   Therapeutic Class  Medication 
   N= 2,705  N= 2,705 
  _____________________ ___________________ 
Therapeutic Class/Medications  n (Percent) n (Percent) 
________________________________________________________________________________________________________________________________________________ 
 Antipsychotics  2 (0.07) 
  Thioridazine    2 (0.07) 
  Mesoridazine    0 (0.00) 
 Antithrombotics 11 (0.40) 
  Dipyridamole, oral short acting  
   (does not apply to extended release  
  combination with aspirin)   9 (0.33) 
  Ticlopidine     2 (0.07) 
 Barbiturates  9 (0.33) 
  Amobarbital     0 (0.00) 
  Butabarbital     1 (0.04) 
  Butalbital     0 (0.00) 
  Mephobarbital   0 (0.00) 
  Pentobarbital    0 (0.00) 
  Phenobarbital    8 (0.29) 
  Secobarbital     0 (0.00) 
 Beta-adrenergic agonist 0 (0.00) 
  Isoxsuprine     0 (0.00) 
 Calcium channel blocker 0 (0.00) 
  Nifedipine, immediate release   0 (0.00) 
 Hormones  144 (5.32) 
  Desiccated thyroid    17 (0.63) 
  Estrogens with or without 
  progestins, oral and patch    107 (3.95) 
  Growth hormone (except as hormone 
  replacement after pituitary gland removal)   0 (0.00) 
  Megestrol     23 (0.85) 
 Hypnotic/anxiolytic 2 (0.07) 
  Chloral hydrate    0 (0.00) 
  Meprobamate    2 (0.07) 
 Laxative  0 (0.00) 
  Mineral oil, oral   0 (0.00) 
 Psychotherapeutic agent 0 (0.00) 






Table 4: Continued 
________________________________________________________________________ 
   Total  Total 
   Individuals by Individuals by 
   Therapeutic Class  Medication 
   N= 2,705  N= 2,705 
  _____________________ ___________________ 
Therapeutic Class/Medications  n (Percent) n (Percent) 
________________________________________________________________________________________________________________________________________________ 
 Skeletal muscle relaxants 173 (6.39) 
  Carisoprodol     20 (0.74) 
  Chlorzoxazone    3 (0.11) 
  Cyclobenzaprine    96 (3.55) 
  Metaxalone     14 (0.52) 
  Methocarbamol   30 (1.11) 
  Orphenadrine    15 (0.55) 
 Sulfonylureas, long duration 132 (4.88) 
  Chlorpropamide    0 (0.00) 
  Glyburide     13  (4.88) 
 Tertiary Tricyclic Antidepressants  80 (2.95) 
  Amitriptyline    71 (2.62) 
  Clomipramine    0 (0.00) 
  Imipramine     9 (0.33) 
  Trimipramine    0 (0.00) 
Excess dose   
 Alpha agonist, Central 
  Reserpine (> 0.1 mg/day)   0 (0.00) 
 Antiarrhythmic  
  Digoxin (> 0.125 mg/day)   62 (2.29) 
 Diuretic 
  Spironolactone > 25 mg/d (avoid 
  in patients with heart failure)   5 (0.18) 
 Tertiary Tricyclic antidepressant 
  Doxepin (> 6mg/day)   22 (0.81) 
Excess duration    
 Anti-infective 
  Nitrofurantoin (avoid for  
  (long-term suppression)   10 (0.37) 
 Nonbenzodiazepine hypnotics 
  Eszopiclone (avoid > 90days)    9 (0.33) 
  Zaleplon (avoid > 90days)    1 (0.04) 






Table 4: Continued 
________________________________________________________________________ 
   Total 
    Individuals 
    N= 2,705 
   ___________________ 
Disease/Condition Medications  n (Percent) 
________________________________________________________________________________________________________________________________________________ 
Drug-disease interaction  
Agitation Benzodiazepines  0 (0.00) 
Chronic kidney  
disease, stages IV  
and V NSAIDs; Triamterene  3 (0.11) 
Dementia and 
cognitive  
impairment Anticholinergics – Benzodiazepines;  
  H2-receptor antagonists; Zolpiderm; 
  Antipsychotics   13 (0.48)  
Delirium Tricyclic antidepressants ;  
  Anticholinergics; Benzodiazepines  
  Chlorpromazine; Corticosteriods 
  H2-receptor antagonists; 
  Meperidine; Sedative hypnotics  
  Thioridazine   2 (0.07) 
Epilepsy or  
Chronic Seizures Bupropion, Chlorpromazine, Clozapine  
  Maprotiline, Olanzapine, Thioridazine  
  Thiothixene, Tramadol   1 (0.04) 
Heart failure NSAIDs; COX-2 inhibitors;  
  Calcium channel blockers (avoid for 
  systolic heart failure) – Diltiazem,  
      Verapamil; Pioglitazone, Rosiglitazone, 
  Cilostazol, Dronedarone   31 (1.14) 
Hypertension Alpha one blockers (avoid use 
  as antihypertensive) - Doxazosin 
     Prazosin, Terazosin  23 (0.85) 
Insomnia Oral decongestants -   
      Pseudoephedrine, Phenylephrine 
  Stimulants – Amphetamine, 
      Methylphenidate, Pemoline  
  Theobromines – Theophylline,  
      Caffeine; Benzodiazepines (avoid  








Table 4: Continued 
________________________________________________________________________ 
   Total 
    Individuals 
    N= 2,705 
   ___________________ 
Disease/Condition Medications  n (Percent) 
________________________________________________________________________________________________________________________________________________ 
Lower urinary  
tract symptoms, 
benign prostatic  
hyperplasia Inhaled anticholinergic agents; 
  Strongly anticholinergic drugs 
  (except antimuscarinics for  
  urinary incontinence) (Avoid in men)  12 (0.44) 
Parkinson’s  
Disease Antipsychotics (except for 
  Quetiapine and Clozapine); 
  Antiemetics – Metoclopraminde,  
      Prochlorperazine, Promethazine   1 (0.44) 
Stress or  
mixed urinary  
incontinence Alpha blockers (avoid in women) -  
      Doxazosin, Prazosin, Terazosin   0 (0.00) 
Syncope Acetylcholinesterate inhibitors;  
  Pheripheral alpha blockers - 
      Doxazosin, Prazosin, Terazosin;  
  Tertiary Tricyclic antidepressants; 
  Chlorpromazine, Thioridazine, 
  Olanzapine   7 (0.26) 
Urinary  
Incontinence Estrogens, oral and transdermal 
  (excludes intravaginal estrogen) 








Excess Duration Category 
 Approximately four percent (3.5%) of individuals in the prevalence sample 
received at least one PIM identified in the excess duration category at any time in 2008 
(95% CI = 2.8 to 4.2) (Table 3).  As shown in Table 4, Zolpiderm, which is potentially 
inappropriate beyond duration of use of ninety days (2.81%) and Nitrofurantion, 
potentially inappropriate for long-term suppression of infection (0.37%), were the most 
prevalent PIMs in the excess duration category.  
Drug-Disease Interaction Category 
 More than three percent (3.2%) of individuals in the prevalence sample received 
at least one PIM identified in the drug-disease interaction category at any time in 2008 
(95% CI = 2.5 to 3.8) (Table 3).  The most prevalent drug-disease interaction PIMs were 
non-steroidal anti-inflammatory drugs, cyclooxygenase-2 inhibitors, calcium channel 
blockers, pioglitazone, rosiglitazone, cilostazol, or dronedarone in individuals with heart 
failure (1.14%); alpha one blockers in individuals with hypertension (0.85%), and 
anticholinergics in individuals with dementia/cognitive impairment (0.48%) (Table 4).  
Overall PIM Use 
 Overall, the one-year prevalence of PIM use was 33.0 percent in 2008 (95% CI = 
31.2 to 34.8) (Table 3).  The three most commonly received PIMs in the prevalence 
sample were glyburide (4.88%), promethazine (4.51%) and estrogens (3.95%).  
Approximately twenty-four percent (23.96%) of individuals received one PIM only, 6.21 
percent received two PIMs only, and 2.84 percent received three or more PIMs 
(Appendix Table C1).  Approximately twenty-nine percent (28.9%) of individuals 
received PIMs identified in one category, and 4.2 percent received PIMs identified in two 





Incidence of Potentially PIM Use 
Sample Selection for Incidence Estimates 
 A total of 2,210 individuals were identified in the sample for incidence estimates, 
meeting criteria of being age 65 years or older in 2008, enrolled in Medicare Part D for 
consecutive months from October 2007 to December 2008, living in the community from 
October 2007 to December 2008, and receiving no PIMs between October 2007 and 
December 2007 (Figure 2). 
Sample Demographic Characteristics  
 Table 5 presents the distribution of the incidence sample by demographic 
characteristics.  The mean age was 77.2 years for PIM users (standard error = 0.32) and 
77.7 years for PIM non-users (standard error = 0.17) (p=0.036).  More PIM users were 
female (62.88%) as compared to PIM non-users (58.28%).  There were more Whites in 
the PIM non-user group (85.67%) than in the PIM user group (79.91%).  A greater 
proportion of PIM users (47.38%) than PIM non-users (36.82%) were living in the South 
region of the US or Puerto Rico.  There were more PIM users at an educational level of 
8
th 
grade or lower (20.22%) as compared to PIM non-users (13.84%).  More PIM users 
(39.74%) than PIM non-users (33.96%) had an annual income of 15,000 dollars or lower.  
Sample Clinical Characteristics  
 Table 6 presents the distribution of the incidence sample by clinical 
characteristics.  The mean number of medications received by PIM users (13.4 






























Figure 2: Sample Selection Flowchart for Incidence Sample 
  
Medicare beneficiaries 65 years or 
older in 2008 
n = 12,017 
 
Beneficiaries enrolled in Part D in 
consecutive months from October 
2007 to December 2008 
n = 4,705 
Beneficiaries with no receipt of 
PIMs between October 2007 and 
December 2007 
n = 2,210 
Beneficiaries living in the 
community from October 2007 to 
December 2008                      





Table 5:  Demographic Characteristics of PIM Incidence Sample 
________________________________________________________________________ 
 PIM Users PIM Non-Users 
 N = 458 N = 1,752 
 ____________________________________ ____________________________________ 




Age (in years) 
 65 to 84 387 84.50 1,405 80.19 0.0363 
 85+ 71 15.50 347 19.81 
Gender 
 Female 288 62.88 1,021 58.28 0.0741 
 Male 170 37.12 731 41.72 
Ethnicity 
 White 366 79.91 1,501 85.67 0.0024 
 Non-White 92 20.09 251 14.33 
Region 
 South or Puerto Rico 217 47.38 645 36.82 0.0003 
 West 87 19.00 358 20.43 
 Midwest 82 17.90 433 24.71 









 Grade/HS Grad 206 45.27 843 48.23 
 Post HS excluding College 91 20.00 342 19.57 
 College Grad/Post Grad 66 14.51 321 18.36 
Income 
 $0 to $15,000 182 39.74 595 33.96 0.0366 
 $15,001 to $30,000 151 32.97 593 33.85 
 $30,001 to $45,000 60 13.10 228 13.01 









Table 6:  Clinical Characteristics of PIM Incidence Sample 
________________________________________________________________________ 
 PIM Users PIM Non-Users 
 N = 458 N = 1,752 
 ____________________________________ ____________________________________ 




Number of Medications 
 0 to 5 41 8.95 652 37.21 <.0001 
 6 to 10 140 30.57 663 37.84 
 11 to 15 123 26.86 306 17.47 
 16+ 154 33.62 131 7.48 
Depression Diagnosis 
 No 366 79.91 1,520 86.76 0.002 
 Yes 92 20.09 232 13.24 
Self-Reported Health Status  
 Poor 37 8.08 87 4.97 <.0001 
 Fair 123 26.86 275 15.70 
 Good 150 32.75 570 32.53 











received by PIM non-users (7.8 medications, standard error = 0.12) (p=<.001).  A greater 
proportion of PIM non-users (86.76%) had diagnosis for depression than PIM users  
 (79.91%).  A greater proportion of PIM users (34.94%) than PIM non-users (20.67%) 
reported their health status as poor or fair.  
One-Year Incidence of                                                                                                     
PIM Use 
Inappropriate Drug Choice Category 
 Table 7 shows the percentages and 95 percent confidence intervals for proportion 
of persons with new receipt of PIMs identified in the inappropriate drug choice category 
at any time in 2008.  More than 17 percent (17.2%) of individuals were prescribed at least 
one PIM identified in the inappropriate drug choice category in 2008 (95% CI = 25.9 to 
29.3).  Table 8 presents the incidence of individual PIMs.  The most three commonly 
prescribed inappropriate drug choice PIMs were promethazine (3.62%), cyclobenzaprine 
(2.68%), and metoclopramide (1.59%). 
Excess Dose Category 
 More than one percent (1.2%) of individuals in the incidence sample received at 
least one PIM identified in the excess dose category at any time in 2008 (95% CI = 0.8 to 
1.7) as shown in Table 7.  The most prevalent excess dose PIMs were Digoxin at a daily 
dose greater than 0.125 milligrams (0.81%) and Doxepin at a daily dose of greater than 6 
milligrams (0.32%) as shown in Table 8.  
Excess Duration Category 
 Approximately three percent (2.6%) of individuals in the incidence sample 





Table 7:  Incidence of Potentially Inappropriate Medications (PIMs) 
________________________________________________________________________ 
               Number of         
  Individuals  % Prevalence          
PIM Category Receiving PIM      N=2,210 95% CI 
________________________________________________________________________________________________________________________________________________ 
At least one PIM 458 20.72 19.03 – 22.41 
 Inappropriate drug choice 380 17.19 15.62 – 18.77 
 Excess dose 27 1.22 0.76 – 1.68 
 Excess duration 58 2.62 1.96 – 3.29  









Table 8:  Incidence of Individual Potentially Inappropriate Medications Received by  
                 Community-Dwelling Medicare Part D Beneficiaries 
________________________________________________________________________ 
   Total  Total 
   Individuals by Individuals by 
   Therapeutic Class  Medication 
   N= 2,210  N= 2,210 
  _____________________ ___________________ 
Therapeutic Class/Medications  n (Percent) n (Percent) 
________________________________________________________________________________________________________________________________________________ 
Inappropriate drug choice     
 Alpha agonists, central 2 (0.09)   
  Guanabenz    0 (0.00) 
  Guanfacine    2 (0.09) 
  Methyldopa    0 (0.00)  
 Analgesics, narcotic 4 (0.18) 
  Meperidine    3 (0.14) 
  Pentazocine    1 (0.04) 
 Analgesics, non-narcotic 54 (2.44) 
  Indomethacin    19 (0.86) 
  Ketorolac, includes parenteral   35 (1.58) 
 Antiarrhythmic  0 (0.00) 
  Disopyramide   0 (0.00) 
 Antihistamines, first generation 128 (5.79) 
  Brompheniramine   4 (0.18) 
  Carbinoxamine   0 (0.00) 
  Chlorpheniramine   10 (0.45) 
  Clemastine    0 (0.00) 
  Cyproheptadine    4 (0.18) 
  Dexbrompheniramine   0 (0.00) 
  Dexchlorpheniramine   1 (0.04) 
  Doxylamine    0 (0.00) 
  Hydroxyzine    33 (1.49) 
  Promethazine    80 (3.62) 
  Triprolidine    0 (0.00) 
 Antiemetics  35 (1.59) 
  Trimethobenzamide    0 (0.00) 
  Metoclopramide (avoid, except  
  for treatment of gastroparesis)    35 (1.59) 
 Antiparkinson agents 0 (0.00) 
  Benztropine, oral   0 (0.00) 
  Trihexyphenidyl    0 (0.00) 
 Antipsychotics  0 (0.00) 
  Thioridazine    0 (0.00) 






Table 8: Continued 
________________________________________________________________________ 
   Total  Total 
   Individuals by Individuals by 
   Therapeutic Class  Medication 
   N= 2,210  N= 2,210 
  _____________________ ___________________ 
Therapeutic Class/Medications  n (Percent) n (Percent) 
________________________________________________________________________________________________________________________________________________ 
 Antithrombotics 3 (0.14) 
  Dipyridamole, oral short acting     
   (does not apply to extended release  
  combination with aspirin)     3 (0.14)  
  Ticlopidine     0 (0.00) 
 Barbiturates  3 (0.13) 
  Amobarbital     0 (0.00) 
  Butabarbital     1 (0.04) 
  Butalbital     0 (0.00) 
  Mephobarbital   0 (0.00) 
  Pentobarbital    0 (0.00) 
  Phenobarbital    2 (0.09) 
  Secobarbital     0 (0.00) 
 Beta-adrenergic agonist 0 (0.00) 
  Isoxsuprine     0 (0.00) 
 Calcium channel blocker 0 (0.00) 
  Nifedipine, immediate release   0 (0.00) 
 Hormones  34 (1.54) 
  Desiccated thyroid    4 (0.18) 
  Estrogens with or without 
  progestins, oral and patch    22 (0.10) 
  Growth hormone (except as hormone 
  replacement after pituitary gland removal)   0 (0.00) 
  Megestrol     8 (0.36) 
 Hypnotic/anxiolytic 0 (0.00) 
  Chloral hydrate    0 (0.00) 
  Meprobamate    0 (0.00) 
 Laxative  0 (0.00) 
  Mineral oil, oral   0 (0.00) 
 Psychotherapeutic agent 0 (0.00) 







Table 8: Continued 
________________________________________________________________________ 
   Total  Total 
   Individuals by Individuals by 
   Therapeutic Class  Medication 
   N= 2,210  N= 2,210 
  _____________________ ___________________ 
Therapeutic Class/Medications  n (Percent) n (Percent) 
________________________________________________________________________________________________________________________________________________ 
 Skeletal muscle relaxants 110 (4.98) 
  Carisoprodol     11 (0.50) 
  Chlorzoxazone    1 (0.04) 
  Cyclobenzaprine    59 (2.68) 
  Metaxalone     11 (0.50) 
  Methocarbamol   20 (0.91) 
  Orphenadrine    10 (0.45) 
 Sulfonylureas, long duration 33 (1.50) 
  Chlorpropamide    0 (0.00) 
  Glyburide     33 (1.50) 
 Tertiary Tricyclic Antidepressants  20 (0.90) 
  Amitriptyline    19 (0.86) 
  Clomipramine    0 (0.00) 
  Imipramine     1 (0.04) 
  Trimipramine    0 (0.00) 
Excess dose   
 Alpha agonist, Central 
  Reserpine (> 0.1 mg/day)   0 (0.00) 
 Antiarrhythmic  
  Digoxin (> 0.125 mg/day)   18 (0.81) 
 Diuretic 
  Spironolactone > 25 mg/d (avoid 
  in patients with heart failure)   2 (0.09) 
 Tertiary Tricyclic antidepressant 
  Doxepin (> 6mg/day)   7 (0.32) 
Excess duration    
 Anti-infective 
  Nitrofurantoin (avoid for  
  (long-term suppression)   7 (0.32) 
 Nonbenzodiazepine hypnotics 
  Eszopiclone (avoid > 90days)    4 (0.18) 
  Zaleplon (avoid > 90days)    1 (0.04) 






Table 8: Continued 
________________________________________________________________________ 
   Total 
    Individuals 
    N= 2,210 
   ___________________ 
Disease/Condition Medications  n (Percent) 
________________________________________________________________________________________________________________________________________________ 
Drug-disease interaction  
Agitation Benzodiazepines  0 (0.00) 
Chronic kidney  
disease, stages IV  
and V NSAIDs; Triamterene  0 (0.00) 
Dementia and 
cognitive  
impairment Anticholinergics – Benzodiazepines;  
  H2-receptor antagonists; Zolpiderm; 
  Antipsychotics   8 (0.36)  
Delirium Tricyclic antidepressants ;  
  Anticholinergics; Benzodiazepines  
  Chlorpromazine; Corticosteriods 
  H2-receptor antagonists; 
  Meperidine; Sedative hypnotics  
  Thioridazine   0 (0.00) 
Epilepsy or  
Chronic Seizures Bupropion, Chlorpromazine, Clozapine  
  Maprotiline, Olanzapine, Thioridazine  
  Thiothixene, Tramadol   0 (0.00) 
Heart failure NSAIDs; COX-2 inhibitors;  
  Calcium channel blockers (avoid for 
  systolic heart failure) – Diltiazem,  
      Verapamil; Pioglitazone, Rosiglitazone, 
  Cilostazol, Dronedarone   18 (0.81) 
Hypertension Alpha one blockers (avoid use 
  as antihypertensive) - Doxazosin 
     Prazosin, Terazosin  7 (0.32) 
Insomnia Oral decongestants -   
      Pseudoephedrine, Phenylephrine 
  Stimulants – Amphetamine, 
      Methylphenidate, Pemoline  
  Theobromines – Theophylline,  
      Caffeine; Benzodiazepines (avoid  







Table 8: Continued 
________________________________________________________________________ 
   Total 
    Individuals 
    N= 2,210 
   ___________________ 
Disease/Condition Medications  n (Percent) 
________________________________________________________________________________________________________________________________________________ 
Lower urinary  
tract symptoms, 
benign prostatic  
hyperplasia Inhaled anticholinergic agents; 
  Strongly anticholinergic drugs 
  (except antimuscarinics for 
  urinary incontinence) (Avoid in men)  7 (0.32) 
Parkinson’s  
Disease Antipsychotics (except for 
  Quetiapine and Clozapine); 
  Antiemetics – Metoclopraminde,  
      Prochlorperazine, Promethazine   1 (0.04) 
Stress or  
mixed urinary  
incontinence Alpha blockers (avoid in women) -  
      Doxazosin, Prazosin, Terazosin   0 (0.00) 
Syncope Acetylcholinesterate inhibitors;  
  Pheripheral alpha blockers - 
      Doxazosin, Prazosin, Terazosin;  
  Tertiary Tricyclic antidepressants; 
  Chlorpromazine, Thioridazine, 
  Olanzapine   0 (0.00) 
Urinary  
Incontinence Estrogens, oral and transdermal 
  (excludes intravaginal estrogen) 







 (95% CI = 2.0 to 3.3) (Table 7).  As shown in Table 8, Zolpiderm, which is potentially 
inappropriate beyond a duration of use of ninety days (2.08%) and Nitrofurantion, 
potentially inappropriate for long-term suppression of infection (0.32%), were the most 
commonly received PIMs in the excess duration category.  
Drug-Disease Interaction Category 
 As presented in Table 7, approximately two percent (1.8%) of individuals in the 
prevalence sample received at least one PIM identified in the drug-disease interaction 
category at any time in 2008 (95% CI = 1.3 to 2.4).  The most prevalent drug-disease 
interaction PIMs were receipt of non-steroidal anti-inflammatory drugs, cyclooxygenase-
2 inhibitors, calcium channel blockers, pioglitazone, rosiglitazone, cilostazol, or 
dronedarone in individuals with heart failure (0.81%),and anticholinergics in individuals 
with dementia or other cognitive impairment (0.36%) (Table 8).  
Overall PIM Use 
 Overall, the one-year incidence of PIM use among community-dwelling Medicare 
beneficiaries was 20.7 percent in 2008 (95% CI = 19.0 to 22.4) (Table 7).   
The three most commonly received PIMs in the incidence sample were promethazine 
(3.62%), cyclobenzaprine (2.68%) and zolpiderm (2.08%).  Over seventeen percent 
(17.06%) of individuals received one PIM only, 2.71 percent received two PIMs only, 
and less than one percent (0.94%) received three or more PIMs (Appendix Table C3).  
Approximately nineteen percent (18.7%) of individuals received PIMs identified in one 
category, and two percent received PIMs identified in two or more categories (Appendix 







Associations between Perceived Provider   
Communication and PIM Use 
Bivariate Associations between Perceived Provider  
Communication and PIM Use 
Table 9 presents the distribution of perceived provider communication index 
scores.  To avoid potential problems from small cell counts in logistic regression 
analysis, index scores were collapsed into five levels, with each level having not less than 
100 observations (Table 10).  The five levels of the perceived provider communication 
variable were “5 to 14,” “15,” “16,” “17 or 18,” and “19 or 20.”  Perceived provider 
communication index scores of 5 to 14 was selected as the reference category.   
Ten events per degree of freedom are required for reliable parameter estimation in 
logistic regression models (Agashivala and Wu 2009; Harrell, Lee et al., 1996; LaValley 
2008; Peduzzi, Concato et al., 1996).  However, because number of excess dose, excess 
duration, or drug-disease interaction PIM users did not satisfy event size requirements for 
reliable models, associations between perceived provider communication and excess 
dose, excess duration or drug-disease interaction PIM use were not included in analyses. 
Bivariate Associations between Perceived Provider 
Communication and Inappropriate Drug Choice PIM Use 
There was no significant difference in mean perceived provider communication 
scores between inappropriate drug choice PIM users (mean score=15.8, Standard 
Error=0.12) and non-users (mean score=15.9, SE=0.05).  In bivariate analysis of 
associations between perceived provider communication and inappropriate drug choice 
PIM use, individuals with perceived provider communication index scores of 17 or 18 
were less likely to use inappropriate drug choice PIMs than those with index scores 
between 5 and 14 (OR=0.49, 95% CI=0.32 to 0.76, p=0.001) (Table 11).  There was no 





Table 9:  Distribution of Perceived Provider Communication Index Scores 
________________________________________________________________________ 
Index Score Frequency      Percent 
_______________________________________________________________________________________________________________________________________________  
 Five 1 0.05 
 Six 0 0.00 
 Seven 5 0.24 
 Eight 1 0.05 
 Nine 3 0.15 
 Ten 13 0.63 
 Eleven 21 1.02 
 Twelve 40 1.95 
 Thirteen 56 2.72 
 Fourteen 157 7.64 
 Fifteen 961 46.74 
 Sixteen 157 7.64 
 Seventeen 217 10.55 
 Eighteen  121 5.89 
 Nineteen 75 3.65 








Table 10:  Grouped Distribution of Perceived Provider Communication Index Scores 
________________________________________________________________________ 
Index Score Frequency      Percent 
_______________________________________________________________________________________________________________________________________________  
 5 to 14 297 14.45 
 15 961 46.74 
 16 157 7.64 
 17 or 18 338 16.44 







Table 11:  Bivariate Associations between Perceived Provider Communication and 
                 Inappropriate Drug Choice PIM Use  
________________________________________________________________________ 
 




Perceived Provider  
Communication Index    
 5 to 14 Reference group 
 15 0.767 0.556 – 1.058 0.106 
 16 0.676 0.407 – 1.124 0.131 
 17 or 18 0.493 0.321 – 0.755 0.001 










with perceived provider communication scores of 15, 16, or 19/20, and individuals with 
index scores between 5 and 14.   
Bivariate Associations between Perceived Provider 
Communication and Overall PIM Use 
There was no significant difference in mean perceived provider communication 
scores between overall PIM users (mean score=15.7, Standard Error=0.11) and PIM non-
users (mean score=15.9, SE=0.05).  Table 12 presents results of bivariate logistic 
regression examining associations between perceived provider communication and 
overall PIM use.  There were no associations found between perceived provider 
communication and overall PIM use.  
Bivariate Associations between Demographic 
Characteristics and PIM Use 
 Age was grouped into two categories, 65 to 84 years, and 85 years or older, with 
the reference category being age 65 to 84 years.  The reference category for gender was 
female.  Ethnicity was categorized as White, or non-White, with White being the 
reference category.  Education was grouped into four categories including 8
th





 grade/high school graduate, post high school education excluding college 
graduation, or college graduate/post graduate.  The reference category for education was 
8
th
 grade or less.  Income was categorized as zero to 15,000 dollars; 15,001 to 30,000 
dollars; 30,001 to 45,000 dollars; or more than 45,000 dollars.  The reference category for 
income was 15,000 dollars or less.  United States census regions were identified in each 
of four categories including West, Midwest, Northeast, or South/Puerto Rico.  The 







Table 12:  Bivariate Associations between Perceived Provider Communication and 
                 Overall PIM Use 
________________________________________________________________________ 
 




Perceived Provider  
Communication Index    
 5 to 14 Reference group 
 15 0.858 0.632 – 1.164 0.326 
 16 0.755 0.470 – 1.212 0.246 
 17 or 18 0.609 0.413 – 0.900 0.013 









Bivariate Associations between Age and PIM Use 
 Based on results of bivariate analysis, there were no associations found between 
age and inappropriate drug choice PIM use (Table 13).  Individuals aged 85 years or  
older had decreased likelihood of overall PIM use than those aged 65 to 84 years 
(OR=0.74, 95% CI=0.56 to 0.98, p=0.037) (Table 14).   
Bivariate Associations between Gender and PIM Use 
 There were no associations found between gender and inappropriate drug choice 
PIM use (Table 15) or associations between gender and overall PIM use in bivariate 
analyses (Table 16). 
Bivariate Associations between Ethnicity and PIM Use 
 Non-Whites had higher likelihood of inappropriate drug choice PIM use than 
Whites (OR=1.56, 95% CI=1.18 to 2.06, p=0.002) (Table 17).  Likewise, non-Whites had 
higher likelihood of overall PIM use than Whites in bivariate analysis (OR=1.50, 95% 
CI=1.15 to 1.96, p=0.003) (Table 18).   
Bivariate Associations between Region and PIM Use 
 Individuals in the West (OR=0.54, 95% CI=0.39 to 0.74, p=0.023), Midwest 
(OR=0.52, 95% CI=0.38 to 0.69, p=<.001), and Northeast regions of the US (OR=0.62, 
95% CI=0.45 to 0.85, p=0.003) had lower likelihood of inappropriate drug choice PIM 
use than those in the South region or Puerto Rico (Table 19).  Individuals in the West 
(OR=0.72, 95% CI=0.55 to 0.96, p=0.023), Midwest (OR=0.56, 95% CI=0.46 to 0.75, 
p=<.001), and Northeast regions of the US (OR=0.68, 95% CI=0.50 to 0.91, p=0.011) 
also had lower likelihood of overall PIM use than those in the South region or Puerto 






Table 13:  Bivariate Associations between Age and Inappropriate Drug Choice PIM Use 
________________________________________________________________________ 
 




Age     
  65 to 84 Reference group  









Table 14:  Bivariate Associations between Age and Overall PIM Use 
________________________________________________________________________ 
 




Age     
  65 to 84 Reference group  









Table 15:  Bivariate Associations between Gender and Inappropriate Drug Choice PIM      
                 Use 
________________________________________________________________________ 
 





 Female Reference group 









Table 16:  Bivariate Associations between Gender and Overall PIM Use     
________________________________________________________________________ 
 





 Female Reference group 









Table 17:  Bivariate Associations between Ethnicity and Inappropriate Drug Choice PIM      
                 Use 
________________________________________________________________________ 
 





 White Reference group 









Table 18:  Bivariate Associations between Ethnicity and Overall PIM Use      
________________________________________________________________________ 
 





 White Reference group 









Table 19:  Bivariate Associations between Region and Inappropriate Drug Choice PIM     
                 Use 
________________________________________________________________________ 
 




Region    
 South or Puerto Rico Reference group 
 West 0.537 0.391 – 0.736 0.001 
 Midwest 0.515 0.381 – 0.697 <.001 









Table 20:  Bivariate Associations between Region and Overall PIM Use      
________________________________________________________________________ 
 




Region    
 South or Puerto Rico Reference group 
 West 0.722 0.546 – 0.956 0.023 
 Midwest 0.563 0.425 – 0.746 <.001 









Bivariate Associations between Education and PIM Use 
 The likelihood of inappropriate drug choice PIM use decreased with higher levels 
of education.  Compared to individuals attaining an educational level of 8
th
 grade or 
lower, individuals at an educational level between 9
th
 grade and high school graduation 
(OR=0.67, 95% CI=0.48 to 0.91, p=0.001), with post high school education excluding 
college graduation (OR=0.62, 95% CI=0.43 to 0.89, p=0.010), or graduating from college  
or graduate school (OR=0.52, 95% CI=0.35 to 0.77, p=0.001) were less likely to use 
inappropriate drug choice PIMs (Table 21). 
 Compared to Individuals at an educational level of 8
th
 grade or less, those 
between 9
th
 grade and high school graduation (OR=0.64, 95% CI=0.48 to 0.85, p=0.002), 
having post high school education excluding college graduation (OR=0.70, 95% CI=0.50 
to 0.98, p=0.036), or graduating from college or graduate school (OR=0.63, 95% CI=0.46 
to 0.87, p=0.004) had lower likelihood of overall PIM use (Table 22).   
Bivariate Associations between Income and PIM Use 
 Individuals earning more than $45,000 per annum were less likely than those 
earning $15,000 or less to receive inappropriate drug choice PIMs (OR=0.56, 95% 
CI=0.39 to 0.79, p=0.001).  Individuals with yearly incomes between $15,001 and 
$30,000 or those with incomes between $30,001 and $45,000 were not significantly 
different in likelihood of inappropriate drug choice PIM use from those earning $15,000 
or less (Table 23).   
 Similarly, individuals earning more than $45,000 per annum had lower likelihood 
of overall PIM use than those earning $15,000 or less (OR=0.63, 95% CI=0.46 to 0.87, 
p=0.004) (Table 24).  Individuals with yearly incomes between $15,001 and $30,000 or 
those with incomes between $30,001 and $45,000 were not significantly different in 





Table 21:  Bivariate Associations between Education and Inappropriate Drug Choice PIM     
                 Use 
________________________________________________________________________ 
 




Education    
 8
th





 Grade/HS Grad 0.671 0.479 – 0.906 0.009 
 Post HS excluding College Grad 0.622 0.434 – 0.893 0.010 









Table 22:  Bivariate Associations between Education and Overall PIM Use      
________________________________________________________________________ 
 




Education    
 8
th





 Grade/HS Grad 0.643 0.484 – 0.854 0.002 
 Post HS excluding College Grad 0.700 0.501 – 0.976 0.036 









Table 23:  Bivariate Associations between Income and Inappropriate Drug Choice PIM     
                 Use 
________________________________________________________________________ 
 




Income    
 $0 to $15,000 Reference group 
 $15,001 to $30,000 0.834 0.643 – 1.081 0.169 
 $30,001 to $45,000 0.803 0.562 – 1.146 0.337 









Table 24:  Bivariate Associations between Income and Overall PIM Use      
________________________________________________________________________ 
 




Income    
 $0 to $15,000 Reference group 
 $15,001 to $30,000 0.832 0.652 – 1.062 0.141 
 $30,001 to $45,000 0.860 0.619 – 1.196 0.375 









Bivariate Associations between Clinical 
Characteristics and PIM Use 
 The reference category for depression diagnosis was not having such diagnosis.  
Number of unique medications received by each individual was grouped into four 
categories including 0 to 5 medications, 6 to 10 medications, 11 to 15 medications, or 16 
medications or more.  The reference category for number of unique medications was zero  
to five.  Self-reported health status was categorized as poor, fair, good, or very 
good/excellent.  The reference category for self-reported health status was poor.   
Bivariate Associations between Depression Diagnosis and PIM Use 
 Having diagnosis for depression diagnosis was associated with higher likelihood 
of inappropriate drug choice PIM use (OR=1.49, 95% CI=1.22 to 1.99, p=0.006) (Table 
25).  Having diagnosis for depression was similarly associated with higher likelihood of 
overall PIM use in bivariate analysis (OR=1.65, 95% CI=1.26 to 2.15, p=0.003) (Table 
26).   
Bivariate Associations between Number of Medications and PIM Use  
 The likelihood of inappropriate drug choice PIM use and overall PIM use 
increased with number of unique medications received by each individual.  Individuals 
receiving 6 to 10 drugs (OR=3.14, 95% CI=2.12 to 4.66, p=<.001), 11 to 15 drugs 
(OR=4.99, 95% CI=3.31 to 7.54, p=<.001), or more than 15 drugs (OR=18.15, 95% 
CI=12.03 to 27.39, p=<.001) were more likely to receive inappropriate drug choice PIMs 
than those receiving 5 drugs or less (Table 27).  Individuals receiving 6 to 10 drugs 
(OR=3.36, 95% CI=2.33 to 4.83, p=<.001), 11 to 15 drugs (OR=6.39, 95% CI=4.38 to 
9.33, p=<.001), or more than 15 drugs (OR=18.64, 95% CI=12.63 to 27.67, p=<.001)  
were at higher likelihood of overall PIM use than those receiving 5 drugs or less (Table 





Table 25:  Bivariate Associations between Depression Diagnosis and Inappropriate Drug  
                 Choice PIM Use 
________________________________________________________________________ 
 





 No Reference group 









Table 26:  Bivariate Associations between Depression Diagnosis and Overall PIM Use      
________________________________________________________________________ 
 





 No Reference group 









Table 27:  Bivariate Associations between Number of Medications and Inappropriate  
                 Drug Choice PIM Use 
________________________________________________________________________ 
 




Number of Medications    
 0 to 5 Reference group 
 6 to 10 3.142 2.121 – 4.656 <.001 
 11 to 15 4.991 3.306 – 7.535 <.001 









Table 28:  Bivariate Associations between Number of Medications and Overall PIM Use      
________________________________________________________________________ 
 




Number of Medications    
 0 to 5 Reference group 
 6 to 10 3.358 2.332 – 4.834 <.001 
 11 to 15 6.392 4.377 – 9.334 <.001 









Bivariate Associations between Self-Reported Health Status and PIM Use 
 Individuals reporting health status as very good/excellent (OR=0.44, 95% 
CI=0.28 to 0.68, p=0.003) had lower likelihood of inappropriate drug choice PIM use 
than those reporting health status as poor (Table 29).  Individuals reporting health status  
as good or fair were not significantly different in likelihood of inappropriate drug choice 
PIM use from those reporting health status as poor (Table 29).   
 Better self-reported health status was associated with lower risk for overall PIM 
use.  Individuals reporting health status as good (OR=0.62, 95% CI=0.41 to 0.95, 
p=0.027) or very good/excellent (OR=0.42, 95% CI=0.28 to 0.65, p=<.001) had lower 
likelihood of overall PIM use than those reporting health status as poor (Table 30).  
Individuals reporting health status as fair were not significantly different in likelihood of 
overall PIM use from those reporting health status as poor (Table 30).   
Multivariate Associations between Perceived Provider 
Communication and PIM Use after Adjusting for Demographic 
and Clinical Characteristics 
Multivariate Associations between Perceived Provider  
Communication and Inappropriate Drug Choice PIM Use  
after Adjusting for Demographic and Clinical Characteristics 
Multiple logistic regression models were developed to assess associations 
between perceived provider communication and use of PIMs identified in the 
inappropriate drug choice category, adjusting for demographic and clinical 
characteristics.  The response variable in the model was inappropriate drug choice PIM 
use.  The predictor variable in the model was perceived provider communication.   
Covariates included in the model were age, gender, ethnicity, region, education, income, 
number of medications, depression diagnosis, and self-reported health status.  A model 





Table 29:  Bivariate Associations between Self-Reported Health Status and Inappropriate  
                 Drug Choice PIM Use 
________________________________________________________________________ 
 




Self-Reported Health Status    
 Poor Reference group 
 Fair 1.152 0.722 – 1.838 0.552 
 Good 0.658 0.418 – 1.036 0.071 










Table 30:  Bivariate Associations between Self-Reported Health Status and Overall PIM 
                 Use      
________________________________________________________________________ 
 




Self-Reported Health Status    
 Poor Reference group 
 Fair 1.052 0.678 – 1.632 0.882 
 Good 0.619 0.405 – 0.946 0.027 









SELECTION procedure in SAS PROC LOGISTIC.  There were no significant 
interactions found, and so the main effects model was retained.  A reduced model was 
developed that included only significant covariates from the initial model and the reduced 
model used for final analyses.  Significant covariates in the reduced model were age, 
region, and number of medications.   
Table 31 presents results of the multiple logistic regression analysis.  The model 
showed good model fit with a non-significant Homer Lemeshow test (p=0.754).  Results 
of bivariate probit models developed to account for selection bias indicated no selection 
bias (rho p-value =0.297) (Appendix Table D1).  Results of link test checking for model 
specification error indicated that the model was properly specified and no relevant 
variables were left out or irrelevant variables included (hat-square p-value =0.994) 
(Appendix Table G1).  Graphical plots of influence statistics as shown in Appendix 
Figure J1 and Appendix Figure J2 indicated presence of subjects with influential 
covariate patterns.  However, removing these subjects from analysis did not alter the 
significance of model parameter estimates and so the reduced model was retained.   
Results from the multiple logistic regression model as shown in Table 31 
indicated individuals having more positive perceived provider communication index 
scores of 17 or 18 were less likely than those with index scores ranging from 5 to 14 to 
use inappropriate drug choice PIMs (OR=0.61, 95% CI=0.38 to 0.96, p=0.034), after 
adjusting for age, region, and number of medications.  However, after adjusting for 
multiple comparisons using a False Discovery Rate correction, no significant associations 
were found between perceived provider communication and inappropriate drug choice 






Table 31: Multivariate Associations between Perceived Provider Communication and 
                Inappropriate Drug Choice PIM Use, Adjusting for Age, Region, and Number  
                of Medications  
________________________________________________________________________ 
 




Perceived Provider  
Communication Index 
 5 to 14 Reference group 
 15 0.926 0.652 – 1.314 0.666 
 16 0.870 0.503 – 1.503 0.616 
 17 or 18 0.608 0.384 – 0.962 0.034 
 19 or 20 1.125 0.732 – 1.730 0.591 
Age     
  65 to 84 Reference group  
  85+ 0.708 0.508 – 0.986 0.041 
Region 
 South or Puerto Rico Reference group 
 West 0.684 0.485 – 0.964 0.030 
 Midwest 0.571 0.409 – 0.797 0.001 
 Northeast 0.632 0.442 – 0.902 0.012 
Number of Medications 
 0 to 5 Reference group 
 6 to 10 3.169 2.079 – 4.829 <.001 
 11 to 15 5.146 3.317 – 7.984 <.001 







Likelihood Ratio Test: Chi-square statistic=263.589, DF=11, p=<.001 






Table 32: Multiplicity Adjusted P-Values for Perceived Provider Communication in 
                Model Examining Associations between Perceived Provider Communication 
                and Inappropriate Drug Choice PIM Use, Adjusting for Age, Region, and  
                Number of Medications  
________________________________________________________________________ 
 




Perceived Provider  
Communication Index 
 5 to 14 Reference group 
 15 0.926 0.652 – 1.314 0.666 
 16 0.870 0.503 – 1.503 0.666 
 17 or 18 0.608 0.384 – 0.962 0.135 
 19 or 20 1.125 0.732 – 1.730 0.666 
________________________________________________________________________________________________________________________________________________ 
a 






Multivariate Associations between Perceived Provider  
Communication and Overall PIM Use after Adjusting for 
Demographic and Clinical Characteristics 
Multiple logistic regression models were developed to assess associations 
between perceived provider communication and overall PIM use, adjusting for 
demographic and clinical characteristics.  The response variable in the model was overall  
PIM use.  The predictor variable in the model was perceived provider communication.  
Covariates included in the model were age, gender, ethnicity, region, education, income, 
number of medical conditions, depression diagnosis, and self-reported health status.  A 
model with all two-way interactions and main effects was examined using the 
FORWARD SELECTION procedure in SAS PROC LOGISTIC.  There were no 
significant interactions found, and so the main effects model was retained.  A reduced 
model was developed that included only significant covariates from the initial model and 
the reduced model used for final analyses.  Significant covariates in the reduced model 
were age, region, and number of medications.   
 Table 33 presents results of the multiple logistic regression analysis.  The model 
showed good model fit with a non-significant Homer Lemeshow test (p=0.810).  Results 
of bivariate probit models developed to account for selection bias indicated no selection 
bias (rho p-value =0.532) (Appendix Table D2).  Results of the link test checking for 
model specification error indicated that the model was properly specified and no relevant 
variables were left out or irrelevant variables included (hat-square p-value =0.913) 
(Appendix Table G2).  Graphical plots of influence statistics as shown in Appendix 
Figure J3 and Appendix Figure J4 indicated presence of subjects with influential 
covariate patterns.  However, removing these subjects from analysis did not alter the 
significance of model parameter estimates and so the reduced model was retained.  As 






Table 33: Multivariate Associations between Perceived Provider Communication and             
                Overall PIM Use, Adjusting for Age, Region, and Number of Medications 
________________________________________________________________________ 
 




Perceived Provider  
Communication Index 
 5 to 14 Reference group 
 15 1.046 0.749 – 1.462 0.790 
 16 0.963 0.577 – 1.608 0.887 
 17 or 18 0.756 0.496 – 1.153 0.194 
 19 or 20 1.082 0.714 – 1.639 0.712 
Age     
  65 to 84 Reference group  
  85+ 0.688 0.506 – 0.937 0.018 
Region 
 South or Puerto Rico Reference group 
 West 0.960 0.704 – 1.309 0.797 
 Midwest 0.645 0.473 – 0.880 0.006 
 Northeast 0.696 0.498 – 0.972 0.033 
Number of Medications 
 0 to 5 Reference group 
 6 to 10 3.330 2.262 – 4.902 <.001 
 11 to 15 6.475 4.335 – 9.673 <.001 





Model Statistics:   
N=2,056 
Likelihood Ratio Test: Chi-square statistic=289.791, DF=11, p=<.001 






communication and overall PIM use, after adjusting for age, region, and number of 
medications. 
Associations between Perceived Provider   
Knowledge and PIM Use 
Bivariate Associations between Perceived Provider  
Knowledge and PIM Use 
Table 34 presents the distribution of perceived provider knowledge index scores.  
To avoid potential problems from small cell counts in logistic regression analysis, index 
scores were collapsed into four levels, with each level having not less than 100 
observations (Table 35).  The four levels of the perceived provider knowledge variable 
were “2 to 5,” “6,” “7,” and “8.”  Perceived provider knowledge index scores of 2 to 5 
was selected as the reference category.  
Ten events per degree of freedom are required for reliable parameter estimation in 
logistic regression models (Harrell, Lee et al. 1996; LaValley 2008; Peduzzi, Concato et 
al. 1996).  However, because number of excess dose, excess duration, or drug-disease 
interaction PIM users did not satisfy event size requirements for reliable models, 
associations between perceived provider knowledge and excess dose, excess duration or 
drug-disease interaction PIM use were not included in analyses. 
Bivariate Associations between Perceived Provider 
Knowledge and Inappropriate Drug Choice PIM Use 
There was no significant difference in mean perceived provider knowledge scores 
between inappropriate drug choice PIM users (mean score=6.5, SE=0.06) and non-users 
(mean score=6.6, SE=0.03).  In bivariate logistic regression analysis, individuals with 
more positive perceived provider knowledge index scores of 6 (OR=0.62, 95% CI=0.42 





Table 34:  Distribution of Perceived Provider Knowledge Index Scores 
________________________________________________________________________ 
Index Score Frequency      Percent 
_______________________________________________________________________________________________________________________________________________  
 Two 4 0.19 
 Three 3 0.15 
 Four 69 3.36 
 Five 71 3.46 
 Six 1,123 54.73  
 Seven 120 5.85  







Table 35:  Grouped Distribution of Perceived Provider Knowledge Index Scores 
________________________________________________________________________ 
Index Score Frequency      Percent 
_______________________________________________________________________________________________________________________________________________  
 2 to 5 147 7.16 
 6 1,123 54.73 
 7 120 5.85  







0.88, p=0.011) were more likely than those with index scores between 2 and 5 to use 
inappropriate drug choice PIMs (Table 36).   
Bivariate Associations between Perceived 
Provider Knowledge and Overall PIM Use 
There was no significant difference in mean perceived provider knowledge scores 
between overall PIM users (mean score=6.5, SE=0.05) and PIM non-users (mean 
score=6.6, SE=0.03).  Table 37 presents results of bivariate logistic regression examining 
associations between perceived provider knowledge and overall PIM use.  There were no 
associations found between perceived provider knowledge and overall PIM use. 
Multivariate Associations between Perceived Provider 
Knowledge and PIM Use after Adjusting for Demographic 
and Clinical Characteristics 
Multivariate Associations between Perceived Provider  
Knowledge and Inappropriate Drug Choice PIM Use after 
Adjusting for Demographic and Clinical Characteristics 
Multiple logistic regression models were developed to assess associations 
between perceived provider knowledge and inappropriate drug choice PIM use, adjusting 
for demographic and clinical characteristics.  The response variable in the model was 
inappropriate drug choice PIM use.  The predictor variable in the model was perceived 
provider knowledge.  Covariates included in the model were age, gender, ethnicity, 
region, education, income, number of medications, depression diagnosis, and self-
reported health status.  A model with all two-way interactions and main effects was 
examined using the FORWARD SELECTION procedure in SAS PROC LOGISTIC.  
There were no significant interactions found, and so the main effects model was retained.  






Table 36:  Bivariate Associations between Perceived Provider Knowledge and 
                 Inappropriate Drug Choice PIM Use 
________________________________________________________________________ 
 




Perceived Provider  
Knowledge Index    
 2 to 5 Reference group 
 6 0.622 0.417 – 0.927 0.019 
 7 0.473 0.252 – 0.891 0.020 









Table 37:  Bivariate Associations between Perceived Provider Knowledge and 
                 Overall PIM Use 
________________________________________________________________________ 
 




Perceived Provider  
Knowledge Index    
 2 to 5 Reference group 
 6 0.739 0.500 – 1.091 0.128 
 7 0.634 0.354 – 1.135 0.125 









model and the reduced model used for final analyses.  Significant covariates in the 
reduced model were age, region, and number of medications. 
Table 38 presents results of the multiple logistic regression analysis.  The model 
showed good model fit with a non-significant Homer Lemeshow test (p=0.845).  Results 
of bivariate probit models developed to account for selection bias indicated no  
selection bias (rho p-value =0.402) (Appendix Table E1).  Results of the link test 
checking for model specification error indicated that the model was properly specified 
and no relevant variables were left out or irrelevant variables included (hat-square p-
value =0.431) (Appendix Table H1).  Graphical plots of influence statistics as shown in 
Appendix Figure K1 and Appendix Figure K2 indicated presence of subjects with 
influential covariate patterns.  However, removing these subjects from analysis did not 
alter the significance of model parameter estimates and so the reduced model was 
retained. 
 Results from the multiple logistic regression model as shown in Table 38 
indicated individuals having more positive perceived provider knowledge index scores of 
six (OR=0.62, 95% CI=0.39 to 0.97, p=0.036), seven (OR=0.44, 95% CI=0.22 to 0.87, 
p=0.018), or eight (OR=0.55, 95% CI=0.34 to 0.88, p=0.012) were less likely than those 
with index scores ranging from two to five to use inappropriate drug choice PIMs, after 
adjusting for age, region, and number of medications.  Moreover, after adjusting for 
multiple comparisons using False Discovery Rate (FDR) correction, individuals having 
more positive perceived provider knowledge index scores of six (OR=0.62, 95% CI=0.39 
to 0.97, FDR=0.036), seven (OR=0.44, 95% CI=0.22 to 0.87, FDR=0.027), or eight 
(OR=0.55, 95% CI=0.34 to 0.88, FDR=0.027) were less likely than those with index 






Table 38: Multivariate Associations between Perceived Provider Knowledge and 
                Inappropriate Drug Choice PIM Use, Adjusting for Age, Region, and  
                Number of Medications  
________________________________________________________________________ 
 




Perceived Provider  
Knowledge Index 
 2 to 5 Reference group 
 6 0.619 0.395 – 0.969 0.036 
 7 0.437 0.219 – 0.869 0.018 
 8 0.547 0.341 – 0.876 0.012 
Age     
  65 to 84 Reference group  
  85+ 0.702 0.504 – 0.977 0.036 
Region 
 South or Puerto Rico Reference group 
 West 0.673 0.477 – 0.948 0.024 
 Midwest 0.600 0.431 – 0.836 0.003 
 Northeast 0.655 0.459 – 0.934 0.019 
Number of Medications 
 0 to 5 Reference group 
 6 to 10 3.238 2.124 – 4.937 <.001 
 11 to 15 5.180 3.338 – 8.040 <.001 







Likelihood Ratio Test: Chi-square statistic=269.848, DF=10, p=<.001 






Table 39: Multiplicity Adjusted P-Values for Perceived Provider Knowledge in Model 
                Examining Associations between Perceived Provider Knowledge and 
                Inappropriate Drug Choice PIM Use, Adjusting for Age, Region, and Number  
                of Medications 
________________________________________________________________________ 
 




Perceived Provider  
Knowledge Index 
 2 to 5 Reference group 
 6 0.619 0.395 – 0.969 0.036 
 7 0.437 0.219 – 0.869 0.027 
 8 0.547 0.341 – 0.876 0.027 
________________________________________________________________________________________________________________________________________________ 
a 






Multivariate Associations between Perceived Provider  
Knowledge and Overall PIM Use after Adjusting for 
Demographic and Clinical Characteristics 
Multiple logistic regression models were developed to assess associations 
between perceived provider knowledge and overall PIM use, adjusting for demographic 
and clinical characteristics.  The response variable in the model was overall PIM use.  
The predictor variable in the model was perceived provider knowledge.  Covariates 
included in the model were age, gender, ethnicity, region, education, income, number of  
medical conditions, depression diagnosis, and self-reported health status.  A model with 
all two-way interactions and main effects was examined using the FORWARD 
SELECTION procedure in SAS PROC LOGISTIC.  There were no significant 
interactions found, and so the main effects model was retained.  A reduced model was 
developed that included only significant covariates from the initial model and the reduced 
model used for final analyses.  Significant covariates included in the reduced model were 
age, and number of medications.   
 Table 40 presents results of the multiple logistic regression analysis.  The model 
showed good model fit with a non-significant Homer Lemeshow test (p=0.844).  Results 
of bivariate probit models developed to account for selection bias indicated no selection 
bias (rho p-value =0.304) (Appendix Table E2).  Results of the link test checking for 
model specification error indicated that the model was properly specified and no relevant 
variables were left out or irrelevant variables included (hat-square p-value =0.878) 
(Appendix Table H2).  Graphical plots of influence statistics as shown in Appendix 
Figure K3 and Appendix Figure K4 indicated presence of subjects with influential 
covariate patterns.  However, removing these subjects from analysis did not alter the 
significance of model parameter estimates and so the reduced model was retained. 
As shown in Table 40, there were no associations found between perceived knowledge 





Table 40: Multivariate Associations between Perceived Provider Knowledge and 
                Overall PIM Use, Adjusting for Age and Number of Medications  
________________________________________________________________________ 
 




Perceived Provider  
Knowledge Index 
 2 to 5 Reference group 
 6 0.730 0.471 – 1.131 0.159 
 7 0.591 0.313 – 1.115 0.104 
 8 0.636 0.403 – 1.005 0.053 
Age     
  65 to 84 Reference group  
  85+ 0.675 0.496 – 0.917 0.012 
Number of Medications 
 0 to 5 Reference group 
 6 to 10 3.368 2.288 – 4.960 <.001 
 11 to 15 6.672 4.473 – 9.952 <.001 







Likelihood Ratio Test: Chi-square statistic=288.568, DF=7, p=<.001 







Associations between Perceived Provider   
Competence and PIM Use 
Bivariate Associations between Perceived Provider  
Competence and PIM Use 
Table 41 presents the distribution of perceived provider competence index scores.  
To avoid potential problems from small cell counts in logistic regression analysis, index 
scores were collapsed into four levels, with each level having not less than 100 
observations (Table 42).  The four levels of the perceived provider competence variable 
were “2 to 5,” “6,” “7,” and “8.”  Perceived provider competence index scores of 2 to 5 
was selected as the reference category.  
Ten events per degree of freedom are required for reliable parameter estimation in 
logistic regression models (Harrell, Lee et al. 1996; LaValley 2008; Peduzzi, Concato et 
al. 1996).  However, because number of excess dose, excess duration, or drug-disease 
interaction PIM users did not satisfy event size requirements for reliable models, 
associations between perceived provider competence and excess dose, excess duration or 
drug-disease interaction PIM use were not included in analyses.  
Bivariate Associations between Perceived Provider 
Competence and Inappropriate Drug Choice PIM Use 
There was no significant difference in mean perceived provider competence scores 
between inappropriate drug choice PIM users (mean score=6.7, SE=0.06) and non-users 
(mean score=6.7, SE=0.02).  Table 43 presents results of bivariate analysis examining 
associations between perceived provider competence and inappropriate drug choice PIM 
use.  There were no associations found between perceived provider competence and 







Table 41:  Distribution of Perceived Provider Competence Index Scores 
________________________________________________________________________ 
Index Score Frequency      Percent 
_______________________________________________________________________________________________________________________________________________  
 Two 2 0.10 
 Three 3 0.15 
 Four 19 0.92 
 Five 106 5.15 
 Six 1,059 51.41  
 Seven 194 9.42  







Table 42:  Grouped Distribution of Perceived Provider Competence Index Scores 
________________________________________________________________________ 
Index Score Frequency      Percent 
_______________________________________________________________________________________________________________________________________________  
 2 to 5 130 6.31 
 6 1,059 51.41  
 7 194 9.42  







Table 43:  Bivariate Associations between Perceived Provider Competence and 
                 Inappropriate Drug Choice PIM Use  
________________________________________________________________________ 
 




Perceived Provider  
Competence Index    
 2 to 5 Reference group 
 6 0.713 0.458 – 1.110 0.135 
 7 0.637 0.361 – 1.123 0.119 









Bivariate Associations between Perceived 
Provider Competence and Overall PIM Use 
There was no significant difference in mean perceived provider competence 
scores between overall PIM users (mean score=6.7, SE=0.05) and PIM non-users (mean 
score=6.7, SE=0.03).  Table 44 presents results of bivariate logistic regression examining 
associations between perceived provider competence and overall PIM use.  There were 
no associations found between perceived provider competence and overall PIM use. 
Multivariate Associations between Perceived Provider 
Competence and PIM Use after Adjusting for Demographic 
and Clinical Characteristics 
Multivariate Associations between Perceived Provider  
Competence and Inappropriate Drug Choice PIM Use after 
Adjusting for Demographic and Clinical Characteristics 
Multiple logistic regression models were developed to assess associations between 
perceived provider competence and inappropriate drug choice PIM use, adjusting for 
demographic and clinical characteristics.  The response variable in the model was 
inappropriate drug choice PIM use.  The predictor variable in the model was perceived 
provider competence.  Covariates included in the model were age, gender, ethnicity, 
region, education, income, number of medications, depression diagnosis, and self-
reported health status.  A model with all two-way interactions and main effects was 
examined using the FORWARD SELECTION procedure in SAS PROC LOGISTIC.  
There were no significant interactions found, and so the main effects model was retained.  
A reduced model was developed that included only significant covariates from the initial 
model and the reduced model used for final analyses.  Significant covariates in the 






 Table 44:  Bivariate Associations between Perceived Provider Competence and 
                 Overall PIM Use 
________________________________________________________________________ 
 




Perceived Provider  
Competence Index    
 2 to 5 Reference group 
 6 0.803 0.525 – 1.229 0.313 
 7 0.771 0.453 – 1.311 0.337 









 Table 45 presents results of the multiple logistic regression analysis.  The model 
showed good model fit with a non-significant Homer Lemeshow test (p=0.372).  Results 
of bivariate probit models developed to account for selection bias indicated no  
selection bias (rho p-value =0.129) (Appendix Table F1).  Results of the link test 
checking for model specification error indicated that the model was properly specified 
and no relevant variables were left out or irrelevant variables included (hat-square p-
value =0.544) (Appendix Table I1).  Graphical plots of influence statistics as shown in  
Appendix Figure L1 and Appendix Figure L2 indicated presence of subjects with 
influential covariate patterns.  However, removing these subjects from analysis did not 
alter the significance of model parameter estimates and so the reduced model was 
retained.  As shown in Table 45, there were no associations were found between 
perceived provider competence and inappropriate drug choice PIM use after adjusting for 
age, region, and number of medications. 
Multivariate Associations between Perceived Provider  
Competence and Overall PIM Use after Adjusting for 
Demographic and Clinical Characteristics 
Multiple logistic regression models were developed to assess associations 
between perceived provider competence and overall PIM use, adjusting for demographic 
and clinical characteristics.  The response variable in the model was overall PIM use.  
The predictor variable in the model was perceived provider competence.  Covariates 
included in the model were age, gender, ethnicity, region, education, income, number of 
medical conditions, depression diagnosis, and self-reported health status.  A model with 
all two-way interactions and main effects was examined using the FORWARD 
SELECTION procedure in SAS PROC LOGISTIC.  There were no significant 






Table 45: Multivariate Associations between Perceived Provider Competence and 
                Inappropriate Drug Choice PIM Use, Adjusting for Age, Region, and  
                Number of Medications  
________________________________________________________________________ 
 




Perceived Provider  
Competence Index 
 2 to 5 Reference group 
 6 0.923 0.567 – 1.504 0.749 
 7 0.821 0.443 – 1.521 0.530 
 8 0.926 0.561 – 1.527 0.763 
Age     
  65 to 84 Reference group  
  85+ 0.702 0.504 – 0.978 0.036 
Region 
 South or Puerto Rico Reference group 
 West 0.679 0.482 – 0.957 0.027 
 Midwest 0.594 0.426 – 0.827 0.002 
 Northeast 0.635 0.444 – 0.908 0.013 
Number of Medications 
 0 to 5 Reference group 
 6 to 10 3.118 2.047 – 4.748 <.001 
 11 to 15 5.064 3.267 – 7.847 <.001 







Likelihood Ratio Test: Chi-square statistic=257.819, DF=10, p=<.001 






developed that included only significant covariates from the initial model and the reduced 
model used for final analyses.  Significant covariates included in the reduced model were 
age, and number of medications.   
 Table 46 presents results of the multiple logistic regression analysis.  The model 
showed good model fit with a non-significant Homer Lemeshow test (p=0.926).  Results 
of bivariate probit models developed to account for selection bias indicated no selection 
bias (rho p-value =0.370) (Appendix Table F2).  Results of the link test checking for 
model specification error indicated that the model was properly specified  
and no relevant variables were left out or irrelevant variables included (hat-square p-
value =0.944) (Appendix Table I2).  Graphical plots of influence statistics as shown in 
Appendix Figure L3 and Appendix Figure L4 indicated presence of subjects with 
influential covariate patterns.  However, removing these subjects from analysis did not 
alter the significance of model parameter estimates and so the reduced model was 
retained.  As shown in Table 46, there were no associations found between perceived 







Table 46: Multivariate Associations between Perceived Provider Competence and 
                Overall PIM Use, Adjusting for Age and Number of Medications  
________________________________________________________________________ 
 




Perceived Provider  
Competence Index 
 2 to 5 Reference group 
 6 1.083 0.679 – 1.727 0.738 
 7 1.026 0.576 – 1.828 0.932 
 8 1.036 0.641 – 1.675 0.884 
Age     
  65 to 84 Reference group  
  85+ 0.669 0.492 – 0.910 0.010 
Number of Medications 
 0 to 5 Reference group 
 6 to 10 3.319 2.256 – 4.883 <.001 
 11 to 15 6.490 4.354 – 9.675 <.001 







Likelihood Ratio Test: Chi-square statistic=278.645, DF=7, p=<.001 
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SUMMARY AND CONCLUSIONS 
Background 
 Potentially inappropriate medications (PIMs) are defined as medications that 
introduce a significant risk of adverse events in older adults or persons aged 65 years or 
older where there exists alternative therapy for treating the same condition that are 
equally effective and safer (Beers, Ouslander et al., 1991; Stuck, Beers et al., 1994).  The 
evidence of associations between PIM use and higher risk for morbidity, mortality, and 
increased health care expenditures make use of such drugs an important public health 
concern (Guaraldo, Cano et al., 2011; Spinewine, Schmader et al., 2007).   
 The Beers criteria are the most accepted and most commonly used measure of 
PIM use in older adults, and were revised in 2012 (American Geriatrics Society 2012 
Beers Criteria Update Expert Panel 2012).  Prior studies have reported rates of PIM use 
based on prior versions of the Beers criteria.  No studies were found that reported 
estimates of PIM use in older adults based on the 2012 Beers criteria, which is the most 
current version of the Beers criteria.  This study estimated rates of PIM use among 
community-dwelling Medicare Part D beneficiaries based on the 2012 Beers criteria.  
Such estimates will provide information on rates of inappropriate drug prescribing in 
Medicare beneficiaries based on current clinical evidence.   
 Providers who are effective communicators, knowledgeable, and competent 
should be able to elicit adequate information from patients about their conditions and 





appropriate therapy.  Because patient perceptions of provider communication, provider 
knowledge, and provider competence have been associated with measures of health 
quality including satisfaction with care and adherence to therapy in prior studies, it is 
expected that patient perceptions of such provider behavior would be associated with 
PIM use, another measure of healthcare quality.  However, evidence is lacking on 
whether patient perceptions of such provider behavior are associated with PIM use.  This 
study will inform on possible associations between patient perceptions of provider 
communication, provider knowledge, and provider competence and PIM use among 
community-dwelling Medicare Part D beneficiaries.  
Objectives 
Study objectives were to: 
1. Determine prevalence of PIM use among community-dwelling Medicare Part D 
beneficiaries, 
2. Determine incidence of PIM use among community-dwelling Medicare Part D 
beneficiaries,  
3. Examine associations between perceived provider communication and PIM use 
among community-dwelling Medicare Part D beneficiaries,  
4. Examine associations between perceived provider knowledge and PIM use   
among community-dwelling Medicare Part D beneficiaries, and  
5. Examine associations between perceived provider competence and PIM use 








 A retrospective observational analysis was conducted to determine the prevalence 
and incidence of PIM use among community-dwelling Medicare beneficiaries, and to 
examine associations between patient perceptions of provider communication, provider 
knowledge, and provider competence and PIM use among community-dwelling Medicare 
beneficiaries.  Data for the analyses were obtained from Medicare Current Beneficiary 
Survey files maintained by the Office of Strategic Planning of the Centers for Medicare 
and Medicaid Services.  Claim files from January 2007 through December 2008 were 
used.   
 Individuals were eligible for inclusion in the prevalence sample if they were aged 
65 years or older in 2008, continuously enrolled in Medicare Part D from October 2007 
through December 2008, and living in the community from October 2007 through 
December 2008.  There were no exclusion criteria for the prevalence sample.  Individuals 
were eligible for inclusion in the incidence sample if they were aged 65 years or older in 
2008, continuously enrolled in Medicare Part D from October 2007 through December 
2008, and living in the community from October 2007 through December 2008.  
Individuals were excluded from the incidence sample if they received PIMs at any time 
between October 2007 and December 2007.  
 Potentially inappropriate medications were identified based on the 2012 Beers 
criteria (American Geriatrics Society 2012 Beers Criteria Update Expert Panel 2012) in 
each of four broad categories including inappropriate drug choice, excess dose, excess 
duration, and drug-disease interaction.  Inappropriate drug choice PIMs are medications 
considered always potentially inappropriate in older adults.  Excess dose PIMs are 
medications considered potentially inappropriate at daily doses beyond specific limits.  
Excess duration PIMs are medications considered potentially inappropriate when used 





considered potentially inappropriate in older adults having specific concomitant 
conditions.  
 The data elements from Medicare Current Beneficiary Survey prescription claim 
files used to identify PIMs were generic name of drug, number of days supplied, drug 
quantity, dosage strength, route of administration, and date of service.  To identify 
whether an individual had diagnosis for a condition listed in the 2012 Beers criteria, 
claims records from January 2007 through December 2008 for each individual were 
examined for condition-specific ICD-9 CM codes.  One source of ICD-9 CM codes was a 
systematic search of the Medline database from January 2008 through May 2013, using 
‘ICD-9 code’ and name of the condition as keywords to identify published articles 
describing use of such codes to identify diagnosis for that condition.  Another source was 
an online searchable database of ICD-9 CM codes compiled from files available from the 
National Center for Health Statistics (National Center for Health Statistics 2009).  A third 
source was the Clinical Classifications Software for ICD 9-CM maintained by the 
Agency for Healthcare Resource and Quality and available online (Agency for 
Healthcare Research and Quality 2010).  Condition-specific ICD-9 CM codes identified 
in at least two of the three sources were used to identify individuals with that condition. 
 To identify use of inappropriate drug choice PIMs, a separate variable was created 
for each inappropriate drug choice PIM and the variable assigned a value of ‘1’ if the 
individual received medication associated with the specific variable in 2008.  Otherwise a 
value of ‘0’ was assigned to the variable.  To identify use of excess dose PIMs, a separate 
variable was created for each excess dose PIM and assigned a value of ‘1’ if the 
individual received medication associated with the specific variable in 2008 and had a 
calculated daily dose that exceeded dose limits for that medication.  Otherwise a value of 
‘0’ was assigned to the variable.  To identify use of excess duration PIMs, a separate 





individual received medication associated with the specific variable in 2008 and had 
duration of use that exceeded duration limits for that medication.  Otherwise a value of 
‘0’ was assigned to the variable.  To identify use of drug-disease interaction PIMs, first 
2007 and 2008 claims records for each individual were examined to determine whether 
the person had diagnosis for a condition listed in this PIM category.  Then a separate 
variable was created for each drug-disease interaction PIM and assigned a value of ‘1’ if 
the individual received medication considered potentially inappropriate for that specific 
condition in 2008 and had diagnosis for the condition prior to receiving the drug.  
Otherwise a value of ‘0’ was assigned to the variable.   
 Patient perceptions of provider communication, provider knowledge and provider 
competence were assessed using previously validated indices (Ward and Thomas 2013).  
The perceived communication index was created from patient responses to five questions 
in the Medicare Current Beneficiary Survey.  The perceived knowledge and perceived 
competence indices were each created from patient responses to two survey questions.    
All questions included in each domain must have been answered for the index to be 
created.  The response to each question was given a value from one to four.  One 
indicated a response of strongly disagree, two indicated disagree, three indicated agree, 
and four indicated strongly agree.  Negatively worded questions were reverse coded and 
values within each domain summed to create each index.  The communication index had 
a theoretical range of 4 to 20.  The knowledge index had a range of 2 to 8, and the 
competence index had a range of 2 to 8.  For all indices, a higher score indicates more 
positive patient perception of physicians. 
 To determine prevalence of PIMs identified in the inappropriate drug choice, 
excess dose, excess duration, and drug-disease interaction categories, percentages and 95 
percent confidence intervals were calculated for individuals receiving PIMs in each of the 





percentages and 95 percent confidence intervals were calculated for the proportion of 
individuals receiving at least one PIM in any of the four PIM categories at any time in 
2008.  To determine incidence of PIMs identified in the inappropriate drug choice, excess 
dose, excess duration, and drug-disease interaction categories, percentages and 95 percent 
confidence intervals were calculated for individuals with new receipt of PIMs in each of 
the four categories at any time in 2008.  To determine incidence of overall PIM use, 
percentages and 95 percent confidence intervals were calculated for the proportion of 
individuals with new receipt of at least one PIM in any of the four PIM categories at any 
time in 2008.   
 Multiple logistic regression models were developed to examine associations 
between perceived provider communication and PIM use, to examine associations 
between perceived provider knowledge and PIM use, and to examine associations 
between perceived provider competence and PIM use.  The incidence of PIM use was 
focused on in these models.   
Results and Discussion 
Prevalence Sample Characteristics 
 A total of 2,705 individuals were identified in the prevalence sample.  The mean 
age for PIM users (76.8 years, Standard Error = 0.24) was less than the mean age for PIM 
non-users (77.6 years, SE = 0.17).  More PIM users were female (67.08%) as compared 
to PIM non-users (58.44%).  There were more Whites in the PIM non-user group 
(85.32%) than in the PIM user group (81.30%).  A greater proportion of PIM users 
(45.91%) than PIM non-users (36.87%) were living in the South region of the US or 
Puerto Rico.  There were more PIM users at an educational level of 8
th 
grade or lower 





non-users (34.00%) had an annual income of 15,000 dollars or less.  The mean number of 
medications received by PIM users (13.4 medications, SE = 0.22) was greater than that 
received by PIM non-users (7.8 medications, SE = 0.17).  More PIM non-users (86.87%) 
had diagnosis for depression than PIM users (77.08%).  A greater proportion of PIM 
users (35.95%) than PIM non-users (20.86%) reported their health status as poor or fair.  
Prevalence of PIM Use 
 Potentially inappropriate medications were identified based on the 2012 Beers 
criteria in each of four broad categories including inappropriate drug choice, excess dose, 
excess duration, and drug-disease interaction.  The one-year prevalence of PIM use 
among community-dwelling Medicare Part D beneficiaries was 27.6 percent for 
inappropriate drug choice PIMs (95% CI = 25.9 to 29.3), 3.3 percent for excess dose 
PIMs (95% CI = 2.6 to 3.9), 3.5 percent for excess duration PIMs (95% CI = 2.8 to 4.2), 
and 3.2 percent for drug-disease interaction PIMs (95% CI = 2.5 to 3.8).  There were no 
studies found that reported PIM prevalence estimates in Medicare beneficiaries based on 
the 2012 Beers criteria which is the most current version of the Beers criteria.  Prior 
studies of PIM use in the Medicare population based on previous versions of the Beers 
criteria reported rates ranging from 21.3 percent to 34.4 percent (Cannon, Choi et al., 
2006; Fick, Waller et al., 2001; Skaar and O'Connor 2012; Stuart, Kamal-Bahl et al., 
2003; Woelfel, Patel et al., 2011).  Cannon et al., Fick et al., and Stuart et al., identified 
PIMs based on a subset of the 1997 Beers criteria consisting solely of inappropriate drug 
choice PIMs, whereas, Woelfel et al. and Skarr et al. identified PIMs based on a subset of 
the 2002 Beers criteria consisting of inappropriate drug choice, excess dose, and excess 
duration PIMs.  However, because previous versions of the Beers criteria differ from the 
2012 Beers criteria, estimates of PIM prevalence in Medicare beneficiaries from prior 





 The overall one-year prevalence of PIM use was 33.0 percent (95% CI = 31.2 to 
34.8) with the most commonly received PIMs including glyburide (4.88%), promethazine 
(4.51%), and estrogens (3.95%).  Overall PIM use was defined as receipt of at least one 
PIM identified in the inappropriate drug choice, excess dose, excess duration, or drug-
disease interaction categories.  There were no studies found that reported PIM prevalence 
rates in Medicare beneficiaries based on the 2012 Beers criteria.  There were also no 
studies found that reported PIM prevalence in Medicare beneficiaries based on prior 
versions of the Beers criteria using the entire criteria.   
Incidence Sample Characteristics 
 A total of 2,210 individuals were identified in the incidence sample.  The mean 
age for PIM users (77.2 years, SE = 0.32) was less than the mean age for PIM non-users 
(77.7 years, SE = 0.17).  More PIM users were female (62.88%) as compared to PIM 
non-users (58.28%).  There were more Whites in the PIM non-user group (85.67%) than 
in the PIM user group (79.91%).  A greater proportion of PIM users (47.38%) than PIM 
non-users (36.82%) were living in the South region of the US or Puerto Rico.  There were 
more PIM users at an educational level of 8
th 
grade or lower (20.22%) as compared to 
PIM non-users (13.84%).  More PIM users (39.74%) than PIM non-users (33.96%) had 
an annual income of 15,000 dollars or less.  The mean number of medications received 
by PIM users (13.4 medications, SE = 0.31) was greater than that received by PIM non-
users (7.8 medications, SE = 0.12).  A greater proportion of PIM non-users (86.76%) had 
diagnosis for depression than PIM users (79.91%).  More PIM users (34.94%) than PIM 







Incidence of PIM Use 
 The one-year incidence of PIM use among community-dwelling Medicare Part D 
beneficiaries was 17.2 percent for inappropriate drug choice PIMs (95% CI = 15.6 to 
18.8), 1.2 percent for excess dose PIMs (95% CI = 0.8 to 1.7), 2.6 percent for excess 
duration PIMs (95% CI = 2.0 to 3.3), and 1.8 percent for drug-disease interaction PIMs 
(95% CI = 1.3 to 2.4).  Sample selection for the incidence sample required exclusion of 
individuals receiving PIMs in the three months prior to the study period.  The overall 
one-year incidence of PIM use was 20.7 percent (95% CI = 19.0 to 22.4), with the most 
commonly initiated PIMs including promethazine (3.62%), cyclobenzaprine (2.68%) and 
zolpiderm (2.08%).  
Associations between Perceived Provider Communication and PIM Use, 
Adjusting for Demographic and Clinical Characteristics 
 Multiple logistic regression models were developed to assess associations 
between perceived provider communication and use of PIMs identified in the 
inappropriate drug choice category, adjusting for age, gender, ethnicity, region, 
education, income, depression diagnosis, number of medications, and self-reported health 
status.  To avoid potential problems from small cell counts in logistic regression analysis, 
perceived provider communication scores were collapsed into five levels of “5 to 14,” 
“15,” “16,” “17 or 18,” and “19 or 20,” with each level having not less than 100 
observations.  A reduced model was developed that included only significant covariates 
and two-way interactions from the initial model and the reduced model used for final 
analyses.  Significant covariates in the reduced model were age, region, and number of 
medications.  Models were similarly developed for overall PIM use with age, region, and 
number of medications included as significant covariates in the reduced model.  





interaction PIM use because there were insufficient number of such PIM users to conduct 
analyses. 
 Perceived provider communication was not associated with inappropriate drug 
choice PIM use after adjusting for age, region, and number of medications.  Perceived 
provider communication was also not associated with overall PIM use after adjusting for 
age, region, and number of medications.  There were no prior studies found that 
examined associations between patient perceptions of provider communication and PIM 
use.  One study was found that examined associations between objective assessments of 
provider communication and medication use (Kawasumi, Ernst et al., 2011).  The authors 
found no associations between provider communication based on test scores from a 
physician licensing examination and appropriate prescribing of recommended 
corticosteroids in patients with out-of-control asthma, but focused on use of only one 
medication class and excluded older adults at higher risk for drug therapy problems.  
However, because the objective measure of provider communication used in the study by 
Kawasumi et al. may not necessarily assess the same construct as the subjective measure 
of provider communication in the current study, comparing findings may be difficult. 
 Finding no associations between patient perceptions of provider communication 
and PIM use were surprising.  Although hypothesized relationships between perceived 
provider characteristics and PIM use were not based upon the former reflecting actual 
provider ability, of the three perceived provider characteristics assessed in this study, 
perceived provider communication was thought to be the one most likely to be associated 
with PIM use.  This is because most patients are better able to directly assess provider 







Associations between Perceived Provider Knowledge and PIM Use, 
Adjusting for Demographic and Clinical Characteristics 
 Multiple logistic regression models were developed to assess associations 
between perceived provider knowledge and inappropriate drug choice PIM use, adjusting 
for age, gender, ethnicity, region, education, income, depression diagnosis, number of 
medications, and self-reported health status.  Perceived provider knowledge scores were 
collapsed into four levels of “2 to 5,” “6,” “7,” and “8,” with each level having not less 
than 100 observations.  A reduced model was developed that included only significant 
covariates and two-way interactions from the initial model and the reduced model used 
for final analyses.  Significant covariates in the reduced model were age, region, and 
number of medications.  Models were similarly developed for overall PIM use with age, 
and number of medications included as significant covariates in the reduced model.   
 There were no associations found between perceived provider knowledge and 
overall PIM use.  However, individuals having more positive perceived provider 
knowledge scores were less likely to use inappropriate drug choice PIMs.  Prior studies 
assessing associations between perceived provider knowledge and PIM use were not 
found.  One study was found that examined associations between objective assessments 
of provider knowledge and non-steroidal anti-inflammatory drug use (Grad, Tamblyn et 
al., 1997).  Grad et al. found no associations between provider knowledge of appropriate 
non-steroidal anti-inflammatory drug prescribing and quality of therapeutic management.  
However, they focused on use of only one medication class and analyzed a sample size of 
only 37 cases.  Nevertheless, because the objective measure of provider knowledge 
applied in the study by Grad et al. may not necessarily assess the same construct as the 
subjective measure of provider knowledge in the current study, comparing findings may 






Associations between Perceived Provider Competence and PIM Use, 
Adjusting for Demographic and Clinical Characteristics 
 Multiple logistic regression models were developed to assess associations 
between perceived provider competence and inappropriate drug choice PIM use, 
adjusting for age, gender, ethnicity, region, education, income, depression diagnosis, 
number of medications, and self-reported health status.  Perceived provider competence 
scores were collapsed into four levels of “2 to 5,” “6,” “7,” and “8,” with each level 
having not less than 100 observations.  A reduced model was developed that included 
only significant covariates and two-way interactions from the initial model and the 
reduced model used for final analyses.  Significant covariates in the reduced model were 
age, region, and number of medications.  Models were similarly developed for overall 
PIM use with age, and number of medications included as significant covariates in the 
reduced model. 
 Perceived provider competence was not associated with inappropriate drug choice 
PIM use or overall PIM use.  No prior studies were found that examined associations 
between patient perceptions of provider competence and PIM use.  One study was found 
that examined associations between objective assessments of provider competence and 
medication use (Kawasumi, Ernst et al. 2011).  The authors found no associations 
between provider competence based on test scores from a physician licensing 
examination and use of recommended steroids in patients with out-of-control asthma, but 
focused on use of only one medication class and excluded older adults at higher risk for 
drug therapy problems.  However, because objective measures of provider competence 
used in the study by Kawasumi et al. may not necessarily assess the same construct as the 








 A few limitations should be noted in interpreting study results.  The study samples 
were limited to community-dwelling Medicare beneficiaries so caution in making 
inferences beyond this population is advised.  The study uses administrative claims data 
from the Medicare Current Beneficiary Survey.  Any incomplete, missing, or erroneous 
data in claims may affect estimates of medication use.  Diagnosis for disease conditions 
listed in the 2012 Beers criteria were identified using ICD-9 CM codes in claims data and 
use of ICD-9 codes in claims data to identify diagnosis may be imperfect due to coding 
variation.  However, the ICD-9 CM codes used in the current study have used in prior 
studies to identify the specific disease conditions.  
 A three-month PIM-free interval was used to identify incident PIM users.  It is 
possible that some individuals included in the incidence sample may have received PIMs 
before the three-month PIM-free interval.  Thirty-seven percent of PIMs listed in the 
2012 Beers criteria could not be identified using information available in claims data and 
so estimates of PIM use in the current study may be conservative.   
Conclusions 
 This study determined prevalence and incidence of PIM use among community-
dwelling Medicare Part D beneficiaries and assessed associations between patients’ 
perceptions of provider communication, provider knowledge, and provider competence 
with PIM use.  The overall one-year prevalence of PIM use was 33 percent.  The overall 
one-year incidence of PIM use was approximately 21 percent.  Because information 
required to identify all PIMs listed in the 2012 Beers criteria were not available, the 
estimates of PIM use may be conservative. 
 It was hypothesized that patients’ perceptions of provider communication, 





Results from this study indicate that more positive patients’ perceptions of provider 
knowledge was associated with lower probability for PIM use.  However, there were no 
associations found between patients’ perceptions of provider communication or provider 
competence and PIM use. 
Implications 
 The considerable use of PIMs among community-dwelling Medicare Part D 
beneficiaries is a significant public health concern given prior evidence of associations 
between such medication use and higher morbidity, mortality, and healthcare 
expenditure.  It is possible that patients’ perceptions of provider knowledge accurately 
reflect actual provider ability.  In which case findings that patients’ perceptions of 
provider knowledge was associated with PIM use may provide some direction to efforts 
to identify provider-specific risk factors for PIM use.  It is also possible that patients’ 
perceptions of provider knowledge do not accurately reflect actual provider ability.  In 
that case the findings may suggest that patients’ perceptions of provider knowledge 
reflect some aspect of the patient-provider interaction that impacts PIM use and this 
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Table A1:  List of Medications Considered Potentially Inappropriate for Use in Persons  
                  Aged 65 Years or Older Based on the 2012 Beers Criteria 
_______________________________________________________________________ 
Therapeutic or  Included in  
Drug class Medication Analysis 
______________________________________________________________________________________________________________________________________________ 
INAPPROPRIATE DRUG CHOICE  
Alpha agonists, central 
 Guanabenz 
 Guanfacine   
 Methyldopa   
Analgesics, narcotic 
 Meperidine   
 Pentazocine   
Analgesics, non-narcotic 
 Indomethacin   
 Ketorolac, includes parenteral   
Antiarrhythmic  
 Disopyramide   
Antihistamines, first generation  
 Brompheniramine   
 Carbinoxamine   
 Chlorpheniramine   
 Clemastine 
 Cyproheptadine    
 Dexbrompheniramine    
 Dexchlorpheniramine    
 Doxylamine    
 Hydroxyzine    
 Promethazine    
 Triprolidine   
Antiemetics 
 Trimethobenzamide   
 Metoclopramide (avoid, except  
 for treatment of gastroparesis)   
Anti-infective  
 Nitrofurantoin (avoid in persons  
 with CrCL < 60 ml/min)  
Antiparkinson agents   
 Benztropine, oral   
 Trihexyphenidyl   
Antipsychotics 
 Thioridazine   






Table 1: Continued 
_______________________________________________________________________ 
Therapeutic or  Included in  
Drug class Medication Analysis 
______________________________________________________________________________________________________________________________________________ 
Antispasmodics (avoid except 
in short-term palliative care to 
decrease oral secretions)  
 Belladonna alkaloids   
 Clidinium-chlordiazepoxide   
 Dicyclomine   
 Hyoscyamine   
 Propantheline   
 Scopolamine   
Antithrombotics 
 Dipyridamole, oral short acting    
  (does not apply to extended release  
 combination with aspirin) 
 Ticlopidine   
Barbiturates 
 Amobarbital   
 Butabarbital   
 Butalbital   
 Mephobarbital   
 Pentobarbital  
 Phenobarbital   
 Secobarbital   
Beta-adrenergic agonist  
 Isoxsuprine   
Calcium channel blocker 
 Nifedipine, immediate release   
Hormones 
 Desiccated thyroid   
 Estrogens with or without 
 progestins, oral and patch   
 Estrogens with or without progestins, 
 topical (acceptable to use low-dose 
 vaginal estrogen creams for treatment 
 of dyspareunia, lower urinary tract 
 infections, and other vaginal  
 symptoms)  
 Growth hormone (except as hormone 
 replacement after pituitary gland 
 removal)   
 Insulin, sliding scale  
 Megestrol   






Table 1: Continued 
_______________________________________________________________________ 
Therapeutic or  Included in  
Drug class Medication Analysis 
_____________________________________________________________________________________________________________________________________________ 
Hormones continued  Methyltestosterone (except used for 
 for moderate to severe hypogonadism)     
 Testosterone (except used for 
 moderate to severe hypogonadism)   
Hypnotic/anxiolytic 
 Chloral hydrate   
 Meprobamate   
Laxative 
 Mineral oil, oral    
Psychotherapeutic agent 
 Ergot mesylates   
Skeletal muscle relaxants 
 Carisoprodol   
 Chlorzoxazone   
 Cyclobenzaprine   
 Metaxalone   
 Methocarbamol 
 Orphenadrine    
Sulfonylureas, long duration 
 Chlorpropamide   
 Glyburide   
Tertiary Tricyclic Antidepressants   
 Amitriptyline   
 Clomipramine   
 Imipramine   
 Trimipramine   
EXCESS DOSE 
Alpha agonist, Central 
 Reserpine (> 0.1 mg/d)  
Antiarrhythmic  
 Digoxin (> 0.125 mg/d)  
Diuretic 
 Spironolactone > 25 mg/d (avoid 
 in patients with heart failure or with 
 CrCl < 30 ml/min)  
Tertiary Tricyclic antidepressants 






Table 1: Continued 
_______________________________________________________________________ 
Therapeutic or  Included in  
Drug class Medication Analysis 
______________________________________________________________________________________________________________________________________________ 
EXCESS DURATION  
Analgesics, non-narcotic 
(avoid chronic use unless other 
alternatives not effective and 
patient can take gastroprotective agent) 
 Non-COX selective NSAIDs, oral 
  Aspirin > 325 mg/d  
  Diclofenac  
  Diflunisal  
  Etodolac  
  Fenoprofen  
  Ibuprofen  
  Ketoprofen  
  Meclofenamate  
  Mefenamic acid  
  Meloxicam  
  Nabumetone  
  Naproxen  
  Oxaprozin  
  Piroxicam   
  Sulindac  
  Tolmetin  
Anti-infective 
 Nitrofurantoin (avoid for  
 (long-term suppression)  
Nonbenzodiazepine hypnotics 
 Eszopiclone (avoid > 90days)   
 Zolpiderm (avoid > 90days)   






Table 1: Continued 
______________________________________________________________________ 
  Included in  




 Benzodiazepines (avoid for treatment 
 of agitation) 
  Alprazolam   
  Estazolam   
  Lorazepam   
  Oxazepam   
  Temazepam   
  Triazolam   
  Clorazepate   
  Chlordiazepoxide   
  Clonazepam 
  Diazepam   
  Flurazepam   
  Quazepam   
Atrial fibrillation 
 Antiarrhythmic drugs, Class Ia, Ic, III  
 (avoid as 1st line treatment  
 for atrial fibrillation)  
  Amiodarone        
  Dofetilide   
   Dronedarone (also avoid in patients  
  with permanent atrial fibrillation)   
  Flecainide   
  Ibutilide    
  Procainamide   
  Propafenone   
  Quinidine   
  Sotalol   
Chronic constipation (avoid 
unless no other alternatives)  
 Oral muscarinics for urinary incontinence 
  Darifenacin  
  Fesoterodine  
  Oxybutynin, oral  
  Solifenacin  
   Tolterodine  
  Trospium  
 Calcium channel blockers  
  Diltiazem,  
  Verapamil  
 First generation antihistamines  





Table 1: Continued 
______________________________________________________________________ 
  Included in  
Disease/Condition Medication Analysis 
_____________________________________________________________________________________________________________________________________________ 
Chronic constipation continued 
  Chlorpheniramine  
  Clemastine   
  Cyproheptadine  
  Dexbrompheniramine   
  Dexchlorpheniramine   
  Diphenhydramine  
  Doxylamine  
  Hydroxyzine  
  Promethazine  
  Tiprolidine 
 Anticholinergics and Antispasmodics 
  Antipsychotics  
  Belladonna alkaloids   
  Clidinium-chlordiazepoxide  
  Dicyclomine  
  Hyoscyamine   
  Propantheline  
  Scopolamine  
  Tertiary tricyclic antidepressants  
  Amitriptyline  
  Clomipramine  
  Doxepin  
  Imipramine  
  Trimipramine  
Chronic kidney disease, 
Stages IV and V  
 NSAIDs    
 Triamterene  
Dementia and 
cognitive impairment Anticholinergics   
 Benzodiazepines   
 H2-receptor antagonists    
 Zolpiderm  
 Antipsychotics   
Delirium 
 All tricyclic antidepressants   
 Anticholinergics   
 Benzodiazepines   
 Chlorpromazine   
 Corticosteriods  
 H2-receptor antagonists   
 Meperidine, Thioridazine   





Table 1: Continued 
______________________________________________________________________ 
  Included in  
Disease/Condition Medication Analysis 
_____________________________________________________________________________________________________________________________________________ 
Epilepsy or Chronic Seizures 
 Bupropion   
 Chlorpromazine   
 Clozapine   
 Maprotiline   
 Olanzapine    
 Thioridazine   
 Thiothixene   
 Tramadol   
Heart failure 
 NSAIDs and COX-2 inhibitors  
 Calcium channel blockers (avoid 
 only for systolic heart failure)  
  Diltiazem,   
  Verapamil   
 Pioglitazone   
 Rosiglitazone    
 Cilostazol   
 Dronedarone   
History of falls 
or fractures (avoid unless 
safer alternatives not available) 
 Anticonvulsants (avoid except for 
 seizure disorders)  
 Antipsychotics   
 Benzodiazepines  
 Nonbenzodiazepine hypnotics  
  Eszopiclone  
  Zaleplon  
  Zolpiderm  
 Tricyclic antidepressants  
 Selective serotonin reuptake- 
 inhibitors  
History of gastric or duodenal ulcers 
 Aspirin (>325mg/d), and Non-  
 Cox2 NSAIDs (avoid unless other 
 alternatives not effective and patient 







Table 1: Continued 
______________________________________________________________________ 
  Included in  
Disease/Condition Medication Analysis 
_____________________________________________________________________________________________________________________________________________ 
Hypertension 
 Clonidine (avoid as 1st line 
 hypertensive)   
 Alpha one blockers (avoid use 
 as antihypertensive) 
  Doxazosin  
  Prazosin  
  Terazosin   
Insomnia 
 Oral decongestants  
  Pseudoephedrine  
  Phenylephrine  
 Stimulants 
  Amphetamine  
  Methylphenidate   
  Pemoline   
 Theobromines 
  Theophylline   
  Caffeine  
 Benzodiazepines (avoid for treatment 
 of insomnia)  
Lower urinary tract symptoms, 
benign prostatic hyperplasia 
 Inhaled anticholinergic agents; 
 Strongly anticholinergic drugs 
 (except antimuscarinics for  
 urinary incontinence) (Avoid in men)  
Parkinson’s disease 
 Antipsychotics (except for 
 Quetiapine and Clozapine)  
 Antiemetics 
  Metoclopraminde   
  Prochlorperazine   
  Promethazine   
Stress or mixed urinary incontinence 
 Alpha blockers (avoid in women) 
  Doxazosin   
  Prazosin   






Table 1: Continued 
______________________________________________________________________ 
  Included in  
Disease/Condition Medication Analysis 
_____________________________________________________________________________________________________________________________________________ 
Syncope 
 Acetylcholinesterate inhibitors   
 Pheripheral alpha blockers  
  Doxazosin   
  Prazosin   
  Terazosin   
 Tertiary Tricyclic antidepressants  
 Chlorpromazine, Thioridazine, and 
 Olanzapine   
Urinary incontinence 
 Estrogen, oral and transdermal 
 (excludes intravaginal estrogen) 
 (Avoid in women)   
_____________________________________________________________________ 
 
 Included in analysis 
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Table B1:  List and Descriptions of ICD-9 Codes Used to Identify Conditions in the 2012 Beers Criteria 
_________________________________________________________________________________________________________ 
Disease or ICD-9CM 
Condition Code Description 
__________________________________________________________________________________________________________________________________________________________________________________________________________________ 
Agitation  3082 [1, 17, 19]  Predominant psychomotor disturbance  
Chronic Kidney  40301 [1, 19] Malignant hypertensive chronic kidney disease, with chronic kidney disease stage V  
Disease, Stages  or end stage renal disease 
IV and V 40311 [1, 19] Benign hypertensive chronic kidney disease, with chronic kidney disease stage V  
  or end stage renal disease 
 40391 [1, 19] Unspecified hypertensive chronic kidney disease, with chronic kidney disease stage V 
  or end stage renal disease 
 40402 [1, 19] Malignant hypertensive heart and chronic kidney disease without heart failure and 
  with chronic kidney disease stage V or end stage renal disease 
 40403 [1, 19] Malignant hypertensive heart and chronic kidney disease with heart failure and 
  with chronic kidney disease stage V or end stage renal disease 
 40412 [1, 19] Benign hypertensive heart and chronic kidney disease without heart failure and with  
  chronic kidney disease Stage V or end stage renal disease or end stage renal disease 
 40413 [1, 19] Benign hypertensive heart and chronic kidney disease with heart failure and   
  chronic kidney disease Stage V or end stage renal disease or end stage renal disease 
 40492 [1, 19] Unspecified hypertensive heart and chronic kidney disease without heart failure and 
  with chronic kidney disease Stage V or end stage renal disease  
 40493 [1, 19] Unspecified hypertensive heart and chronic kidney disease with heart failure and 
  chronic kidney disease Stage V or end stage renal disease  
 5854 [1, 9, 15, 19, 21, 23] Chronic kidney disease, stage IV 
 5855 [1, 9, 15, 19, 21, 23] Chronic kidney disease, stage V 
 5856 [1, 9, 15, 19, 21, 23] Chronic kidney disease, stage IV requiring chronic dialysis 
 586 [9, 19] Renal failure unspecified 
Delirium 29011 [1, 7, 18, 19] Presenile dementia with delirium 
 2903 [1, 7, 18, 19] Senile dementia with delirium 
 29041 [1, 7, 18, 19] Vascular dementia with delirium 
 29281 [1, 18, 19] Drug-induced delirium 










Table 1: Continued 
_________________________________________________________________________________________________________ 
Disease or ICD-9CM 
Condition Code Description 
__________________________________________________________________________________________________________________________________________________________________________________________________________________ 
 2931 [1, 7, 18, 19] Subacute delirium 
 78009 [1, 7, 19] Alteration of consciousness, other 
Dementia and  04611 [1, 10, 19] Variant Creutzfeldt-Jakob disease 
Cognitive  04619 [1, 10, 19] Other and unspecified Creutzfeldt-Jakob disease 
Impairment 0463 [1, 10, 19] Progressive multifocal leukoencephalopathy 
 0941 [1, 10, 19] General paresis 
 2900 [1, 10, 12, 19] Senile dementia, uncomplicated 
 29010 [1, 10, 12, 19] Presenile dementia, uncomplicated 
 29011 [1, 10, 12, 19] Presenile dementia, with delirium 
 29012 [1, 10, 12, 19] Presenile dementia, with delusional features 
 29013 [1, 10, 12, 19] Presenile dementia, with depressive features 
 2902 [19] Senile dementia with delusional or depressive features 
 29020 [1, 10, 12, 19] Senile dementia with delusional features 
 29021 [1, 10, 12, 19] Senile dementia with depressive features 
 2903 [1, 10, 12, 19] Senile dementia with delirium 
 2904 [1, 10, 12, 19] Vascular dementia 
 29040 [1, 10, 12, 19] Vascular dementia, uncomplicated 
 29041 [1, 10, 12, 19] Vascular dementia with delirium 
 29042 [1, 10, 12, 19] Vascular dementia with delusions 
 29043 [1, 10, 12, 19] Vascular dementia with depressed mood 
 2909 [1, 19] Unspecified senile psychotic condition 
 2912 [1, 10, 19] Alcohol-induced persisting dementia 
 29282 [1, 10, 19] Drug-induced persisting dementia 
 29283 [1, 10, 19] Drug-induced persisting amnestic dementia 
 2940 [1, 10, 19] Amnestic syndrome (Korsakoff’s psychosis or syndrome, nonalcoholic) 
 2941 [1, 10, 12, 19] Dementia in other diseases 
 29410 [1, 10, 12, 19] Dementia in conditions classified elsewhere without behavioral disturbance 
 29411 [1, 10, 12, 19] Dementia in conditions classified elsewhere with behavioral disturbance 










Table 1: Continued 
_________________________________________________________________________________________________________ 
Disease or ICD-9CM 
Condition Code Description 
__________________________________________________________________________________________________________________________________________________________________________________________________________________ 
 29421 [1, 10, 12] Dementia, unspecified with behavioral disturbance 
 2948 [1, 10, 19] Other specific organ brain syndrome (chronic) 
 2949 
[10, 19]
 Unspecified persistent mental disorders due to conditions classified elsewhere 
 3310 [1, 10, 12, 19] Alzheimer’s disease 
 3311 [1, 10, 12, 19] Frontotemporal dementia 
 33111 [1, 12, 19] Pick disease 
 33119 [1, 12, 19] Other frontotemporal dementia 
 3312 [1, 10, 12, 19] Senile degeneration of brain 
 3317 [1, 10, 19] Cerebral degeneration in diseases classified elsewhere 
 33182 [1, 10, 12, 19] Dementia with Lewy bodies 
 33183 [1, 10, 12, 19] Mild cognitive impairment, so stated 
 33189 [1, 10, 19] Other cerebral degeneration 
 3319 [1, 10, 19] Cerebral degeneration, unspecified 
 3330 [1, 10, 19] Other degenerative disorders of the basal ganglia 
 4830 [1, 10, 19] Cognitive deficits 
 797 [1, 10, 12, 19] Senility without mention of psychosis 
 78093 [1, 10, 19] Memory loss 
Epilepsy or  3332 [1, 16, 19] Progressive myoclonic epilepsy 
Chronic seizures 34500 [1, 11, 14, 16, 19] Generalized nonconvulsive epilepsy without mention of intractable epilepsy 
 34501 [1, 11, 14, 16, 19] Generalized nonconvulsive epilepsy with intractable epilepsy 
 34510 [1, 11, 14, 16, 19] Generalized convulsive epilepsy without mention of intractable epilepsy 
 34511 [1, 11, 14, 16, 19] Generalized convulsive epilepsy with intractable epilepsy 
 3452 [1, 11, 14, 16, 19] Petit mal status 
 3453 [1, 11, 14, 16, 19] Grand mal status 
 34540 [1, 11, 14, 16, 19] Localization-related (focal) (partial) epilepsy and epileptic syndromes with 
  complex partial seizures without mention of intractable epilepsy 
 34541 [1, 11, 14, 16, 19] Localization-related (focal) (partial) epilepsy and epileptic syndromes with 
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 34550 [1, 11, 14, 16, 19] Localization-related (focal) (partial) epilepsy and epileptic syndromes with simple 
  partial seizures without mention of intractable epilepsy 
 34551 [1, 11, 14, 16, 19] Localization-related (focal) (partial) epilepsy and epileptic syndromes with simple 
  partial seizures and intractable epilepsy 
 34570 [1, 11, 14, 16, 19] Epilepsia partialis continua without mention of intractable epilepsy 
 34571 [1, 11, 14, 16, 19] Epilepsia partialis continua with intractable epilepsy 
 34580 [1, 11, 14, 16, 19] Other forms of epilepsy and recurrent seizures without mention of intractable epilepsy 
 34581 [1, 11, 14, 16, 19] Other forms of epilepsy and recurrent seizures with intractable epilepsy 
 34590 [1, 11, 14, 16, 19] Epilepsy, unspecified without mention of intractable epilepsy 
 34591 [1, 11, 14, 16, 19] Epilepsy, unspecified with intractable epilepsy 
 78031 [1, 11, 14, 16, 19] Febrile convulsions (simple), unspecified 
 78032 [1, 11, 14, 16, 19] Complex febrile convulsions  
 78033 [1, 11, 14, 16] Post traumatic convulsions  
 78039 [1, 11, 14, 16, 19] Other convulsions 
Heart Failure 39891 [1, 6, 19, 22] Rheumatic heart failure (congestive) 
 40201 [1, 6, 8, 19, 22] Malignant hypertensive heart disease with heart failure 
 40211 [1, 6, 8, 19, 22] Benign hypertensive heart disease with heart failure 
 40291 [1, 6, 8, 19, 22] Unspecified hypertensive heart disease with heart failure 
 40401 [1, 6, 8, 19, 22] Malignant hypertensive heart and chronic kidney disease with heart failure and chronic 
  kidney disease stage I through stage IV, or unspecified 
 40403 [1, 6, 8, 19, 22] Malignant hypertensive heart and chronic kidney disease with heart failure and chronic 
  kidney disease stage V or end stage renal disease 
 40411 [1, 8, 19, 22] Benign hypertensive heart and chronic kidney disease with heart failure and chronic 
  kidney disease stage I through stage IV, or unspecified 
 40413 [1, 6, 8, 19, 22] Benign hypertensive heart and chronic kidney disease with heart failure and chronic 
  kidney disease stage V or end stage renal disease 
 40491 [1, 6, 8, 19, 22] Unspecified hypertensive heart and chronic kidney disease with heart failure and 
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 40493 [1, 6, 8, 19, 22] Unspecified hypertensive heart and chronic kidney disease with heart failure and 
   chronic kidney disease stage V or end stage renal disease 
 4280 [1, 6, 8, 19, 22] Congestive heart failure, unspecified 
 4281 [1, 6, 8, 19, 22] Left heart failure 
 42820 [1, 8, 19, 22] Systolic heart failure, unspecified 
 42821 [1, 8, 19, 22] Systolic heart failure, acute 
 42822 [1, 8, 19, 22] Systolic heart failure, chronic 
 42823 [1, 8, 19, 22] Systolic heart failure, acute on chronic 
 42830 [1, 8, 19, 22] Diastolic heart failure, unspecified 
 42831 [1, 8, 19, 22] Diastolic heart failure, acute 
 42832 [1, 8, 19, 22] Diastolic heart failure, chronic 
 42833 [1, 8, 19, 22] Diastolic heart failure, acute on chronic 
 42840 [1, 8, 19, 22] Combined systolic and diastolic heart failure, unspecified 
 42841 [1, 8, 19, 22] Combined systolic and diastolic heart failure, acute 
 42842 [1, 8, 19, 22] Combined systolic and diastolic heart failure, chronic 
 42843 [1, 8, 19, 22] Combined systolic and diastolic heart failure, acute on chronic 
 4289 [1, 6, 8, 19, 22] Heart failure, unspecified 
Hypertension 4010 [1, 4, 5, 19] Malignant essential hypertension 
 4011 [1, 4, 5, 19] Benign essential hypertension 
 4019 [1, 4, 5, 19] Unspecified essential hypertension 
 40200 [1, 4, 5, 19]  Malignant hypertensive heart disease, without heart failure 
 40201 [1, 4, 5, 19]  Malignant hypertensive heart disease, with heart failure 
 40210 [1, 4, 5, 19] Benign hypertensive heart disease, without heart failure 
 40211 [1, 4, 5, 19] Benign hypertensive heart disease, with heart failure 
 40290 [1, 4, 5, 19] Unspecified hypertensive heart disease without heart failure 
 40291 [1, 4, 5, 19] Unspecified hypertensive heart disease with heart failure 
 40300 [1, 4, 5, 19] Malignant hypertensive chronic kidney disease with chronic kidney disease  
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 40301 [1, 4, 5, 19] Malignant hypertensive chronic kidney disease with chronic kidney disease  
  stage V or end stage renal disease 
 40310 [1, 4, 5, 19] Benign hypertensive chronic kidney disease with chronic kidney disease  
  stage I to stage IV, or unspecified 
 40311 [1, 4, 5, 19] Benign hypertensive chronic kidney disease with chronic kidney disease  
  stage V or end stage renal disease 
 40390 [1, 4, 5, 19] Unspecified hypertensive chronic kidney disease with chronic kidney disease  
  stage I to stage IV, or unspecified 
 40391 [1, 4, 5, 19] Unspecified hypertensive chronic kidney disease with chronic kidney disease  
  stage V or end stage renal disease 
 40400 [1, 4, 5, 19] Malignant hypertensive heart and chronic kidney disease with chronic kidney disease  
  without heart failure and with chronic kidney disease stage I to stage IV, unspecified 
 40401 [1, 4, 5, 19] Malignant hypertensive heart and chronic kidney disease with chronic kidney disease  
  with heart failure and with chronic kidney disease stage I to stage IV, unspecified 
 40402 [1, 4, 5, 19] Malignant hypertensive heart and chronic kidney disease with chronic kidney disease  
  without heart failure and with chronic kidney disease stage V or end stage renal 
  disease 
 40403 [1, 4, 5, 19] Malignant hypertensive heart and chronic kidney disease with chronic kidney disease  
  with heart failure and with chronic kidney disease stage V or end stage renal 
  disease 
 40410 [1, 4, 5, 19] Benign hypertensive heart and chronic kidney disease with chronic kidney disease  
  without heart failure and with chronic kidney disease stage I to stage IV, unspecified 
 40411 [1, 4, 5, 19] Benign hypertensive heart and chronic kidney disease with chronic kidney disease  
  with heart failure and with chronic kidney disease stage I to stage IV, unspecified 
 40412 [1, 4, 5, 19] Benign hypertensive heart and chronic kidney disease with chronic kidney disease  
  without heart failure and with chronic kidney disease stage V or end stage renal 
  disease 
 40413 [1, 4, 5, 19] Benign hypertensive heart and chronic kidney disease with chronic kidney disease  
  with heart failure and with chronic kidney disease stage V or end stage renal 
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 40490 [1, 4, 5, 19] Unspecified hypertensive heart and chronic kidney disease with chronic kidney 
   disease without heart failure and with chronic kidney disease stage I to stage IV, 
   unspecified 
 40491 [1, 4, 5, 19] Unspecified hypertensive heart and chronic kidney disease with chronic kidney 
   disease with heart failure and with chronic kidney disease stage I to stage IV, 
   unspecified 
 40492 [1, 4, 5, 19] Unspecified hypertensive heart and chronic kidney disease with chronic kidney 
  disease without heart failure and with chronic kidney disease stage V or end stage 
   renal disease 
 40493 [1, 4, 5, 19] Unspecified hypertensive heart and chronic kidney disease with chronic kidney 
   disease with heart failure and with chronic kidney disease stage V or end stage  
  renal disease 
 40501 [1, 4, 5, 19] Malignant secondary hypertension, renovascular 
 40509 [1, 4, 5, 19] Malignant secondary hypertension, other 
 40511 [1, 4, 5, 19] Benign secondary hypertension, renovascular 
 40519 [1, 4, 5, 19] Benign secondary hypertension, other 
 40591 [1, 4, 5, 19] Unspecified secondary hypertension, renovascular 
 40599 [1, 4, 5, 19] Unspecified secondary hypertension, other 
 4160 [1, 19] Primary pulmonary hypertension 
 4168 [1, 19] Secondary pulmonary hypertension 
 4372 [1, 5, 19] Hypertensive encephalopathy 
 4591 [1, 19] Chronic venous hypertension due to deep vein thrombosis 
 45930 [1, 19] Chronic venous hypertension without complications 
 45931 [1, 19] Chronic venous hypertension with ulcer 
 45932 [1, 19] Chronic venous hypertension with inflammation 
 45933 [1, 19] Chronic venous hypertension with ulcer and inflammation 
 45939 [1, 19] Chronic venous hypertension with other complications 
 5723 [1, 19] Portal hypertension 
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Insomnia 04672 [1, 19] Fatal familial insomnia 
 30740 [1, 13, 19] Nonorganic sleep disorder, unspecified 
 30741 [1, 3, 13, 19] Transient disorder of initiating or maintaining sleep 
 30742 [1, 3, 13, 19] Persistent disorder of initiating or maintaining sleep 
 30749 [1, 3, 19] Specific disorders of sleep of nonorganic origin, other 
 32700 [1, 19] Organic insomnia, unspecified 
 32701 [1, 19] Insomnia due to medical condition classified elsewhere 
 32702 [1, 19] Insomnia due to mental disorder 
 32709 [1, 19] Other organic insomnia 
 78050 [1, 3, 13, 19] Sleep disorders, unspecified 
 78051 [1, 19] Insomnia with sleep apnea, unspecified 
 78052 [1, 3, 13, 19] Insomnia, unspecified 
 78055 [1, 3] Irregular sleep-wake rhythm, unspecified 
 78056 [1, 3] Sleep stage dysfunctions 
 78059 [1, 3, 19] Sleep disturbances, other 
Lower Urinary Tract  60000 [1, 19] Benign hypertrophy of prostrate without urinary obstruction and lower urinary 
Symptoms or Benign  tract symptoms 
Benign Prostatic  60001 [1, 19] Benign hypertrophy of prostrate without urinary obstruction and lower urinary 
Hyperplasia  tract symptoms 
 60010 [1, 19] Nodular prostrate without urinary obstruction 
 60011 [1, 19] Nodular prostrate with urinary obstruction 
 60020 [1, 19] Benign localized hyperplasia of prostrate without urinary obstruction and lower 
  urinary tract symptoms 
 60021 [1, 19] Benign localized hyperplasia of prostrate with urinary obstruction and lower 
  urinary tract symptoms 
 6003 [1, 19]  Cyst of prostrate 
 60090 [1, 19]  Hyperplasia of prostrate, unspecified, without urinary obstruction and other 
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 60091 [1, 19]  Hyperplasia of prostrate, unspecified, with urinary obstruction and other 
  lower urinary tract symptoms 
Parkinson’s Disease 09482 [1, 19] Syphilitic Parkinsonism 
 33182 [1, 19] Dementia with Parkinson’s 
 3320 [1, 19, 20, 24] Paralysis agitans 
 3321 [1, 19, 20, 24] Secondary Parkinsonism 
 3330 [1, 19, 20, 24] Other degenerative diseases of the basal ganglia 
 3331 [1, 19, 20] Essential and other specified forms of tremor 
 7810 [1, 19, 24] Abnormal involuntary movements 
Stress or Mixed  6256 [1, 2, 19, 25] Stress incontinence, female 
Urinary Incontinence 78832 [1, 19] Stress incontinence, male 
 78833 [1, 19, 25] Mixed incontinence, (female) (male) 
Syncope 33701 [1, 19] Carotid sinus syncope 
 7802 [1, 8, 14, 19] Syncope and collapse 
 9921 [1, 19] Heat syncope 
Systolic Heart Failure 42820 [1, 8, 19, 22] Systolic heart failure, unspecified 
 42821 [1, 8, 19, 22] Systolic heart failure, acute 
 42822 [1, 8, 19, 22] Systolic heart failure, chronic 
 42823 [1, 8, 19, 22] Systolic heart failure, acute on chronic 
 42840 [1, 8, 19, 22] Combined systolic and diastolic heart failure, unspecified 
 42841 [1, 8, 19, 22] Combined systolic and diastolic heart failure, acute 
 42842 [1, 8, 19, 22] Combined systolic and diastolic heart failure, chronic 
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Urinary Incontinence 3076 [1, 19] Urinary incontinence of nonorganic origin 
 59651 [1, 2, 19] Hypertonicity of bladder 
 59652 [1, 2, 19] Low bladder compliance 
 59659 [1, 2, 19] Other functional disorder of bladder 
 59981 [1, 2, 19] Urethral hypermobility 
 59982 [1, 2, 19, 25] Intrinsic (urethral) sphincter deficiency 
 59983 [1, 2, 19] Urethral instability 
 6256 [1, 2, 19] Stress incontinence, female 
 78830 [1, 2, 19, 25] Urinary incontinence, unspecified 
 78831 [1, 2, 19] Urge incontinence 
 78832 [1, 19] Stress incontinence, male 
 78833 [1, 2, 19, 25] Mixed incontinence, (female) (male) 
 78834 [1, 2, 19, 25] Incontinence without sensory awareness 
 78835 [1, 19] Post-void dribbling 
 78836 [1, 19] Nocturnal enuresis 
 78837 [1, 2, 19, 25] Continuous leakage 
 78838 [1, 19] Overflow incontinence 
 78839 [1, 19, 25] Other urinary incontinence 
 78891 [1, 19] Urinary incontinence due to cognitive impairment or severe physical disability 
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Total Count of PIMs Received in Each Category and Distribution by                      







Table C1:  Total Count of PIMs Received in Each Category by Individuals in 
                  Prevalence Sample  
________________________________________________________________________ 
   Number of Number of 
   Individuals  Individuals  
   by Category by PIM Use 
   N= 2,705  N= 2,705 
   _____________________ _____________________ 
Number of PIMs in Category  n    (Percent) n    (Percent)  
________________________________________________________________________________________________________________________________________________ 
At least one PIM 893 (33.01)  
 One    648 (23.96) 
 Two   168 (6.21) 
 Three   53 (1.96) 
 Four   15 (0.55) 
 Five    5 (0.18) 
 Six    4 (0.15) 
Inappropriate drug choice 747 (27.62) 
 One    586 (21.67) 
 Two   128 (4.73) 
 Three   27 (1.00) 
 Four   4 (0.15) 
 Five    2 (0.07) 
Excess dose 88 (3.25)   
 One    87 (3.22) 
 Two   1 (0.04) 
Excess duration 94 (3.48)  
 One    92 (3.40) 
 Two   2 (0.07) 
Drug-disease interaction 86 (3.18) 
 One    67 (2.48) 
 Two   12 (0.44) 
 Three   3 (0.11) 
 Four   3 (0.11) 
 Five    0 (0.00) 








Table C2:  Distribution of Individuals in Prevalence Sample by Number of PIM  
                  Categories Received  
________________________________________________________________________ 
Number of  Number of Individuals       Percent 
PIM Categories by PIM Use in Category N = 2,705 
_______________________________________________________________________________________________________________________________________________  
 Zero 1,812 66.9  
 One 781 28.9 
 Two 102 3.8 







Table C3:  Total Count of PIMs Received in Each Category by Individuals in   
                  Incidence Sample       
________________________________________________________________________ 
   Number of Number of 
   Individuals  Individuals  
   by Category by PIM Use 
   N= 2,210  N= 2,210 
   _____________________ _____________________ 
Number of PIMs in Category  n    (Percent) n    (Percent)  
________________________________________________________________________________________________________________________________________________ 
At least one PIM 458 (20.72)   
  One   377 (17.06) 
  Two   60 (2.71) 
  Three   15 (0.67)  
  Four   4 (0.18) 
  Five   0 (0.00) 
  Six   2 (0.09) 
Inappropriate drug choice 380 (17.19) 
  One   335 (15.16) 
  Two   39 (1.76) 
  Three   5 (0.23) 
  Four   1 (0.05) 
Excess dose 27 (1.22)    
  One   27 (1.22)  
Excess duration 58 (2.62)   
  One   58 (2.62) 
Drug-disease interaction 40 (1.80)  
  One   32 (1.45) 
  Two   5 (0.23) 
  Three   1 (0.05) 








Table C4:  Distribution of Individuals in Incidence Sample by Number of PIM Categories 
                  Received  
________________________________________________________________________ 
Number of  Number of Individuals       Percent 
PIM Categories by PIM Use in Category N = 2210 
_______________________________________________________________________________________________________________________________________________  
 Zero 1,752 79.8  
 One 414 18.7 
 Two 41 1.9 








Associations between Perceived Provider Communication and PIM Use after Adjusting 







Table D1:  Associations between Perceived Provider Communication and Inappropriate  
                  Drug Choice PIM Use after Adjusting for Demographic and Clinical  
                  Characteristics using Bivariate Probit Models 
 
 
Seemingly unrelated bivariate probit Number of obs = 2051 
 Wald chi2(27) = 346.83  
Log likelihood = -2154.2042 Prob > chi2 = 0.0000 
 
---------------------------------------------------------------------------------------------------------- 
 | Coef. Std. Err. z P>|z| [95% Conf. Interval] 
--------------------+------------------------------------------------------------------------------------ 
Idc| 
 _Icommindx3_2 | .5062558 .40038 1.26 0.206 -.2784746 1.290986 
 _Iagegroup_2 | -.2078162 .0916011 -2.27 0.023 -.3873511 -.0282813 
 _Imed_count_2 | .7967579 .1233712 6.46 0.000 .5549548 1.038561 
 _Imed_count_3 | .5541809 .1069133 5.18 0.000 .3446347 .7637272 
 _Imed_count_4 | 1.514999 .153835 9.85 0.000 1.213488 1.81651 
 _Iregion_2 | .0069781 .1260474 0.06 0.956 -.2400702 .2540264 
 _Iregion_3 | .2797041 .0998346 2.80 0.005 .0840319 .4753764 
 _Iregion_4 | .0953641 .1117949 0.85 0.394 -.1237499 .3144782 
 _cons | -2.00183 .1754024 -11.41 0.000 -2.345612 -1.658048 
--------------------+------------------------------------------------------------------------------------- 
_Icommindx3_2 | 
 _Iagegroup_2 | .0600585 .0738462 0.81 0.416 -.0846774 .2047943 
 _Igender_2 | .132023 .0627505 2.10 0.035 .0090342 .2550117 
 _Iethnicity_2 | -.1214484 .0871801 -1.39 0.164 -.2923182 .0494215 
 _Ipay_2 | -.0127646 .0749439 -0.17 0.865 -.1596519 .1341227 
 _Ipay_3 | -.0119781 .1011484 -0.12 0.906 -.2102252 .1862691 
 _Ipay_4 | -.2434472 .0959027 -2.54 0.011 -.4314131 -.0554813 
 _Imed_count_2 | -.0105917 .087424 -0.12 0.904 -.1819396 .1607562 
 _Imed_count_3 | -.019629 .0712981 -0.28 0.783 -.1593708 .1201127 
 _Imed_count_4 | .0451804 .1044842 0.43 0.665 -.1596049 .2499657 
 _Iregion_2 | .2526829 .0918288 2.75 0.006 .0727017 .4326641 
 _Iregion_3 | .1027587 .0752479 1.37 0.172 -.0447244 .2502418 
 _Iregion_4 | .0604281 .0868763 0.70 0.487 -.1098463 .2307026 
 _Ieducation_2 | -.0536702 .0905525 -0.59 0.553 -.2311499 .1238094 
 _Ieducation_3 | -.3031493 .1107774 -2.74 0.006 -.5202689 -.0860296 
 _Ieducation_4 | -.1372714 .1074467 -1.28 0.201 -.347863 .0733203 
 _Idepress_d_2 | .0903394 .08704 1.04 0.299 -.0802558 .2609345 
 _Igenhelth2_2 | .18493 .069074 2.68 0.007 .0495475 .3203126 
 _Igenhelth2_3 | .2497615 .0884607 2.82 0.005 .0763817 .4231414 
 _Igenhelth2_4 | .0755502 .130898 0.58 0.564 -.1810052 .3321056 
 _cons | .2733175 .1317817 2.07 0.038 .0150302 .5316049 
---------------------+------------------------------------------------------------------------------------ 
 /athrho | -.2910475 .2771954 -1.05 0.294 -.8343406 .2522455 
---------------------+------------------------------------------------------------------------------------ 
 rho | -.2830987 .2549796   -.6827998 .2470283  
----------------------------------------------------------------------------------------------------------- 






Table D2:  Associations between Perceived Provider Communication and Overall PIM 
                  Use after Adjusting for Demographic and Clinical Characteristics using 
                  Bivariate Probit Models 
 
 
Seemingly unrelated bivariate probit Number of obs = 2051 
 Wald chi2(27) = 351.68  
Log likelihood = -2245.3755 Prob > chi2 = 0.0000 
 
----------------------------------------------------------------------------------------------------------- 
 | Coef. Std. Err. z P>|z| [95% Conf. Interval] 
---------------------+------------------------------------------------------------------------------------ 
Pim | 
 _Icommindx3_2 | 3422409 4259827 0.80 0.422 -.4926698 1.177152 
 Iagegroup_2 | .2104524 .0878372 -2.40 0.017 -.3826102 -.0382947 
 _Imed_count_2 | .9755782 .1144262 8.53 0.000 .7513069 1.19985 
 _Imed_count_3 | .605426 .100242 6.04 0.000 .4089553 .8018967 
 _Imed_count_4 | 1.602259 .136659 11.72 0.000 1.334412 1.870106 
 _Iregion_2 | .0323901 .12181 0.27 0.790 -.206353 .2711332 
 _Iregion_3 | .2367586 .0947546 2.50 0.012 .0510431 .4224742 
 _Iregion_4 | .2147245 .1060303 2.03 0.043 .0069088 .4225401 
 _cons | -1.854069 .2099093 -8.83 0.000 -2.265483 -1.442654 
---------------------+------------------------------------------------------------------------------------- 
_Icommindx3_2 | 
 _Iagegroup_2 | .0612903 .0738489 0.83 0.407 -.0834509 .2060315 
 _Igender_2 | .1389918 .0624783 2.22 0.026 .0165365 .2614471 
 _Iethnicity_2 | -.1153682 .0886043 -1.30 0.193 -.2890294 .058293 
 _Ipay_2 | -.0186492 .0751982 -0.25 0.804 -.166035 .1287366 
 _Ipay_3 | -.0149661 .1029711 -0.15 0.884 -.2167857 .1868535 
 _Ipay_4 | -.2424427 .0966211 -2.51 0.012 -.4318167 -.0530687 
 _Imed_count_2 | -.0127245 .0873237 -0.15 0.884 -.1838759 .1584269 
 _Imed_count_3 | -.0203094 .0713021 -0.28 0.776 -.1600589 .1194402 
 _Imed_count_4 | .0432067 .1045837 0.41 0.680 -.1617737 .2481871 
 _Iregion_2 | .2541524 .0918407 2.77 0.006 .074148 .4341568 
 _Iregion_3 | .1021415 .0752758 1.36 0.175 -.0453964 .2496794 
 _Iregion_4 | .0593768 .086977 0.68 0.495 -.1110951 .2298487 
 _Ieducation_2 | -.0543133 .0925748 -0.59 0.557 -.2357565 .12713 
 _Ieducation_3 | -.3052152 .1121884 -2.72 0.007 -.5251003 -.0853301 
 _Ieducation_4 | -.1310915 .1080553 -1.21 0.225 -.3428761 .080693 
 _Idepress_d_2 | .1008831 .0864256 1.17 0.243 -.068508 .2702743 
 _Igenhelth2_2 | .1866289 .0697543 2.68 0.007 .049913 .3233449 
 _Igenhelth2_3 | .2493972 .0891962 2.80 0.005 .0745759 .4242186 
 _Igenhelth2_4 | .0817562 .1321498 0.62 0.536 -.1772526 .340765 
 _cons | .2653313 .1344871 1.97 0.049 .0017414 .5289212 
--------------------+------------------------------------------------------------------------------------- 
 /athrho | -.1738983 .2775919 -0.63 0.531 -.7179685 .3701718 
--------------------+------------------------------------------------------------------------------------- 
 rho | -.1721663 .2693637  -.6156493 .354142 
----------------------------------------------------------------------------------------------------------- 







Associations between Perceived Provider Knowledge and PIM Use after Adjusting for 







Table E1:  Associations between Perceived Provider Knowledge and Inappropriate Drug 
                  Choice PIM Use after Adjusting for Demographic and Clinical Characteristics  
                  using Bivariate Probit Models 
 
 
Seemingly unrelated bivariate probit Number of obs = 2047 
 Wald chi2(27) = 355.06  
Log likelihood = -2244.1918 Prob > chi2 = 0.0000 
 
---------------------------------------------------------------------------------------------------------- 
 | Coef. Std. Err. z P>|z| [95% Conf. Interval] 
---------------------+------------------------------------------------------------------------------------ 
Idc | 
_ Iknowindx3_2 | -.4989673 .4291858 -1.16 0.245 -1.340156 .3422214 
 _Iagegroup_2 | -.2256142 .0926558 -2.43 0.015 -.4072162 -.0440123 
_ Imed_count_2 | .8199352 .1158974 7.07 0.000 .5927805 1.04709 
_ Imed_count_3 | .576448 .10443 5.52 0.000 .3717689 .7811271 
_ Imed_count_4 | 1.598469 .1268645 12.60 0.000 1.349819 1.847119 
 _Iregion_2 | .0176394 .1271057 0.14 0.890 -.2314832 .2667621 
 _Iregion_3 | .2680323 .1006097 2.66 0.008 .0708408 .4652238 
 _Iregion_4 | .0773035 .1117905 0.69 0.489 -.1418017 .2964088 
 _cons | -1.515713 .2789818 -5.43 0.000 -2.062507 -.9689187 
---------------------+------------------------------------------------------------------------------------ 
_ Iknowindx3_2 | 
 _Iagegroup_2 | -.1092435 .0744504 -1.47 0.142 -.2551635 .0366766 
 _Igender_2 | -.1110661 .0626558 -1.77 0.076 -.2338692 .0117371 
_ Iethnicity_2 | .114341 .0871137 1.31 0.189 -.0563987 .2850806 
 _Ipay_2 | .0121317 .0749354 0.16 0.871 -.134739 .1590023 
 _Ipay_3 | .0133216 .1015813 0.13 0.896 -.185774 .2124173 
 _Ipay_4 | .1640031 .0965678 1.70 0.089 -.0252662 .3532725 
_ Imed_count_2 | .1281933 .087807 1.46 0.144 -.0439054 .3002919 
 _Imed_count_3 | .0893872 .0720439 1.24 0.215 -.0518161 .2305906 
_ Imed_count_4 | .2568974 .1041376 2.47 0.014 .0527914 .4610033 
 _Iregion_2 | -.2460176 .0921855 -2.67 0.008 -.4266979 -.0653373 
 _Iregion_3 | -.1189223 .0755962 -1.57 0.116 -.267088 .0292434 
 _Iregion_4 | -.0640113 .0871444 -0.73 0.463 -.2348111 .1067885 
_ Ieducation_2 | .003087 .0909406 0.03 0.973 -.1751533 .1813273 
_ Ieducation_3 | .3185727 .1104477 2.88 0.004 .1020991 .5350462 
_ Ieducation_4 | .0867452 .107895 0.80 0.421 -.1247251 .2982156 
_ Idepress_d_2 | -.0644477 .0864153 -0.75 0.456 -.2338186 .1049232 
 _Igenhelth2_2 | -.1392557 .0688543 -2.02 0.043 -.2742077 -.0043037 
_ Igenhelth2_3 | -.312822 .0895336 -3.49 0.000 -.4883047 -.1373394 
_ Igenhelth2_4 | -.1693519 .1344086 -1.26 0.208 -.432788 .0940842 
 _cons | -.3224825 .132848 -2.43 0.015 -.5828598 -.0621052 
---------------------+------------------------------------------------------------------------------------ 
 /athrho | .2467007 .2920354 0.84 0.398 -.3256782 .8190796 
---------------------+------------------------------------------------------------------------------------ 
 rho | .2418148 .2749588   -.3146321 .6745686 
----------------------------------------------------------------------------------------------------------- 






Table E2:  Associations between Perceived Provider Knowledge and Overall PIM Use 
                  after Adjusting for Demographic and Clinical Characteristics using Bivariate 
                  Probit Models 
 
 
Seemingly unrelated bivariate probit Number of obs = 2047 
 Wald chi2(27) = 355.06  
Log likelihood = -2244.1918 Prob > chi2 = 0.0000 
 
---------------------------------------------------------------------------------------------------------- 
 | Coef. Std. Err. z P>|z| [95% Conf. Interval] 
--------------------+------------------------------------------------------------------------------------ 
pim | 
_ Iknowindx3_2 | -.5489017 .3981071 -1.38 0.168 -1.329177 .2313739 
 _Iagegroup_2 | -.2405217 .087314 -2.75 0.006 -.4116539 -.0693894 
_ Imed_count_2 | .9852611 .1129046 8.73 0.000 .7639722 1.20655 
_ Imed_count_3 | .6089598 .0985486 6.18 0.000 .4158081 .8021115 
_ Imed_count_4 | 1.649516 .1284045 12.85 0.000 1.397848 1.901184 
 _cons | -1.275228 .2329358 -5.47 0.000 -1.731774 -.8186824 
---------------------+------------------------------------------------------------------------------------ 
_ Iknowindx3_2 | 
 _Iagegroup_2 | -.1092694 .0743746 -1.47 0.142 -.2550409 .0365021 
 _Igender_2 | -.1108913 .0619911 -1.79 0.074 -.2323917 .010609 
_ Iethnicity_2 | .1179734 .0867095 1.36 0.174 -.0519741 .2879209 
 _Ipay_2 | .0116595 .0743197 0.16 0.875 -.1340044 .1573234 
 _Ipay_3 | .0068793 .1016583 0.07 0.946 -.1923672 .2061259 
 _Ipay_4 | .1617336 .0962103 1.68 0.093 -.0268352 .3503024 
_ Imed_count_2 | .1298819 .0875685 1.48 0.138 -.0417492 .301513 
_ Imed_count_3 | .0905978 .0719937 1.26 0.208 -.0505073 .2317028 
_ Imed_count_4 | .2585306 .1040002 2.49 0.013 .0546939 .4623673 
 _Iregion_2 | -.2470651 .0912798 -2.71 0.007 -.4259701 -.0681601 
 _Iregion_3 | -.1446654 .0772202 -1.87 0.061 -.2960142 .0066834 
 _Iregion_4 | -.0855806 .0878254 -0.97 0.330 -.2577153 .0865541 
_ Ieducation_2 | .0156857 .0925846 0.17 0.865 -.1657768 .1971482 
_ Ieducation_3 | .3259347 .1102334 2.96 0.003 .1098811 .5419882 
_ Ieducation_4 | .0888782 .1074443 0.83 0.408 -.1217088 .2994651 
_ Idepress_d_2 | -.0700456 .0846811 -0.83 0.408 -.2360175 .0959263 
_ Igenhelth2_2 | -.1367353 .0688295 -1.99 0.047 -.2716387 -.0018319 
_ Igenhelth2_3 | -.3080866 .0897946 -3.43 0.001 -.4840809 -.1320923 
_ Igenhelth2_4 | -.1712973 .133739 -1.28 0.200 -.4334209 .0908263 
 _cons | -.3191247 .130808 -2.44 0.015 -.5755037 -.0627458 
---------------------+------------------------------------------------------------------------------------- 
 /athrho | .2901004 .2793267 1.04 0.299 -.2573698 .8375706  
---------------------+------------------------------------------------------------------------------------- 
 rho | .2822272 .2570777   -.2518338 .6845201 
------------------------------------------------------------------------------------------------------------ 








Associations between Perceived Provider Competence and PIM Use after Adjusting for 







Table F1:  Associations between Perceived Provider Competence and Inappropriate Drug 
                  Choice PIM Use after Adjusting for Demographic and Clinical Characteristics  
                  using Bivariate Probit Models 
 
 
Seemingly unrelated bivariate probit Number of obs = 2055 
 Wald chi2(26) = 354.30  
Log likelihood = -2193.4568 Prob > chi2 = 0.0000 
 
---------------------------------------------------------------------------------------------------------- 
 | Coef. Std. Err. z P>|z| [95% Conf. Interval] 
---------------------+------------------------------------------------------------------------------------ 
Idc | 
_ Icmpindx3_2 | -.7091829 .3773197 -1.88 0.060 -1.448716 .0303501 
 _Iagegroup_2 | -.2310595 .0896202 -2.58 0.010 -.4067119 -.055407 
_ Imed_count_2 | .7768859 .1252515 6.20 0.000 .5313974 1.022374 
_ Imed_count_3 | .5492973 .1053881 5.21 0.000 .3427405 .7558541 
_ Imed_count_4 | 1.518502 .153705 9.88 0.000 1.217245 1.819758 
 _Iregion_2 | -.034141 .1237087 -0.28 0.783 -.2766057 .2083237 
 _Iregion_3 | .2379918 .1009708 2.36 0.018 .0400927 .435891 
 _Iregion_4 | .0789298 .1084252 0.73 0.467 -.1335797 .2914393 
 _cons | -1.316405 .3220982 -4.09 0.000 -1.947706 -.6851041 
---------------------+------------------------------------------------------------------------------------ 
_ Icmpindx3_2  | 
 _Iagegroup_2 | -.1194297 .0729747 -1.64 0.102 -.2624575 .0235982 
_ Iethnicity_2 | -.0257932 .0847452 -0.30 0.761 -.1918907 .1403042 
 _Ipay_2 | -.0698384 .0710055 -0.98 0.325 -.2090067 .0693299 
 _Ipay_3 | -.0638936 .097002 -0.66 0.510 -.254014 .1262269 
 _Ipay_4 | .0852041 .0912987 0.93 0.351 -.0937381 .2641464 
_ Imed_count_2 | .0592401 .0865755 0.68 0.494 -.1104446 .2289249 
_ Imed_count_3 | .0779837 .0707379 1.10 0.270 -.06066 .2166273 
_ Imed_count_4 | .1744868 .1028578 1.70 0.090 -.0271107 .3760843 
 _Iregion_2 | -.2728877 .0907508 -3.01 0.003 -.450756 -.0950194 
 _Iregion_3 | -.1444222 .0743548 -1.94 0.052 -.290155 .0013105 
 _Iregion_4 | -.0683931 .0864378 -0.79 0.429 -.2378081 .1010218 
_ Ieducation_2 | .0978144 .0865948 1.13 0.259 -.0719083 .2675371 
_ Ieducation_3 | .3599551 .1079578 3.33 0.001 .1483617 .5715486 
_ Ieducation_4 | .1657627 .1037874 1.60 0.110 -.0376569 .3691824 
_ Idepress_d_2 | .0782289 .0816266 0.96 0.338 -.0817562 .238214 
_ Igenhelth2_2 | -.1721875 .0676807 -2.54 0.011 -.3048392 -.0395358 
 _Igenhelth2_3 | -.2702774 .0870802 -3.10 0.002 -.4409515 -.0996034 
_ Igenhelth2_4 | -.1209927 .1275527 -0.95 0.343 -.3709914 .129006 
 _cons | -.1284341 .1273528 -1.01 0.313 -.378041 .1211728 
---------------------+------------------------------------------------------------------------------------ 
 /athrho | .4718199 .2980834 1.58 0.113 -.1124127 1.056053 
---------------------+------------------------------------------------------------------------------------ 
 rho | .4396686 .2404613   -.1119416 .7841484 
----------------------------------------------------------------------------------------------------------- 






Table F2:  Associations between Perceived Provider Competence and Overall PIM Use  
                  after Adjusting for Demographic and Clinical Characteristics using Bivariate  
                  Probit Models 
 
 
Seemingly unrelated bivariate probit Number of obs = 2055 
 Wald chi2(24) = 336.19  
Log likelihood = -2286.3292 Prob > chi2 = 0.0000 
 
---------------------------------------------------------------------------------------------------------- 
 | Coef. Std. Err. z P>|z| [95% Conf. Interval] 
---------------------+------------------------------------------------------------------------------------ 
pim | 
_ Icmpindx3_2 | -.4400994 .4278292 -1.03 0.304 -1.278629 .3984305 
 _Iagegroup_2 | -.2397496 .0880708 -2.72 0.006 -.4123652 -.0671341 
_ Imed_count_2 | .9749466 .1151439 8.47 0.000 .7492687 1.200624 
_ Imed_count_3 | .6077318 .0982472 6.19 0.000 .4151709 .8002927 
 _Imed_count_4 | 1.63522 .1292781 12.65 0.000 1.38184 1.888601 
 _cons | -1.302598 .2632806 -4.95 0.000 -1.818619 -.7865778 
---------------------+------------------------------------------------------------------------------------ 
_ Icmpindx3_2  | 
 _Iagegroup_2 | -.1336924 .073249 -1.83 0.068 -.2772578 .009873 
 _Igender_2 | -.1119321 .0615512 -1.82 0.069 -.2325703 .0087061 
_ Iethnicity_2 | -.0375685 .0864454 -0.43 0.664 -.2069983 .1318614 
 _Ipay_2 | -.0503682 .0729806 -0.69 0.490 -.1934074 .0926711 
 _Ipay_3 | -.0361766 .1012371 -0.36 0.721 -.2345977 .1622446 
 _Ipay_4 | .1152524 .0953795 1.21 0.227 -.0716881 .3021928 
 _Imed_count_2 | .062052 .0865434 0.72 0.473 -.1075699 .2316739 
 _Imed_count_3 | .076361 .0708107 1.08 0.281 -.0624254 .2151475 
_ Imed_count_4 | .1755447 .1027903 1.71 0.088 -.0259206 .37701 
 _Iregion_2 | -.2768844 .0902787 -3.07 0.002 -.4538274 -.0999413 
 _Iregion_3 | -.1655117 .0760963 -2.18 0.030 -.3146578 -.0163656 
 _Iregion_4 | -.0916177 .0873887 -1.05 0.294 -.2628963 .0796609 
_ Ieducation_2 | .0867248 .0911586 0.95 0.341 -.0919428 .2653923 
_ Ieducation_3 | .3677971 .1103822 3.33 0.001 .151452 .5841423 
_ Ieducation_4 | .1458636 .1065873 1.37 0.171 -.0630437 .354771 
_ Idepress_d_2 | .057528 .0829317 0.69 0.488 -.1050151 .2200712 
_ Igenhelth2_2 | -.1700465 .0687804 -2.47 0.013 -.3048536 -.0352393 
_ Igenhelth2_3 | -.271415 .0881145 -3.08 0.002 -.4441163 -.0987137 
_ Igenhelth2_4 | -.1259037 .1307503 -0.96 0.336 -.3821696 .1303622 
 _cons | -.0620662 .1308727 -0.47 0.635 -.3185719 .1944396 
---------------------+------------------------------------------------------------------------------------ 
 /athrho | .2704912 .2937355 0.92 0.357 -.3052197 .8462022 
---------------------+------------------------------------------------------------------------------------ 
 rho | .2640819 .2732506   -.2960821 .6890802 
----------------------------------------------------------------------------------------------------------- 







Results of Link Test Checking for Model Specification Error in Model Assessing 







Table G1:  Results of Link Test Checking for Model Specification Error in Model 
                  Assessing Associations between Perceived Provider Communication and  
                  Inappropriate Drug Choice PIM Use 
 
 
Logistic regression Number of obs = 2056 
 LR chi2(2) = 263.59  
 Prob > chi2 = 0.0000 
Log likelihood = -823.48519 Pseudo R2 = 0.1380 
 
---------------------------------------------------------------------------------------------------------- 
 idc | Coef. Std. Err. z P>|z| [95% Conf. Interval] 
-------------------- +------------------------------------------------------------------------------------ 
 _hat | 1.001152 .1675696 5.97 0.000 .6727216 1.329582 
 _hatsq | .0004439 .0591827 0.01 0.994 -.1155521 .1164399 







Table G2:  Results of Link Test Checking for Model Specification Error in Model  
                  Assessing Associations between Perceived Provider Communication and  
                  Overall PIM Use 
 
 
Logistic regression Number of obs = 2056 
 LR chi2(2) = 289.80  
 Prob > chi2 = 0.0000 
Log likelihood = -917.38495 Pseudo R2 = 0.1364 
 
---------------------------------------------------------------------------------------------------------- 
 pim | Coef. Std. Err. z P>|z| [95% Conf. Interval] 
-------------------- +------------------------------------------------------------------------------------ 
 _hat | 1.014559 .1485744  6.83 0.000 .7233587 1.30576 
 _hatsq | .0062903 .0577114  0.11 0.913 -.106822 .1194027 








Results of Link Test Checking for Model Specification Error in Model Assessing 







Table H1:  Results of Link Test Checking for Model Specification Error in Model  
                 Assessing Associations between Perceived Provider Knowledge and 
                  Inappropriate Drug Choice PIM Use 
 
 
Logistic regression Number of obs = 2052 
 LR chi2(2) = 270.48  
 Prob > chi2 = 0.0000 
Log likelihood = -826.94653 Pseudo R2 = 0.1406 
 
---------------------------------------------------------------------------------------------------------- 
 idc | Coef. Std. Err. z P>|z| [95% Conf. Interval] 
-------------------- +------------------------------------------------------------------------------------ 
 _hat | .8857866 .1582626 5.60 0.000 .5755976 1.195976 
 _hatsq | -.0460731 .0584731 -0.79 0.431 -.1606783  .0685322 







Table H2:  Results of Link Test Checking for Model Specification Error in Model  
                  Assessing Associations between Perceived Provider Knowledge and Overall  
                  PIM Use 
 
 
Logistic regression Number of obs = 2052 
 LR chi2(2) = 288.59  
 Prob > chi2 = 0.0000 
Log likelihood = -922.25327 Pseudo R2 = 0.1353 
 
---------------------------------------------------------------------------------------------------------- 
 pim | Coef. Std. Err. z P>|z| [95% Conf. Interval] 
-------------------- +------------------------------------------------------------------------------------ 
 _hat | .9796952 .1466363 6.68 0.000 .6922934 1.267097 
 _hatsq | -.0090337 .0586339 -0.15 0.878 -.123954 .1058867 








Results of Link Test Checking for Model Specification Error in Model Assessing 







Table I1:  Results of Link Test Checking for Model Specification Error in Model 
                Assessing Associations between Perceived Provider Competence and  
                 Inappropriate Drug Choice PIM Use 
 
 
Logistic regression Number of obs = 2060 
 LR chi2(2) = 258.19  
 Prob > chi2 = 0.0000 
Log likelihood = -826.95584 Pseudo R2 = 0.1350 
 
---------------------------------------------------------------------------------------------------------- 
 idc | Coef. Std. Err. z P>|z| [95% Conf. Interval] 
-------------------- +------------------------------------------------------------------------------------ 
 _hat | .9043291 .1707122 5.30 0.000 .5697393 1.238919 
 _hatsq | -.0375075 .061843 -0.61 0.544 -.1587176 .0837026 







Table I2:  Results of Link Test Checking for Model Specification Error in Model 
                Assessing Associations between Perceived Provider Competence and Overall  
                PIM Use 
 
 
Logistic regression Number of obs = 2060 
 LR chi2(2) = 278.65  
 Prob > chi2 = 0.0000 
Log likelihood = -922.59694 Pseudo R2 = 0.1312 
 
---------------------------------------------------------------------------------------------------------- 
 pim | Coef. Std. Err. z P>|z| [95% Conf. Interval] 
-------------------- +------------------------------------------------------------------------------------ 
 _hat | 1.009905 .1544907 6.54 0.000 .7071085 1.312701 
 _hatsq | .0042961 .0606534 0.07 0.944 -.1145825 .1231747 










Diagnostic Plots of Influence Statistics for Model Assessing Associations between 









Figure J1: Plots of Pearson Residual, Deviance Residual, Leverage, and CI  
 Displacements C against Case Number for Model Assessing Associations 
 between Perceived Provider Communication and Inappropriate Drug Choice 








Figure J2:  Plots of Pearson Chi-Square Difference and Deviance Difference against 
  Predicted Probability for Model Assessing Associations between Perceived 









Figure J3: Plots of Pearson Residual, Deviance Residual, Leverage, and CI  
 Displacements C against Case Number for Model Assessing Associations 









Figure J4:  Plots of Pearson Chi-Square Difference and Deviance Difference against 
  Predicted Probability for Model Assessing Associations between Perceived 








Diagnostic Plots of Influence Statistics for Model Assessing Associations between 









Figure K1:  Plots of Pearson Residual, Deviance Residual, Leverage, and CI  
  Displacements C against Case Number for Model Assessing Associations 
  between Perceived Provider Knowledge and Inappropriate Drug Choice 









Figure K2:  Plots of Pearson Chi-Square Difference and Deviance Difference against 
  Predicted Probability for Model Assessing Associations between Perceived 









Figure K3:  Plots of Pearson Residual, Deviance Residual, Leverage, and CI  
  Displacements C against Case Number for Model Assessing Associations 









Figure K4:  Plots of Pearson Chi-Square Difference and Deviance Difference against 
  Predicted Probability for Model Assessing Associations between Perceived 








Diagnostic Plots of Influence Statistics for Model Assessing Associations between 









Figure L1: Plots of Pearson Residual, Deviance Residual, Leverage, and CI  
 Displacements C against Case Number for Model Assessing Associations 
 between Perceived Provider Competence and Inappropriate Drug Choice 









Figure L2:  Plots of Pearson Chi-Square Difference and Deviance Difference against 
  Predicted Probability for Model Assessing Associations between Perceived 









Figure L3: Plots of Pearson Residual, Deviance Residual, Leverage, and CI  
 Displacements C against Case Number for Model Assessing Associations 









Figure L4:  Plots of Pearson Chi-Square Difference and Deviance Difference against 
  Predicted Probability for Model Assessing Associations between Perceived 
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